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Introduction
Epidemiology and background
Otitis media (OM), or middle ear infection, is one of the most frequent diseases during 
childhood and the most common motive for young children to visit a physician. In many 
countries, OM is the most common reason for children to receive antibiotics or to undergo 
surgery (1-4). Although severe complications such as mastoiditis and meningitis are rare, 
their morbidity is high (5). Costs for general healthcare, in which OM plays a very signifi-
cant role, are estimated to be around 5 billion dollars in the US annually (1,4,6,7). 
 OM is a common denominator for a variety of middle ear diseases that can be 
divided into different categories. These include acute otitis media (AOM) and otitis media 
with effusion (OME) (8,9). AOM is defined as the presence of middle ear effusion accom-
panied by signs of acute inflammation of the middle ear, such as otalgia, otorrhea, fever, 
and malaise or irritability of the child (4). OME on the other hand can either develop as a 
sequel of AOM or develop de novo, the primary symptom being hearing loss due to the 
presence of middle ear fluid in the middle ear cavity but in the absence of signs of acute 
inflammation (10). 
  Seventy-five percent of all individuals are confronted with at least one episode of 
AOM in a life-time, with a peak during the first 6-18 months of life (7,11). In 10-20% of all 
children up to one year old, recurrence of at least three AOM episodes will occur. Recur-
rent AOM is defined as 3 or more episodes within 6 months time, or 4 or more episodes in 
a period of 12 months. In 50%, middle ear effusions are present 4-6 weeks after the acute 
onset, which diminish by half after 3 months. In case the effusion persists for more than 3 
months, the disease is defined as chronic OME (COME) (12).  
 A number of factors are associated with an increased risk to develop OM. Although 
family predisposition is not well understood (11), it is generally assumed that there is a 
genetic basis. For example, Emonts et al. have demonstrated an association between the 
PAI 1 4G/4G genotype and recurrent AOM in children under the age of 4 (13). In another 
study, they observed that polymorphisms in the inflammatory response genes of TNF-α, 
IL-6 and IL-10 contributed to increased susceptibility to AOM in otitis-prone children (14). 
There is also an increased prevalence among Native Americans, Aboriginals and Inuit, 
suggesting genetic predisposition for OM (15). 
 Related to the home environment, the presence of older siblings increases the expo-
sure to potential middle ear pathogens and respiratory viruses, and consequently, the risk 
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to develop OM. In addition, lack of breast-feeding, pacifier use, low socioeconomic status 
and exposure to tobacco smoke also contribute to the risk of developing otitis media. Fur-
thermore, daycare center attendance is another environmental factor which increases the 
risk for OM as a result of increased exposure to respiratory viruses and middle ear patho-
gens (4,11,16). Finally, children younger than 6 months of age, with craniofacial abnormali-
ties, immune deficiencies, or a history of recent ear surgery are at risk to develop OM (17). 
Diagnosis, complications and sequelae
Initial OM diagnosis is based on signs, symptoms and otoscopic findings with physical 
examination. In case of complicated, recurrent or persistent OM episodes, referral to an 
otolaryngologist or pediatrician (in particular when immune deficiencies are suspected) 
is warranted. To confirm OM diagnosis, otoscopy needs to be supported by audiometry 
and tympanometry (18). Sequelae of OM manifested in the tympanic membrane include 
atrophy, myringosclerosis, retraction, adhesion and perforation (19). Complications of OM, 
for example mastoiditis, meningitis, petrositis, labyrintitis and cerebral venous thrombosis, 
appear in approximately 0.5% of the OM cases (20).
Figure 1. Typical otoscopic findings of the tympanic membrane 
in the unaffected middle ear and during OM: (A), healthy tympanic 
membrane; (B), tympanic membrane during AOM; (C), tympanic 
membrane during COME; (D) tympanic membrane after insertion 
of a ventilation tube (adapted from http://me.hawkelibrary.com).
 A.  B.
 C  D.
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Treatment
Although OM management has no universal standard yet, it may imply watchful waiting, 
antibiotic treatment, adenoidectomy, insertion of ventilation tubes or vaccination (Figure 
2). Accurate diagnosis is often difficult, because signs and symptoms might overlap with 
symptoms of other respiratory infections (21). In addition, diagnosis relies on otoscopy 
(inspection of the tympanic membrane) and tympanometry (functional testing of the tym-
panic membrane), which is done inconsistently. Hence, AOM diagnosis is estimated to be 
incorrect in 30% of the cases (Figure 2). 
 The Wait and See Approach is a primary care strategy designed in The Netherlands, 
in which children suffering from AOM do not receive antibiotic treatment in the first 48-72 
hours, but do receive adequate analgesics (4,22). This strategy, at present implemented 
in most international guidelines, is preferred in uncomplicated AOM for selected children 
based upon diagnostic certainty, age, illness severity, and assurance of follow-up (22). 
Although guidelines among countries are fairly similar, adherence of physicians to these 
guidelines is poor (23,24)(Figure 2). Importantly, untreated AOM has a high rate of spon-
taneous resolution, and a plausible viral origin is often neglected. Nevertheless antibiotic 
prescription rates to treat OM remain high, varying from 31% in the Netherlands to 98% in 
Australia and the United States (1). Consequently, if antibiotics are used in diseases which 
are mostly self-limiting, development of antimicrobial resistance will be enhanced (7) (Fig-
ure 2). 
 Whether antibiotic treatment contributes to the cure of rAOM or COME is still a mat-
ter of debate (25-27). Tympanostomy tube insertion and adenoidectomy are two surgical 
interventions for children suffering from rAOM or COME, primarily to establish (transient) 
improvement of hearing levels (8,28,29). Nevertheless, optimal treatment with regard to 
these children remains highly controversial (Figure 2). For example, Schilder et al. demon-
strated a wide discrepancy in ventilation tube insertion among countries for the treatment 
of COME in children aged 0-14 years (29), and a similar phenomenon holds true for ade-
noidectomy: annual adenoidectomy rates differ significantly between countries (30). For 
adenoidectomy there is a significant benefit regarding the resolution of middle ear fluid, 
the benefits to hearing are small. The benefits of ventilation tubes to hearing improvement 
diminishes during the first year. Thus far, the effect of ventilation tube insertion on speech 
and language development has not been demonstrated (29). 
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Vaccines and vaccine development
Vaccines are a relatively new treatment strategy to combat OM. Vaccination efficacy against 
OM diseases is currently limited, and directed against very few bacterial OM pathogens, 
and even fewer viral OM pathogens. The pneumococcal conjugate vaccine (PCV7), imple-
mented in the Dutch National Immunization Program in 2006, is primarily designed to tar-
get pneumococcal invasive disease, and the introduction of this vaccine reduced the over-
all OM incidence by 6-9% (31-34). Moreover, PCV7 and the recently launched PCV10 and 
PCV13 vaccines are thought (i) to delay the first pneumococcal AOM episode in children, 
(ii) to reduce emergency room visits, (iii) to reduce antibiotic resistance, and (iv) to reduce 
the need for ventilation tube insertion (35). However, once recurrent acute otitis media has 
been established, no reduction in otitis media episodes occurs after vaccination, not even 
reduction of OM caused by the serotypes included in the conjugate vaccine (36). 
 In the Netherlands, PCV7 has recently been replaced by PCV10 (PHiD-CV, Synflorix) 
(37,38). PCV13 (13-valent, Prevenar) has replaced PCV7 in the childhood immunization 
schedules of the USA and UK in 2010 (39). Since the current conjugate vaccines are only 
directed against a limited number of pneumococcal serotypes, serotype replacement and 
pathogen replacement can occur, with a reduced overall vaccine effect as a consequence.
PCV10 is the first vaccine in which components of multiple OM pathogens are combined: 
PREVENTION
DIAGNOSIS
Vaccines
AOM  1) 2) rAOM  4) COME  4)
Pain managment
(Watchful)
waiting
Antibiotics  3) Ventilation
tubes
Adenoid-
ectomy
ement
TREATMENT
Figure 2. OM diagnosis, treatment and obstacles to overcome. 1) AOM diagnosis estimated 
to be wrong in 30% of the cases; 2) International consensus on AOM guidelines, however, 
interpretation of the guideline remains difficult; 3) Empirical prescription of antibiotics, and 
consequently increasing antibiotic resistance; 4) No international consensus in rAOM and 
COME treatment.
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the Haemophilus influenzae protein D is combined with 10 distinct pneumococcal polysac-
charides in a conjugate formulation in order to reduce OM induced by Streptococccus 
pneumoniae and H. influenzae (40). Future vaccines that are protective against all S. pneu-
moniae serotypes and that contain bacterial components that elicit protection against all 
three major bacterial OM pathogens (S. pneumoniae, H. influenzae and Moraxella catarrha-
lis), are considered to have a very significant potential to reduce the burden of OM dis-
ease (2,7,41,42). Viral relevance in OM should not be underestimated, however, due to 
the manufacturing complexity it is unlikely to produce a combined multiple bacterial-viral 
vaccine in the near future (16).
Clinical microbiology
OM episodes are usually preceded by asymptomatic nasopharyngeal colonization with 
one or more of the major OM pathogens, i.e. S. pneumoniae, H. influenzae and/or M. 
catarrhalis  (Figure 3) (9). The rate of colonization is age-dependent, increases from infan-
cy to early childhood and remains high in adulthood (43). A population-based prospective 
cohort study in the Netherlands enrolled 1079 children and determined the carriage rate of 
the aforementioned pathogens: S. pneumoniae (8.3%, 31.3% and 44.5%, measured at 1.5 
months, 6 months and 14 months, respectively), H. influenzae (7.2%, 23.8% and 31.7%, 
respectively) and M. catarrhalis (11.8%, 29.9% and 29.7% respectively) (44). The preva-
lence of nasopharyngeal carriage is increased in those coming in close inter-individual 
contact, for example when attending day-care or when having older siblings (45). Some 
studies conclude that colonization of the nasopharynx at an early stage, predisposes chil-
dren for development of rAOM (46), whereas others cannot confirm this association (47). 
In addition, OM-prone children display increased carriage rates of these bacterial patho-
gens compared to healthy controls (31,48,49). Furthermore, the density of colonization 
appears to be important in determining the likelyhood of progression to OM (50).
 As determined by clinical studies performed in the US and Europe S. pneumoniae 
and H. influenzae are responsible for 80% of all AOM episodes, and M. catarrhalis in 3 
to 20% (11,51). Since OME can develop as a sequel of AOM, these pathogens are often 
found in middle ear effusions from children with OME. Whether these bacteria are also 
important in the development of de novo OME, is not yet clear (11,52). 
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Microbial pathogenesis
S. pneumoniae is an encapsulated, Gram-positive diplococcus, whereas H. influenzae is 
a Gram-negative rod-shaped bacterium that can be either capsulated (typeable) or unen-
capsulated (non-typeable). M. catarrhalis is an unencapsulated, Gram-negative diplococ-
cus. 
 Since the introduction of the heptavalent conjugate vaccine, a significant reduction 
in otitis media due to S. pneumoniae strains and an increase in otitis media due to non-
typeable H. influenzae have been reported (32). Non-typeable H. influenzae is a significant 
cause of OM in children, but is also known to exacerbate COPD or persist chronically in 
adults with COPD (53). M. catarrhalis, although previously thought to be primarily a commen-
sal, is currently considered to be a true pathogen of the upper and lower respiratory tract. 
S. pneumoniae
Adhesion. In order to reside in the middle ear cavity, S. pneumoniae needs to adhere to 
the epithelium. Various factors e.g. Ami/AliAB, IgA1 protease, PavA, NanA, PsaA, PspA, 
PspC, and pneumolysin have shown their significant contribution to nasopharyngeal colo-
nization (54-59). Thus far, research investigating the contribution of the specific virulence 
factors in OM has been scarce. Type four pili (TFP), adhesins which are believed to also 
mediate colonization of the nasopharynx and OM, have been investigated extensively over 
the last years and have shown to be present in pathogen S. pneumoniae, albeit not invari-
ably present in all strains (60,61).
Figure 3. Schematic representation of nasopharyngeal colonization and OM (adapted from 
K.M. Mason, http://masonlab.nchresearch.org/). 
Ear
Canal
Outer
Ear
Ear Drum
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COLONIZATION
Eustachian Tube
(to throat)
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 Invasion. The proportion of internalized pneumococci in resting pulmonary cells is 
only 0.1% of the adherent bacteria (62).
 Toxicity. Another important molecule that is associated with pneumococcal virulence 
is pneumolysin. This hemolysin is intracellularly produced by S. pneumoniae and released 
by the action of cell-bound autolysin. The multiple biological activities of pneumolysin, such 
as inhibition of ciliar function on epithelial and endothelial cells and masking of hydrogen 
peroxide release have been shown to interfere with eukaryotic host-cell function and the 
immune system (63). 
 Immune evasion. The capsular polysaccharide of S. pneumoniae is considered to 
be the major virulence factor (64). The role of the capsule is mainly of protective nature, 
as it allows pneumococci to evade phagocytosis by immune cells by inhibiting comple-
ment deposition and activation at the bacterial surface. The pneumococcus can regulate 
the thickness of its capsule during colonization, allowing the bacterium to expose surface 
molecules that facilitate adherence to the epithelium (64,65). At present, over 90 pneumo-
coccal capsular polysaccharide types are recognized. The distinct capsular structures are 
used to serologically discriminate S. pneumoniae strains. S. pneumoniae has developed 
several mechanisms to resist the effects of complement in innate immunity (66). The pneu-
mococcal capsule is a key factor in this resistance, acting not only to limit access to cell 
bound complement, but also reducing the amount of complement deposited. In addition, 
the toxin pneumolysin and the pneumococcal surface proteins PhtB, PspA and PspC con-
tribute to serum resistance (63). 
H. influenzae
Adhesion. Hap adhesin, HMW1/2 and Hia are all virulence factors involved in H. influenzae 
adhesion (for review, see (67)). Type four pili have also been found to be expressed by H. 
influenzae. Fifteen percent of H. influenzae strains, both typeable and non-typeable, is able 
to express these pili (67). Phosphorcholine (ChoP), a phase variable LOS-component, has 
been shown to contribute to the LOS-dependent adherence of NTHi to epithelial cells (67). 
 Invasion. ChoP may influence invasion via interaction with the platelet activating fac-
tor (PAF) receptor on the host cell surface (67). Tong et al. demonstrated a critical role 
for ChoP in a chinchilla model of infection: H. influenzae infection with the ChoP positive 
phenotype promoted enhanced nasopharyngeal colonization and development of OM.
 H. influenzae, like M. catarrhalis, is found in reticular crypt epithelial cells of adenoids 
removed from children with chronic OM or adenoidal hypertrophy (68,69). Experiments 
with human bronchial epithelial cells revealed that H. influenzae invasion begins with exten-
sion of host cell microvilli and the formation of lamellipodia (70).
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 Immune evasion. Some of the H. influenzae isolates are covered with an immune 
evasive polysaccharide capsule, with six antigenic serotypes, designated a to f, being 
identified (43). In contrast to S. pneumoniae, most H. influenzae pathogens cultured from 
the upper respiratory tract are unencapsulated (64,71).
 Non-typeable H. influenzae is generally considered to be a serum-sensitive patho-
gen, but it has also developed strategies to inhibit complement mediated lysis (53). For 
example, various LOS components, e.g. lytC, lex2B and losA, have been found to affect 
serum resistance (72-75). 
M. catarrhalis
Adhesion. Several macromolecules contribute to M. catarrhalis adhesion, i.e. UspA, MID/
Hag, McaP, OMP CD and surface exposed structures such as type IV pili and LOS struc-
tures (for review, see (76) ). 
 Invasion. A macropinocytosis-like mechanism of cellular invasion in different epithe-
lial cell types, as described for H. influenzae, was also observed for M. catarrhalis (77,78). 
Once intracellular, the bacteria were found to reside in vacuolar structures. Furthermore, 
UV-killed bacteria were used to demonstrate that M. catarrhalis actively invade the epithe-
lial cells, as no structural changes in the epithelial membrane were observed with UV-killed 
bacteria and no bacterial structures were found inside cells (77,78). 
 Immune evasion. Resistance to complement-mediated killing is an important aspect 
of the M. catarrhalis pathogenicity, with almost all isolates recovered from OM or COPD 
patients being resistant to the bactericidal effect of normal human serum (79). UspA2, 
OMP CD, OMP E, CopB and LOS are examples of important factors responsible for com-
plement evasion by M. catarrhalis (76). 
Biofilm formation and polymicrobial infection
Biofilms are organizationally structured and specialized communities of adherent micro-
organisms embedded in a complex extracellular substance, which provides a protective 
life style (80). The capacity of S. pneumoniae, H. influenzae and/or M. catarrhalis to form 
biofilms has been implicated by in vitro assays (81-84), and has been found to be pre-
sent in vivo on the middle ear mucosa of children with OM (85). Biofilms may contribute 
to the persistence of pathogens and the resistance of OM to antibiotic treatment (85,86). 
Although the occurrence of the OM pathogens in biofilms is generally accepted, there is 
still debate about the definition of a biofilm, and consequently, whether all OM pathogens 
fulfill all criteria to be called ‘biofilm producer’ (87). However, detailed elucidation of the 
relevance of biofilms in the pathogenesis of OM is considered to be very important in the 
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development of new approaches to treat and prevent OM (88). 
Bacterial-viral co-infection
The synergistic effect of viral upper respiratory tract infections on bacterial super-infection 
is well recognized (89). Rhinovirus, adenovirus, enterovirus, influenza and parainfluenza-
virus, as well as respiratory syncytial virus, human coronavirus, human metapneumovirus 
and human bocavirus are pathogens, which are considered to play a causal role in upper 
respiratory tract infections and OM and are known to facilitate bacterial super-infections 
(16). Viruses are considered to cause Eustachian tube dysfunction, to increase adherence 
of bacteria to epithelial cells resulting in a rise in bacterial colonization of the nasopharynx, 
and to modulate the host’s immune function (52). Detection of viral pathogens is primarily 
performed in clinical studies rather than applied for diagnostic purposes, since viral detec-
tion does not affect treatment policy at present. As a result of detection difficulties using 
viral culture, the presence of viruses have been underestimated in the past. With the intro-
duction of the (multiplex) polymerase chain reaction (PCR) amplification technology, the 
detection of viruses improved significantly. Importantly, one should realize that viral com-
ponents may be vanished before OM becomes manifest due to bacterial super-infection, 
and consequently, their involvement in OM might be underestimated.
Immunology
The innate immune system offers the first line of defence to microbial pathogens. Epithe-
lial surfaces, mucins and digestive enzymes, i.e. lysozyme, lactoferrin, β-defensins, col-
lectins and surfact proteins A and D, form the first barrier against microorganisms (90). 
In addition, when microbes do penetrate the body, innate defence systems capable of 
distinguishing self from non-self structures are required. A set of pattern recognition recep-
tors (PRRs) expressed by a wide variety of human cells recognize pathogen associated 
molecular patterns (PAMPs), in a pathogen-specific manner. The PRRs are expressed on 
a wide variety of cells of the innate immune system, including polymorphonuclear phago-
cytes, monocytes/macrophages, dendritic cells, natural killer cells and to some extent epi-
thelial or endothelial cells. Also part of innate immunity is the complement system, com-
prising over 30 serum and membrane proteins which, when activated, form a cascade of 
reactions contributing to the elimination of invading microorganisms (63). Activation of the 
complement system (i.e. the classical, alternative and mannose-binding lectin pathways) 
will establish opsonization of the pathogens, chemotaxis and activation of leukocytes, and 
direct killing of pathogens. Recognition of the pathogens by immune cells within the respira-
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tory tract generates an array of pro-inflammatory and anti-inflammatory cytokines (91). For 
example, the cytokines TNF-a, IL-1β, IL-6, IL-8 and IL-10 play a pivotal role mediating the 
inflammatory response during the process of immune activation in the middle ear. In addi-
tion, CD14, initially characterized as the LPS receptor, is involved in responses to com-
ponents of both gram positive and negative bacteria as well as mycobacteria, fungi and 
possibly viruses. CD14 is suggested to play a central role in the innate immune defence 
against many upper respiratory tract pathogens (52). 
 Adaptive immunity mainly depends on antibody mediated phagocytosis through 
complement- and Fc-receptors expressed on neutrophils and monocytes/macrophages. 
In children with recurrent OM both increased as normal serum levels of IgA, IgM, IgG and 
IgG1 are detected, for IgG2 both normal and decreased levels have been found (52,92). 
More recently, it has been described that otitis-prone children have suboptimal circulating 
functional T-helper memory and reduced IgG responses to S. pneumoniae or H. influenzae 
upon colonization and AOM. This immune dysfunction is considered to cause susceptibil-
ity to recurrent AOM infections (93). 
Animal models
In order to study in molecular detail the microbial pathogenesis and host response during 
OM at an experimental level, animal models are warranted. Multiple animal models have 
been developed to study various aspects of the OM disease process, to increase our 
understanding of OM pathogenesis, and to design and improve preventive and treatment 
strategies (94). Models using mice (94-97), rats (98-101), gerbils, guinea pigs, chinchillas 
(102-104), and monkeys (105) have been applied over the past decades. Each animal 
model has its specific advantages. For example, chinchillas have relatively large middle 
ear cavities, are often used in case large amounts of middle ear fluid are necessary (106). 
For genetic studies, well characterized rats and mice are primarily used (106). Due to the 
increasing availability of knockouts and transgenics, mice are increasingly becoming the 
model of choice (97). Importantly, a plethora of data indicate that human disease is very 
accurately modeled in the mouse. Consequently, insight gained in murine studies can be 
translated to humans in many cases. One of the limitations of the experimental models 
currently used to study the bacterial pathogenesis of OM is the artificial ‘invasiveness’ of 
the procedures, i.e. direct inoculation of pathogens into the middle ear cavity, and hence, 
bypassing the natural route of infection.
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Study aim and outline of the thesis
In order to study the role of bacterial and viral pathogens and the host response during 
rAOM and OME, a prospective clinical cohort study was performed. In addition, a mouse 
model was developed, which allowed us to study the OM pathogenesis in molecular detail. 
The aim of this project was to increase the understanding of the underlying mechanisms 
of OM disease, and consequently, to support future management strategies. 
 To gain novel insight in the epidemiology of OM, in particular rAOM and OME, we 
performed a prospective clinical cohort study, and investigated whether the microbial pro-
files of middle ear fluid obtained from these children could be used to differentiate between 
rAOM and OME (Chapter 2). We also studied the effect of bacteria and viruses present 
in middle ear fluid in both rAOM and OME patients on the local inflammatory cytokine 
response (Chapter 3). Subsequently, we determined the protein specific humoral immune 
responses in serum and MEF of these patients in order to investigate the immunogenic-
ity of putative vaccine candidates of M. catarrhalis and S. pneumoniae (Chapter 4). In 
Chapter 5 non-typeable H. influenzae isolates obtained from the middle ear and the naso-
pharynx of our clinical study population were investigated in further immunological detail, 
in particular at the level of complement resistance. We investigated whether increased 
serum resistance of NTHi was related to the development of OM, and importantly, which 
molecular microbiological mechanisms contributed to serum resistance. 
 In order to study pneumococcal pathogenesis in an experimental setting, we devel-
oped a novel, non-invasive murine OM model (Chapter 6). Subsequently, the contribution 
of the S. pneumoniae proteins Streptococcal lipoprotein rotamase A (SlrA) and the Putative 
protease maturation protein A (PpmA) to OM pathogenesis was investigated. These two 
proteins were previously shown to play a pivotal role in i.e. colonization and adherence. 
The contribution of the S. pneumoniae DHH family proteins in experimental pneumococcal 
disease and their immune protective potential was investigated in Chapter 7. In Chapter 8, 
the involvement of the Pneumococcal serine rich repeat protein (PsrP) in biofilm formation 
was studied extensively. Finally, Chapter 9 discusses the major findings in a summarizing 
fashion. 
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Abstract
Objectives
Otitis media (OM) is one of the most frequent diseases of childhood, with a minority of 
children suffering from recurrent acute otitis media (rAOM) or chronic otitis media with 
effusion (COME), both of which are associated with significant morbidity. We investigated 
whether the microbiological profiling could be used to differentiate between these two 
conditions.
Methods
Children up to five years of age, with rAOM (n=45) or COME (n=129) and scheduled 
for tympanostomy tube insertion were enrolled in a prospective study between 2008 and 
2009. Middle ear fluids (n=119) and nasopharyngeal samples (n=173) were collected 
during surgery for bacterial culture and PCR analysis to identify Streptococcus pneumo-
niae, Haemophilus influenzae and Moraxella catarrhalis, and to detect 15 distinct respira-
tory viruses.
Results
The occurrence of bacterial and viral pathogens in middle ear fluids did not significantly 
differ between patients suffering from rAOM and COME. In both patient cohorts, H. influ-
enzae and rhinovirus were the predominant pathogens in the middle ear and nasopharynx. 
Nasopharyngeal carriage with two or three bacterial pathogens was associated with the 
presence of bacteria in middle ear fluid (P=0.04). The great majority of the bacteria iso-
lated from middle ear fluid were genetically identical to nasopharyngeal isolates from the 
same patient. 
Conclusions
Based on these results, we propose that the common perception that rAOM is associated 
with recurrent episodes of microbiologically-mediated AOM, whereas COME is generally a 
sterile inflammation, should be reconsidered.
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Introduction
Otitis media (OM) is one of the most frequent diseases during childhood and the most 
common reason for young children to visit a physician. In many countries, it is the most 
common reason for children to receive antibiotics or to undergo surgery (1-3). 
 OM is a common denominator for a variety of middle ear diseases that can be 
divided into various categories, including acute otitis media (AOM) and otitis media with 
effusion (OME) (4). AOM is defined as the presence of middle ear effusion accompanied 
by signs of acute inflammation of the middle ear, such as otalgia, otorrhea, fever, and 
malaise or irritability of the child (3,5). OME, on the other hand, can either develop as a 
sequel to AOM, or develop de novo, the primary symptom being hearing loss due to the 
presence of middle ear fluid in the middle ear cavity (but in the absence of signs of acute 
inflammation) (6). Albeit often self-limiting, in 10-20% of the cases OM can result in chronic 
OME (COME) or recurrent AOM (rAOM) disease (7). 
 Although there is currently no universal standard for OM management, several 
options are available to the clinician, namely: watchful waiting, antibiotic treatment, ade-
noidectomy, ventilation tube insertion, or vaccination. AOM management generally involves 
adequate analgesics with an optional observation period for 48-72 hours (5). Thereafter, 
antibiotic treatment or, in the case of recurrent infections, antibiotic prophylaxis or ventila-
tion tube insertion are considered (5,8,9). In contrast, for OME disease, medical interven-
tion is appropriate only if persistent clinical benefits can be achieved in the absence of 
spontaneous resolution. Therefore, healthy children with OME are observed for at least 
3 months before medical intervention is considered, in which case surgical treatment 
involving the insertion of ventilation tubes or adenoidectomy is feasible (3,10). Vaccination 
against OM diseases is currently very limited, being directed against very few bacterial 
OM pathogens, and only one of the viral OM pathogens, i.e. the influenza vaccine. The 
heptavalent pneumococcal conjugate vaccine is primarily directed against pneumococcal 
invasive disease, whereas the introduction of vaccination only reduced the overall OM 
incidence by 6-9% due to serotype or pathogen replacement (11). However, herd immunity 
may induce a further decline in OM incidence, in line with nasopharyngeal colonization 
studies 3 years after the introduction of the vaccine (12,13).
 A key element in the pathogenesis of OM is the nasopharynx, as this niche is the 
reservoir for bacterial pathogens involved in middle ear infections (4). Colonization of the 
nasopharynx with Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrh-
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alis (the three most important bacterial pathogens associated with OM disease) at an early 
stage, has been shown to predispose children for development of rAOM (14). In addition, 
OM-prone children have increased carriage rates of these bacterial pathogens compared 
to healthy controls (15,16). In AOM, S. pneumoniae is the most frequently detected patho-
gen in middle ear fluid, followed by non-typeable H. influenzae and M. catarrhalis (17-19). 
However, H. influenzae tends to predominate in COME, followed in a lesser extent by S. 
pneumoniae and M. catarrhalis (20). In general, bacteria have been found less frequently 
in the middle ear of children suffering from COME compared to AOM (approximately 30% 
versus 70%, respectively) (17). 
 In addition, many studies over the past decades have shown a close association 
between AOM and respiratory viral infections (21-24). Viral upper respiratory tract infec-
tions (URI) predispose children to AOM, as infection may cause Eustachian tube dysfunc-
tion, and facilitate an increase in adherence of bacteria to epithelial cells, resulting in a 
rise in bacterial colonization of the nasopharynx and a modulation of the host’s immune 
function (25-27). Nevertheless, studies describing specific associations between respira-
tory viruses and bacteria in rAOM and COME are scarce.
 In this study, we investigated bacterial and viral colonization and infection in the 
middle ear and nasopharynx of children diagnosed with rAOM or COME. In particular, the 
contribution of 3 major bacterial pathogens (S. pneumoniae, H. influenzae and M. catarrha-
lis) in the absence or presence of 15 distinct respiratory viruses was studied in relation to 
rAOM and COME disease.
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Materials & Methods
Study design
A cohort of children up to five years of age who suffered from rAOM or COME was exam-
ined in this prospective clinical study. The cohort was enrolled at a secondary and a ter-
tiary care hospital in Nijmegen, the Netherlands, from April 1st 2008 to July 1st 2009, and 
included children suffering from rAOM or COME who underwent surgery for the insertion 
of ventilation tubes. Recurrent AOM was defined as 3 or more episodes of AOM in the 
last 6 months or 4 episodes in the last 12 months (28). The COME patient population 
consisted of children who had experienced a period of persistent OM with effusion last-
ing longer than 3 months. RAOM or COME diagnosis was made by an otolaryngologist in 
routine clinical practice based upon signs, symptoms, otoscopy and audiometry includ-
ing tympanometry. Patients with a history of malignancy, organ transplantation or immune 
deficiency were excluded from participation, as well as patients with recent elective ear 
surgery or systemic infectious diseases. Children with AOM and/or fever (T ≥ 38°C) at 
the time of ventilation tube insertion were rescheduled for the procedure. Adenoidectomy 
performed in the same surgical setting was not considered to be an exclusion criterion. 
Patient characteristics and risk factors were acquired using a questionnaire, collected at 
the day of ventilation tube insertion. Ethical permission was obtained from the Committee 
on Research Involving Human Subjects in January 2008 (CMO 2007/239, international trial 
register number: NCT00847756).
Clinical samples 
Per child, one middle ear fluid sample and one nasopharyngeal sample was collected. 
Middle ear fluid was collected during surgery using a middle ear fluid aspiration system 
(Kuijpers Instruments, Groesbeek, The Netherlands) (29), nasopharyngeal samples, taken 
through the nose, were obtained using a cotton wool swab (192C, Copan, Brescia, Italy). 
Middle ear fluid was suspended in 2 ml saline and divided into aliquots for bacterial cul-
ture, bacterial PCR, and viral multiplex PCR. The nasopharyngeal samples were used for 
bacterial culture and thereafter stored at -80°C in 1 ml of 80% glycerol for subsequent viral 
analysis.
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Microbiology
Middle ear fluid and nasopharyngeal samples were cultured directly after collection accord-
ing to standard laboratory procedures (14) to determine the presence of S. pneumoniae, 
H. influenzae and M. catarrhalis. Thereafter, bacteria were stored at -80°C in appropriate 
media containing an additional 15% (S. pneumoniae, H. influenzae) or 50% glycerol (M. 
catarrhalis). The less frequently described otopathogens Staphylococcus aureus, Strepto-
coccus pyogenes, Haemophilus parainfluenzae, Pseudomonas aeruginosa and Alloicoccus 
otitidis were also included in the analysis if detected during bacterial culture.
 To further characterize the bacterial isolates, all S. pneumoniae and H. influenzae 
isolates were cultured overnight on, respectively, blood agar and chocolate agar plates 
at 37°C supplemented with 5% CO2. Pneumococcal isolates were serotyped using the 
Quellung reaction (Statens Serum Institute, Copenhagen, Denmark) and multiplex PCR as 
described previously (30). H. influenzae isolates were serotyped using slide agglutination 
according to the manufacturer’s instructions (Becton Dickinson, Breda, The Netherlands) (31).
 S. pneumoniae, H. influenzae or M. catarrhalis obtained from middle ear fluid, as 
well as the equivalent pathogen isolated from the nasopharynx of the same patient, were 
further analyzed using multilocus sequence typing (MLST). Genomic DNA was isolated 
using a Qiagen Genomic-tip 20/G Kit (Venlo, The Netherlands) according to the manufac-
turer’s instructions. DNA amplification of the MLST loci and sequencing was performed as 
described previously (32-35). Quantitative DNA analysis of S. pneumoniae, H. influenzae 
and M. catarrhalis by real-time PCR was performed as previously described. The respec-
tive genes chosen for bacterial quantification were the S. pneumoniae ply gene (36), H. 
influenzae 16S rRNA gene (37) and the M. catarrhalis ompJ gene (38).
Virology
Middle ear fluid and nasopharyngeal samples were analyzed by multiplex PCR as previ-
ously described (39). Briefly, upon thawing, nucleic acids were extracted from each sample 
using the MagNA Pure LC System and the MagNA Pure LC Total Nucleic Acid Isolation Kit 
(Roche Applied Science, Almere, The Netherlands) according to manufacturer’s instruc-
tions. A multiplex real-time PCR assay targeting 15 different viral pathogens was used. 
This assay was designed for the detection of the specific viral genomes of influenza virus 
(IV) type A and B, coronavirus (CoV) 229E and OC43, human bocavirus (hBoV), enterovi-
rus (EV), adenovirus (AdV), parechovirus (PeV), parainfluenza virus (PIV) types 1-4, human 
metapneumovirus (hMPV), rhinovirus (RV) and respiratory syncytial virus (RSV). An internal 
control consisting of phocine herpesvirus (PhPV, IC DNA control) and equine arthritis virus 
(EAV, IC RNA control) was included in the assay. RNA was reverse transcribed to cDNA 
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using the TaqMan Reverse Transcription Reagents kit (Applied Biosystems, Nieuwekerk 
aan de IJssel, The Netherlands) in a 50 μl reaction mix containing 20 μl of nucleic acid 
isolate and random hexamers as primers (2.5μM), according to the manufacturer’s instruc-
tions. PCRs were performed on the LightCycler 480 instrument using LightCycler 480 
Probes Master Mix (Roche Diagnostics). Validated primer/probe-mixes were purchased 
from Diagenode (Liège, Belgium) and used according to the manufacturer’s instructions. 
Cycling conditions were 95°C for 5 minutes, followed by 50 cycles of 95°C for 15 seconds 
and 55°C for 15 seconds and 72 C for 20 seconds.
Statistical analysis
Statistical analyses were performed using the Statistical Package of Social Sciences ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). The chi-square test or Mann-Whitney U-test was 
used when appropriate to calculate the statistical differences between patient baseline 
characteristics. The chi-square test was used in the analysis of categorical data obtained 
from bacterial culture, bacterial PCR and viral PCR. A P-value < 0.05 was considered 
statistically significant.
page            36 | Microbial profi ling in childhood rAOM and COMEChapter 2
 
 
rAOM 
n=25 (%) 
 
COME 
n=94 (%) 
 
P-value 
Male sex 17/25 (69) 52/94 (55) 0.09 
 < 2 years of age  7 (28) 13 (14) 0.09 
    
Presence of middle ear fluid (MEF) 25/25 (100) 94/94 (100) - 
 4 URTI in the preceding year  8/22 (36) 21/86 (24) 0.26 
Recent antibiotic use 9/25 (36) 9/94 (10) < 0.01 
History of ENT surgery 8/18 (44) 37/67 (55) 0.42 
Asthma/wheezing 2/23 (87) 7/87 (8) 0.92 
Allergic rhinitis 2/22 (9) 4/86 (5) 0.42 
Eczema 3/23 (13) 11/86 (13) 0.97 
    
Birth weight, mean, (g, [SD]) 3291 [624] 3308 [791] 0.82 
Breast feeding < 3 months 15/23 (65) 51/87 (59) 0.57 
PCV7 immunization  11/25 (44) 20/94 (21) 0.02 
Tobacco smoke exposure 8/21 (38) 26/84 (31) 0.53 
Older siblings 11/18 (61) 47/74 (64) 0.85 
Day care attendance 10/22 (46) 40/84 (48) 0.86 
 
Significant differences are marked in bold. 
The MEF of 4 patients could not be collected for bacterial culture. 
Upper respiratory tract infections. 
The PCV7 vaccine was introduced in Dutch National Immunization Program for children 
born after 01-04-2006.
1
2
3
3
2
1
Mean age, years [SD] 3.3 [1.69] 4.02 [1.43] 0.10
Table 1. Characteristics of the pediatric study population.
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Results
rAOM and COME cannot be differentiated based on bacterial infection
A total of 176 children were enrolled in the study. Selected demographic and clinical char-
acteristics of the cohort are shown in Table 1. Recurrent AOM was mostly diagnosed at 
a younger age, while the prevalence of COME increased with age (rAOM 75% during 
the first year of life vs. 17% at 5 years of age; COME 25% during the first year of life 
vs. 83% at 5 years of age). A middle ear fluid specimen was collected from 69% of the 
children (n=119), with a significant difference in the presence of middle ear fluid and OM 
diagnosis (rAOM n=26 (58%) vs. COME n=97 (75%), P=0.02). Children suffering from 
rAOM presented with less ENT-related surgery in their medical history when compared to 
children suffering from COME, but received significantly more antibiotics in the year prior 
to surgery.
Microbial profiling does not differentiate between rAOM and COME
The frequency of S. pneumoniae, H. influenzae and M. catarrhalis in middle ear fluid and 
the nasopharynx is shown in Table 2. In total, 117 samples were screened for bacterial 
presence by both, bacterial culture and PCR. Not surprisingly, PCR detected bacterial DNA 
in a statistically significant percentage of culture-negative middle ear effusions: S. pneu-
moniae in 4.1% (NS), H. influenzae in 16.5% (P<0.01) and M. catarrhalis in 19% (P<0.01).
 Importantly, the presence of each specific pathogen, measured using conventional 
culture techniques or PCR, was not significantly different between the rAOM and COME 
cohorts (Table 2). 
The presence of multiple bacterial species of middle ear fluid was sporadic 
The presence of multiple bacterial species within middle ear fluids (based on bacterial 
culture) was sporadic: co-infection by S. pneumoniae and H. influenzae was observed in a 
single patient only, as was co-infection by H. influenzae and M. catarrhalis. 
 Based on the PCR results, the presence of multiple bacterial pathogens was spora-
dic and similar in rAOM (10%) and COME (15%). In rAOM S. pneumoniae and M. catarrha-
lis were both detetected in 1 child (4%), H. influenzae and M. catarrhalis in 2 children (8%), 
and all 3 pathogens in 1 child (4%). In children suffering from COME, S. pneumoniae and 
M. catarrhalis were both detected in 3 children (3%), M. catarrhalis and H. influenzae in 5 
children (5%), and S. pneumoniae and H. influenzae in 2 children (2%).
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Bacterial nasopharyngeal carriage is associated with bacterial presence in the middle ear
H. influenzae was the most frequently detected bacterial pathogen in the nasopharynx and 
was equally present in both the rAOM and COME cohort (68% versus 70%, respectively, 
Table 2). Colonization of the nasopharynx by S. pneumoniae occurred in 44% of the rAOM 
patients, compared to 61% of COME patients, while M. catarrhalis was detected in the 
nasopharynx of 48% of the rAOM and 43% of the COME patients. Eight percent and 10% 
of the children were culture negative for nasopharyngeal carriage in rAOM and COME dis-
ease, respectively (Table 2). Of note, co-colonization of two or more bacterial pathogens in 
the nasopharynx was significantly associated with the presence of bacteria in middle ear 
fluid (P=0.04).
Bacteria in the nasopharynx and middle ear are often genetically identical. 
The presence of S. pneumoniae or H. influenzae in middle ear fluid correlated positively 
with the presence of the same species in the nasopharynx ( S. pneumoniae, P=0.05; H. 
influenzae, P=0.04). M. catarrhalis was found in the nasopharynx of 42% of the children, 
with simultaneous occurrence of M. catarrhalis in the middle ear in 8% of the children; this 
latter association was not significant. 
 Serotype analysis of the 5 S. pneumoniae isolates cultured from middle ear fluid 
revealed the following serotypes: 23A (n=1), 23F (n=1), 6B (n=1), 19A (n=1) and 7F 
(n=1). In all cases, the corresponding serotype was also found in the nasopharynx. No 
statistically significant differences were observed between the 68 nasopharyngeal S. pneu-
rAOM
n=25
COME 
n=94
rAOM
n=24
COME 
n=93
rAOM
n=251
COME 
n=941
No bacteria, n (%) 18 (72) 64 (68) 9 (38) 45 (48) 2 (8) 9 (10) 
S. pneumoniae,n (%) 0 (0) 5 (5) 3 (13) 6 (7) 11 (44) 57 (61) 
H. influenzae,n (%) 6 (24) 18 (19) 10 (42) 30 (32) 17 (68) 66 (70) 
M. catarrhalis,n (%) 1 (4) 9 (10) 7 (29) 22 (24) 12 (48) 40 (43) 
1MEF positive patients only.  
Bacterial culture MEF Bacterial PCR MEF Bacterial culture nasopharynx
Table 2.          Frequency of S. pneumoniae, H. influenzae and M. cattarrhalis in middle ear fluid  
            (MEF) and the nasopharynx of children suffering from rAOM and COME
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moniae isolates, regarding pneumococcal vaccine types (i.e. those present in heptavalent 
Pneumococcal Conjugate Vaccine) and non-vaccine types (NVT, rAOM 72%; COME, 69%), 
nor between typeable and non-typeable (NT) pneumococcal strains (NT: rAOM 9%; COME 
2%) when comparing rAOM and COME cohorts.
 Twenty-two of the H. influenzae isolates cultured from the middle ear were non-type-
able (rAOM 83%; COME 100%), compared to 80 non-typeable isolates cultured from the 
nasopharynx (rAOM 95%; COME 94%). Serotype E was detected in 4% of the middle ear 
fluid and 4% of the nasopharynx specimens. Serotype B was detected in 1 nasopharyn-
geal specimen. 
 MLST analysis revealed that the majority of nasopharyngeal and middle ear fluid 
isolates obtained from the same child were genetically identical (S. pneumoniae and M. 
catarrhalis 100%; H. influenzae 80%). Further, no clonal relationships were observed for any 
of the 3 bacterial pathogens, i.e. there was no evidence to suggest that isolates originated 
from a single “founder” isolate spreading throughout the community when the respective 
isolates were compared to their pathogen-specific databases.
 
Rhinovirus dominates in both rAOM and COME and contributes to bacterial colonization
Rhinovirus was the most frequently detected virus in middle ear fluids in both patient 
cohorts, followed by enterovirus, coronavirus and parainfluenza viruses (Table 3). The 
presence of enterovirus in middle ear fluids was associated with the presence of rhino-
virus, as 8 out of the 9 enterovirus-positive middle ears were also positive for rhinovirus 
(P=0.01). Nevertheless, in the vast majority of the virus-positive samples only a single 
virus was detected.
 Rhinovirus was also the most frequently detected virus in the nasopharynx, followed 
by enterovirus, parainfluenza viruses 1-4 and coronavirus (Table 3). Nasopharyngeal colo-
nization with enterovirus was significantly more frequent in rAOM patients than in COME 
patients (P=0.04). In contrast to the results obtained from middle ear fluids, no association 
between rhinovirus and enterovirus could be found in the nasopharynx. Similar to middle 
ear fluid, in the majority of the virus-positive nasopharyngeal samples only a single virus 
was detected (74%). 
 Interestingly, a significant association was observed for bacterial-viral co-occurrence 
in the nasopharynx. In more detail, the presence of a virus was accompanied by the pres-
ence of a bacterium in 92% of the virus positive nasopharyngeal samples, whereas virus 
was present in 74% of the bacterial positive nasopharyngeal samples (P=0.02). More 
specifically, the presence of S. pneumoniae and H. influenzae was significantly associ-
ated with the presence of rhinovirus (P=0.05 and P<0.01, respectively), and the presence 
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of M. catarrhalis was significantly associated with the presence of enterovirus (P=0.02). 
However, no significant difference in bacterial-viral co-colonization of the nasopharynx was 
detected between children with rAOM or COME.
 Middle ear fluid Nasopharynx 
 rAOM  COME rAOM 1 COME1 
 n=25 (%) n=862 (%) n=223 (%)  n=813 (%) 
no viruses detected, n (%) 10 (40) 40 (47) 5 (23) 23 (28) 
Rhinovirus, n (%) 11 (44) 38 (44) 11 (50) 43 (53) 
Enterovirus, n (%) 2 (8) 7 (8) 5 (23) 6 (7) 
Coronavirus, n (%) 2 (8) 2 (2) 1 (5) 3 (4) 
Parainfluenzavirus, 1-4, n (%) 1 (4) 1 (1) 2 (9) 8 (10) 
Others, n (%)4 0 (0) 7 (8) 4 (18)  15 (19) 
Significant differences are shown in bold. P=0.04.
 
1MEF positive patients.  
2The MEF of 8  COME patients could not be collected for viral PCR.  
3 The nasopharyngeal swab of respectively 3 rAOM and 13  COME patients could not be used 
for viral PCR. 
4Adenovirus, influenzavirus type A and B, hMPV, hPeV, hBV, RSV.  
Table 3.           Presence of viruses in middle ear fluid and the nasopharynx of children suffering
             from rAOM and COME
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Discussion
In this prospective study, we investigated whether the clinical signs and symptoms specific 
for rAOM and COME could be microbiologically differentiated by the presence of bacteria 
and viruses in middle ear fluid. The results of our study show that the most predominant 
bacterial pathogen associated with middle ear fluids obtained from children suffering from 
rAOM and COME is non-typeable H. influenzae, and that the presence of S. pneumoniae, 
H. influenzae or M. catarrhalis is not significantly different between children with rAOM or 
COME. With respect to the nasopharynx (and similar to the results obtained using mid-
dle ear fluids), the most frequent bacterial pathogen detected within both patient cohorts 
was non-typeable H. influenzae. The predominance of H. influenzae in the middle ear and 
nasopharynx of rAOM and COME patients is similar to other otitis media studies per-
formed elsewhere (40,41). 
 MLST analysis of the isolates indicated that the pathogens present in the nasophar-
ynx and middle ear were genetically identical within the same child. The S. pneumoniae, 
H. influenzae and M. catarrhalis genotypes isolated from the total cohort of children com-
prised a genetically heterogeneous population structure, i.e. the isolates were genetically 
highly diverse, even though they all originated from a relatively restricted geographical 
region of The Netherlands. Importantly, the bacterial pathogens that were detected in 
the middle ear fluids of our cohorts tended to be genetically identical (using MLST) to 
those isolates cultured from the nasopharynx (80% to 100%), a finding that correlates 
with previously published data. Studies investigating the genetic relatedness of bacteria 
obtained from different locations of the upper respiratory tract, and within a single patient 
are scarce. Various approaches to determine the genetic relatedness of nasopharyngeal 
and OM isolates have been described, however MLST was only used once, a technique 
that is considered to be the gold standard regarding bacterial genotyping (42-44). 
 Rhinoviruses have been implicated in the pathogenesis of OM (45,46) and showed 
to be the most frequently found virus in the nasopharynx and middle ear of both COME 
and rAOM patients. Co-infection of rhinovirus and enterovirus was found in the middle ear, 
but not in the nasopharynx. Co-occurrence of these viruses has been previously described 
by Rezes et al., who found rhinovirus in middle ear fluid in 4.8% of the 17 children, entero-
virus in 23.8% and both rhino- and enterovirus in 14.3% (46). Nevertheless, in our study 
the co-occurrence of multiple viruses in middle ear fluid or in the nasopharynx was rare. 
In the nasopharynx of our OM patients we found a single virus in 46% and 2 viruses in 
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9%, in contrast to healthy children as described by Bogaert et al. (47). They found two or 
more viruses in the majority of the virus positive nasopharyngeal samples, in 96 children 
up to two years of age (47). In our cohort only 15% of the children under the age of 2 had 
maximal two viruses in the nasopharynx. This finding suggests that in symptomatic chil-
dren suffering from OM one virus is predominant in the nasopharynx, whereas in healthy 
children more viruses can be present without clinical significance. 
 The ability of upper respiratory tract viruses to facilitate secondary bacterial infec-
tion in AOM has been described extensively in the literature (27,48,49). Influenza A and S. 
pneumoniae, RSV and H. influenzae are two examples of viral-bacterial interaction inves-
tigated in both animal models and human studies (50). To our knowledge this is the first 
report describing a highly significant association for the co-occurrence of bacteria and 
virus in the nasopharynx of rAOM and COME patients. More specifically, nasopharyngeal 
co-colonization of rhinoviruses with either S. pneumoniae, or H. influenzae, was statistically 
significant. Pitkaranta et al. observed a positive correlation between the presence of S. 
pneumoniae or M. catarrhalis and rhinovirus in the nasopharynx, but not of H. influenzae 
and rhinovirus (45). However, the authors focused on nasopharyngeal samples of OM-
prone children, and exclusion criteria for their study were either recent or expected ventila-
tion tube insertion and COME diagnosis (45). In the present study, no association between 
the co-occurrence of these viruses and bacteria was observed in middle ear fluids for both 
rAOM and COME cohorts, likely caused by the relatively low number of bacteria detected 
in middle ear fluid. In addition, since viruses can predispose to bacterial super-infection, it 
is possible that they are already cleared from the middle ear cavity at the time of surgery. 
 There are a few limitations of this study. First, the number of children with rAOM 
enrolled in this study is limited. Second, although we used internationally accepted defini-
tions for rAOM and COME, the timing of clinical sampling in relation to the exact onset of 
OM is unknown. Finally, while bacteria can colonize and persist in the human respiratory 
tract for months, infection with respiratory viruses results in acute viral replication, which is 
cleared within days to weeks. As a consequence, the persistence of bacterial DNA prob-
ably exceeds that of viruses.
 In conclusion, we performed a prospective cohort study to investigate the frequency 
and types of bacterial and viral pathogens in the middle ear and nasopharynx of children 
suffering from rAOM or COME. Our results show that the same pathogenic bacterial spe-
cies and viruses are implicated in the pathogenesis of both rAOM and COME disease. 
Further, our findings do not support the general assumption that the microbial profile is 
pathognomonic for either rAOM or COME, or that COME is merely a consequence of per-
sistent sterile inflammation in the middle ear.
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Abstract 
Background
Viral upper respiratory tract infections have been described as an important factor in the 
development of otitis media (OM), although it is unclear whether they facilitate bacterial 
OM or can directly cause OM. To clarify the role of viral infections in otitis media, we com-
pared the relative contribution of viruses and bacteria with the induction of inflammatory 
cytokine responses in the middle ear of children suffering from OM.
Methods 
Children up to 5 years of age, with recurrent or chronic episodes of OM and scheduled 
for ventilation tube insertion were enrolled in a prospective study. Middle ear fluids (MEFs, 
n = 116) were collected during surgery, and quantitative PCR was performed to detect 
bacterial and viral otopathogens, i.e. Streptococcus pneumoniae, Haemophilus influenzae, 
Moraxella catarrhalis and 15 respiratory viruses. Finally, concentrations of the inflammatory 
mediators IL-1β, IL-6, IL-8, IL-10, IL-17a and TNF-α were determined.
Results
MEFs were clustered into four groups, based on the detection of viruses (28%), bacteria 
(27%), both bacteria and viruses (27%) or no otopathogens (19%). Bacterial detection was 
associated with significantly elevated concentrations of cytokines compared to MEF with-
out bacteria (P < 0.001 for all cytokines tested) in a bacterial load- and species-dependent 
manner. In contrast, the presence of viruses was not associated with changes in cytokine 
values, and no synergistic effect between viral-bacterial co-infections was observed. 
Conclusions
The presence of bacteria, but not viruses, is associated with an increased inflammatory 
response in the middle ear of children with recurrent or chronic OM.
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Introduction 
Many studies over the past decades have demonstrated that respiratory viral infections 
can directly cause acute otitis media (AOM) (1,2). However, respiratory viruses may also 
indirectly facilitate AOM by inducing migration of bacterial otopathogens up the Eustachian 
tube and bacterial replication in the middle ear cavity. For example, synergistic relation-
ships between bacterial and viral pathogens have been described for S. pneumoniae 
and both respiratory syncytial virus (RSV) and influenza A virus (3,4). Although the exact 
mechanisms underlying these relationships are currently not fully understood, increased 
bacterial adherence in the nasopharynx, serous exudates and reduced ciliary activity in the 
Eustachian tube as a result of viral infection have all been suggested to play a role in OM. 
Importantly, whilst epidemiological data and animal studies suggest that bacterial, viral as 
well as bacterial-viral co-infections may all play a role in AOM, their relative contribution 
to the induction of inflammation and the development of OM, particularly in patients with 
more chronic forms of OM, remains largely unknown. 
 Cytokines play a pivotal role in mediating the inflammatory response during OM. 
For example, IL-1β and TNF-α, primarily produced by macrophages, initiate the acute 
inflammatory response and have been shown to contribute to pathological changes in 
the middle ear, including mucosal damage, bone erosion, fibrosis and sensorineural hear-
ing loss (5-8). Another important cytokine in the context of OM is IL-8. It is secreted by 
several cell types and is an important chemotactic attractant for neutrophils (9). Two other 
cytokines, IL-6 and IL-10, have both been shown to play an important role during chron-
ic OM (8,10,11). IL-6 plays a role in the activation of cytotoxic T cells, B-cell maturation 
and the induction of bone resorption. Whilst the anti-inflammatory cytokine IL-10 prevents 
excessive inflammation and damage to the host by suppressing the immune response 
(8), strong IL-10 responses can also increase susceptibility to bacterial infections, as has 
been described for S. pneumoniae (12). Another cytokine that may play a role in OM is 
IL-17a, which is produced by activated Th17-cells. IL-17a can stimulate the expression of 
IL-6, but can also activate neutrophils and enhance the production of nitric oxide (NO) 
(13), and is known to play an important role in the response against extracellular bacterial 
pathogens. Although high levels of IL-17a have been associated with other chronic inflam-
matory diseases, such as allergic asthma and rheumatoid arthritis (13,14), its relevance in 
the context of OM has not been extensively studied. 
 In this study, we investigated the local cytokine response in recurrent and chronic 
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OM. In particular, we investigated whether the presence of viruses and bacteria in the 
middle ear was associated with an increased inflammatory response. An important 
question that we sought to address is whether viral infections can enhance middle ear 
inflammation during co-infection with bacterial pathogens.
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Materials & Methods
Study design
This retrospective clinical study comprises a cohort of children up to five years of age, suf-
fering from recurrent or chronic episodes of OM and scheduled for ventilation tube inser-
tion. The cohort was enrolled at a secondary and a tertiary referral hospital in Nijmegen, 
the Netherlands, from April 1st 2008 to July 1st 2009. Recurrent AOM was defined as having 
had three or more episodes of AOM in the last six months or four episodes in the last 12 
months (15). The COME patient population consisted of children who had experienced 
a period of persistent OM with effusion lasting longer than three months. Patients were 
diagnosed by an otolaryngologist based on signs, symptoms, otomicroscopy and audi-
ometry including tympanometry. Patients with a history of malignancy, organ transplanta-
tion or immune deficiency were excluded from this study, as well as patients with recent 
elective ear surgery or systemic infectious diseases. Children with acute OM and/or fever 
(T ≥ 38.0°C) at the time of ventilation tube insertion were rescheduled for the procedure. 
Adenoidectomy performed in the same surgical setting was not considered to be an exclu-
sion criterion. Patient characteristics and risk factors were acquired using a questionnaire. 
Ethical permission was obtained from the Committee on Research Involving Human Sub-
jects in January 2008 (CMO 2007/239, international trial register number: NCT00847756).
Clinical samples 
MEF was collected during surgery using a middle ear fluid aspiration system (Kuijpers 
Instruments, Groesbeek, The Netherlands) (16), suspended in 2 mL 0.9% NaCl and divid-
ed into aliquots for  bacterial PCR, viral PCR and cytometric bead array. Aliquots were 
stored at -80oC until further use. Per child one MEF sample from one ear was obtained.
Microbiology
MEF was cultured according to standard laboratory procedures to determine the presence 
of Streptoccus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. To deter-
mine the amount of bacteria present in MEF, quantitative real-time PCR (qRT-PCR) was 
performed. PCR primers and probes were developed using Primer Express v3 software 
(Applied Biosystems). The respective genes chosen for the detection of specific bacte-
rial species were pneumolysin (ply) for S. pneumoniae (17), 16S rRNA for H. influenzae 
(18) and outer membrane protein J (ompJ) for M. catarrhalis (19). For quantification pur-
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poses, calibration curves were prepared and included in every qRT-PCR run, using a dilu-
tion series (108, 105 and 103 CFU/mL) of pooled S. pneumoniae TIGR4, non-typeable H. 
influenzae 86-028NP and M. catarrhalis RH4. All calibration pools were tested in triplicate 
in each qRT-PCR run and a new calibration curve was generated for every batch of MEF 
tested. Variation between the calibration curves was negligible and therefore considered to 
be suitable for standardization. 
 Genomic DNA was extracted from 50μL of MEF and from pooled calibration controls 
using the MagNaPure – LC system, according to the manufacturer’s instructions (Roche 
Applied Sciences). DNA extract was resuspended in 100 L of extraction buffer. Reaction 
mixtures for qRT-PCR contained 18 pmoles of each primer, 4 pmoles of probe, 1x TaqMan 
Fast Universal PCR Master Mix No AmpErase® UNG (2X) and 7 L of extracted DNA in a 
final volume of 20μL. A “fast” real time PCR protocol was used for all PCRs, comprising 
a two-step PCR thermocycling program of 95oC for 3 seconds followed by 60oC for 30 
seconds for a total of 40 PCR cycles. 
Virology
DNA was extracted from 500μL of MEF using the MagNA Pure-LC System. A multiplex 
real-time PCR assay containing 15 different viral pathogens was used, which was designed 
to detect specific viral genes belonging to influenza virus (IV) type A and B, coronavirus 
(CoV) 229E and OC43, human bocavirus (hBoV), enterovirus (EV), adenovirus (AdV), pare-
chovirus (PeV), parainfluenzavirus (PIV) types 1-4, human metapneumovirus (hMPV), rhino-
virus (RV) and respiratory syncytial virus (RSV) (20). An internal control comprising phocine 
herpesvirus (PhPV, IC DNA control) and equine arthritis virus (EAV, IC RNA control) was 
included in each assay run. RNA was reverse transcribed to cDNA using the TaqMan 
Reverse Transcription Reagents kit (Applied Biosystems), according to the manufactur-
er’s instructions. PCRs were performed on the LightCycler 480 instrument using Light-
Cycler 480 Probes Master Mix (Roche Diagnostics). Validated primer/probe-mixes were 
purchased from Diagenode (Liege, Belgium) and used according to the manufacturer’s 
instructions. Cycling conditions were 95°C for 5 minutes, followed by 50 cycles of 95°C 
for 15 seconds and 55°C for 15 seconds and 72°C for 20 seconds. The semi-quantitative 
amount of virus was determined based on the cycle threshold (Ct) value.
Detection of cytokines
Concentrations of IL-1β, IL-6, IL-8, IL-10, IL-17a and TNF-α cytokines in MEF were deter-
mined using commercially available cytometryc bead array (CBA) kits, according to the 
instructions of the manufacturer (Becton Dickinson, Breda, the Netherlands). All buffers 
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used in this protocol were obtained from the BD CBA Soluble Protein Master Buffer Kit (BD 
Pharmingen). The detection limit was 1.1 pg/mL for IL-1β, 0.7 pg/mL for TNF-α, 0.13 pg/mL 
for IL-10, 0.6 pg/mL for IL-6, 1.8 pg/mL for IL-8 and 0.3 pg/mL for IL-17. The samples were 
measured on a FACSCanto II, using FCAP software (BD Biosciences).
Statistical analysis
Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and 
GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA). The demographic charac-
teristics of the study cohort were investigated using one-way ANOVA and the chi-square 
test. One-way ANOVA with the Bonferroni correction was performed on log-transformed 
cytokine levels (mean, 95% CI) in order to calculate the statistical significance between 
groups (presence of bacteria, viruses, viruses / bacteria or no pathogens, respectively). 
Spearman’s rank correlation was used to calculate the correlation coefficient between 
cytokine levels with H. influenzae and M. catarrhalis bacterial loads. Univariate analysis of 
variance was used to compare cytokine levels and bacterial load of H. influenzae positive 
MEFs with M. catarrhalis positive MEFs (mean, 95% CI).
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Results
PCR detection indicates that the majority of MEFs from chronic OM patients con-
tain DNA from otopathogens
To determine the presence of otopathogens during chronic OM, qRT-PCR was performed 
on 116 MEF samples from a clinical cohort of children suffering from rAOM or COME. 
Specifically, we determined the presence of the bacterial pathogens S. pneumoniae, H. 
influenzae and M. catarrhalis, as well as 15 respiratory viruses associated with OM (Table 
1). In order to investigate the middle ear fluids for the presence of bacteria and viruses 
we measured the volume of middle ear fluid collected and described the consistency of 
the MEF. Neither the amount of middle ear fluid, nor the consistency of the middle ear 
fluid was associated with the detection of bacteria or viruses (data not shown). Out of 116 
patients, 32 (28%) tested positive only for viruses, 31 samples (27%) contained only bac-
teria, and 31 MEFs (27%) contained both bacteria and viruses. Although the vast majority 
of patients tested positive for at least one of the known otopathogens, a smaller but signifi-
cant group (n=22, 19%) of patients tested PCR-negative for all of the otopathogens (Table 
1). With regard to the demographic characteristics of the study cohort, children under the 
age of two (n=19) were significantly more often co-infected with both bacteria and virus 
when all four clustered groups of MEFs were compared (Chi-square test, p=0.03, Table 
1), although the sample size is small. 
 Of the viral pathogens that were detected, rhinovirus was by far the most frequently 
detected respiratory virus (n=53, 44%), followed by enterovirus (n=9, 8%) and human 
coronavirus (n=4, 3%). For the bacterial pathogens, H. influenzae and M. catarrhalis were 
the predominate bacterial pathogens, with 37% (n=43) and 25% (n=32) of samples PCR-
positive for either pathogen, respectively. Unexpectedly, S. pneumoniae was only detected 
in 8% (n=9) of the MEFs. 
Cytokine responses are increased in the presence of bacteria but not viruses
To determine whether the presence of viruses and/or bacteria affected the cytokine 
response, levels of the primary cytokines IL-1β and TNF-α, the secondary cytokines IL-6 
and IL-8, and the regulatory cytokines IL-10 and IL-17a were measured in MEFs. Invariably, 
cytokine levels were increased when bacteria were detected compared to samples without 
bacteria (P<0.001 for all cytokines tested). Conversely, the presence of virus in MEFs was 
not associated with an increase in cytokine levels compared to MEFs without pathogens 
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Cytokine  Mean cytokine level (Log10 CFU/mL) 95% CI of difference
1 P-value2 
 H. influenzae M. catarrhalis Lower bound Upper bound  
      
IL-1ȕ 2.48 1.78 1.91 2.36 0.003 
TNF-Į 1.17 0.97 0.81 1.34 0.443 
IL-6 3.28 2.80 2.86 3.29 0.014 
IL-8 3.54 3.19 3.23 3.50 0.014 
IL-10 1.78 1.20 1.27 1.71 0.012 
IL-17a 1.28 1.09 0.86 1.51 0.564 
 
Significant differences are shown in bold. 
1 CI, confidence interval. 
2 Univariate analysis of variance. 
Figure 1. Effect of bacterial and viral pathogens on cytokine response in the middle ear. P 
values indicate between-group differences and are calculated using 1-way ANOVA on log-
transformed cytokine levels (mean, 95% CI). ANOVA indicates analysis of variances; CI, con-
fidence interval.
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Table 2. H. influenzae-associated and M. catarrhalis-associated cytokine levels
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(Figure 1). Additionally, no significant changes were observed between samples contain-
ing only bacteria versus MEFs containing both bacteria and viruses, suggesting a more 
indirect role for viral infections.
 Samples were screened for bacterial presence by both bacterial culture and PCR. 
Not surprisingly, PCR detected bacterial DNA in a significant percentage of culture negative 
effusions: S. pneumoniae in 4.1% (NS), H. influenzae in 16.5% (P<0.001) and M. catarrhalis 
in 19% (P<0.001). However, the effect of bacterial pathogens detected with bacterial cul-
ture did not significantly alter the results obtained by qPCR as shown in Figure 1.
 As our clinical cohort contained both patients diagnosed with rAOM or COME, we 
also compared the cytokine profiles of these groups in response to the presence of either 
bacteria or viruses. Although the sample size is limited, we found no significant changes 
in MEF cytokine levels between rAOM and COME. 
Cytokine levels correlate significantly with bacterial load
Having established that the presence of bacterial DNA corresponds to a general increase 
in cytokine levels, we then investigated whether this observation was dependent on the 
amount and the type of bacteria. First, MEFs positive for multiple bacterial species (12%) 
were excluded in order to facilitate analysis of the pathogen-specific cytokine response. 
Comparing cytokine levels to bacterial load showed a significant correlation for both H. 
influenzae and M. catarrhalis (P<0.05 for IL-1β, TNF-α, IL-6 and IL-8 for both pathogens; 
see Figure 2). Although a similar trend was observed for S. pneumoniae, no statistical 
significance was reached due to the small number of MEFs in which S. pneumoniae was 
detected (n=9). To investigate whether the cytokine response differed between the two 
dominant bacterial species, i.e. H. influenzae and M. catarrhalis, we also compared the 
cytokine levels and bacterial loads of these two groups. We found that the detection of H. 
influenzae was associated with significantly higher levels of IL-1β, IL-6, IL-8 and IL-10 as 
compared to M. catarrhalis (Table 2). Taken together, these data strongly suggest a direct 
role for bacterial but not viral pathogens in the inflammatory cytokine response during 
chronic OM. This effect is not only dependent on the bacterial load as measured by qRT-
PCR, but is also affected by the bacterial species.
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Figure 2. Cytokine responses are associated with bacterial load of H. influenzae (A-F) or M. 
catarrhalis (G-L). Cytokines (IL-1β, TNF-α, IL-6, IL-8, IL-10 and IL-17a) in the middle ear fluid 
of OM patients are plotted against the amount of bacteria, as derived from quantitative PCR. 
Each dot represents a single MEF sample. P values were calculated using Spearman rank 
correlation.
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Discussion
In this study, we sought to investigate the respective contributions of bacterial and viral 
otopathogens to middle ear inflammation, one of the hallmarks of chronic OM. By relating 
the presence of pathogens to the cytokine response in the middle ear fluid of a cohort of 
patients suffering from recurrent acute OM and chronic OM, we show that  the detection 
of bacteria by qRT-PCR is directly associated with an increase in inflammatory cytokines. 
In contrast to previous observations describing an association between cytokine response 
profiles and virus-induced acute otitis media (21,22), our data suggest that the MEF 
cytokine response is not significantly different when viruses are detected. These data sug-
gest a more indirect role for virus infections in the inflammatory response, in particular for 
rhinovirus, during chronic OM. 
 OM comprises a spectrum of clinical manifestations, varying from acute otitis media 
(AOM) to recurrent (rAOM) and chronic (COME) episodes (23). Whereas (r)AOM is typi-
cally denoted by an acute onset, acute inflammation and the presence of middle ear fluid, 
COME is characterized by the presence of an asymptomatic middle-ear effusion (23,24). 
Whilst previous studies have reported a relatively low recovery of viable pathogens (30%) 
that are typically found in AOM, other studies using PCR detection techniques have shown 
a much higher detection rate of bacterial DNA (i.e. 77%). Although the detection of bacteri-
al DNA does not necessarily reflect the presence of viable bacteria, these studies suggest 
that patients with chronic OM do not always have sterile effusions, as previously thought 
(25). 
 In this study, we found no significant differences in cytokine levels between rAOM 
and COME patients. This finding might partially be explained by the fact that at the time 
of surgery, children did not suffer from acute OM and/or fever, since acute inflammation 
is contra-indicative for ventilation tube insertion. Consequently, it may be expected that 
cytokine levels in rAOM are lower than during an episode of AOM. Nonetheless, these 
data suggest that the distinction between COME and rAOM patients cannot easily be 
made in the non-acute phase. An interesting finding was the observation that interestingly, 
even in OM patients with no detectable pathogens, cytokine levels in general were high 
(up to 1×104 pg/mL). As children enrolled in this study did not suffer from acute inflamma-
tion, this suggest that their inflammatory response remains elevated even in the absence 
of detectable pathogens. One potential explanation for the high cytokine levels in these 
patients may be the presence of bacterial or viral pathogens not included in this analysis. 
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In addition, bacteria in biofilms, intracellular persistence of bacteria or bacterial compo-
nents undetectable by PCR may still provoke inflammation in the middle ear cavity (26,27). 
 We demonstrate that the detection of the three major bacterial OM pathogens is 
associated with a significantly elevated inflammatory cytokine response compared to MEFs 
without bacteria. Thus far, clinical data describing the innate immune response in the mid-
dle ear to otopathogens are scarcely available. Whilst most studies have focused on acute 
forms of OM, significantly less studies have addressed the cytokine response of children 
suffering from chronic forms of OM. Similar to our study, Skovsberg et al. compared the 
presence of viral and bacterial pathogens to the cytokine response. Although this study 
focused on children with acute OM in which the tympanic membrane ruptured spontane-
ously, it is important to note that they also found an association between the presence of 
bacteria and increased levels of cytokines (28). Thus, both their and our study point to an 
important role for bacteria in the inflammatory cytokine response during OM. In contrast 
to the study by Skovsberg, we also assessed the impact of bacterial load on the cytokine 
response. We found that the amount of bacteria was strongly associated with increased 
cytokine levels, in particular for H. influenzae, and to a lesser extent for M. catarrhalis. Pre-
vious studies have suggested that infection with M. catarrhalis results in less severe OM in 
comparison to other bacterial pathogens (29). Our data also support this hypothesis, as 
M. catarrhalis in general was associated with a weaker cytokine response compared to H. 
influenzae. 
 In parallel to the use of bacterial PCR, we also cultured the middle ear fluid to detect 
viable S. pneumoniae, H. influenzae and M. catarrhalis. Although PCR-based detection 
methods are much more sensitive compared to culture-based methods (25), we found 
that the use of data obtained with bacterial culture did not alter our results (data not 
shown). 
 In this study, rhinovirus was by far the most dominant respiratory virus, as 81% of all 
virus-containing MEFs were positive for rhinovirus. Rhinovirus has been shown to play an 
important role in lower respiratory tract pathology, where it can provoke exacerbations of 
cystic fibrosis, asthma and COPD (14,30-32). One mechanism by which rhinoviruses can 
induce inflammation during co-infection with bacterial pathogens is through the liberation 
of planktonic bacteria from biofilms. This in turn may cause increased recognition by the 
innate immune system, resulting in an increased cytokine response, as demonstrated in 
cystic fibrosis airway epithelial cells (31). In contrast to the established role of rhinovirus in 
lower respiratory tract infections, its role in disease pathogenesis of the upper respiratory 
tract, in particular during OM, remains enigmatic. For instance, rhinoviruses are commonly 
detected in subjects with mild symptoms or even from asymptomatic individuals (33,34). 
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In a study performed by Pitkaranta et al. in which rhinovirus RNA was detected by in situ 
hybridization, rhinovirus RNA was not found in any of the 18 middle ear biopsies of chil-
dren with longstanding OME. In contrast, seven out of eight adenoid biopsies were posi-
tive for rhinovirus. These results show that children with longstanding OME do not have 
a rhinovirus infection in the middle ear mucosa, although the same children frequently 
harbor large amounts of rhinovirus RNA in their adenoid tissue (35). Nevertheless, some 
studies have suggested that rhinovirus may play a role in the development of chronic 
OM with effusion (COME) (36;37). The contribution of rhinovirus in the middle ear may be 
more indirect in that they facilitate bacterial replication, but do not trigger an inflammatory 
response themselves. 
 There are a number of limitations to this study. First, the appearance of a significant 
amount of fluid into the middle ear cavity is a pathological condition that is not apparent 
in healthy individuals. Consequently, it is not possible to include healthy controls. Further-
more, although we used internationally accepted definitions for rAOM and COME, the tim-
ing of clinical sampling in relation to the exact onset of OM infection is unknown. Moreo-
ver, whilst bacteria can colonize and persist in the human respiratory tract for weeks to 
months, infection with any of the 15 tested respiratory viruses results in acute viral replica-
tion, which is cleared within days to weeks. As a consequence, the persistence of bacterial 
DNA probably exceeds that of viruses (38,39). 
 Importantly, in 19% and 27% of the MEFs, no pathogens or only viral pathogens 
were detected, respectively. In these patients, cytokine responses were relatively low, as 
compared to those that contained bacteria. As such, subsequent destructive effects such 
as sensorineural hearing loss and bone erosion as induced by e.g. IL-1β may be limited 
in these patients. This raises the question whether it is valid to discriminate recurrent and 
chronic OM patients based on the detection of (bacterial) pathogens and/or cytokine pro-
file in the middle ear. In addition to clinical presentation, measurement of bacterial load 
and cytokine levels may assist in the guidance of treatment to appropriately accommodate 
patients who are at risk to develop complications.
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Abstract
A prospective clinical cohort study was established to investigate the humoral immune 
response in middle ear fluids (MEF) and serum against bacterial surface proteins in chil-
dren suffering from recurrent acute otitis media (rAOM) and chronic otitis media with effu-
sion (COME), using Luminex xMAP technology. The association between the humoral 
immune response and the presence of M. catarrhalis and S. pneumoniae in the nasophar-
ynx and middle ear was also studied.
 The levels of antigen-specific IgG, IgA and IgM showed extensive inter-individual var-
iation. No significant difference in anti-M. catarrhalis and S. pneumoniae serum and MEF 
MFI values (anti-M. catarrhalis and anti-pneumococcal IgG levels) was observed between 
the rAOM or COME groups for all antigens tested.
 No significant difference was observed for M. catarrhalis and S. pneumoniae colo-
nization and serum IgG levels against the Moraxella and pneumococcal antigens. Similar 
to the antibody response in serum, no significant difference in IgG, IgA and IgM levels 
in MEF was observed for all M. catarrhalis and S. pneumoniae antigens between OM M. 
catarrhalis or S. pneumoniae positive and OM M. catarrhalis or S. pneumoniae negative 
children suffering from either rAOM or COME. Finally, results indicated a strong correlation 
between antigen-specific serum and MEF IgG levels.
 We observed no significant in vivo expressed anti-M. catarrhalis or anti-S. pneumo-
niae humoral immune responses using a range of putative vaccine candidate proteins. 
Other factors such as Eustachian-tube dysfunction, viral load, and genetic and environ-
mental factors may play a more important role in the pathogenesis of OM, and in particular 
in the development of rAOM or COME.
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Introduction
Otitis media (OM) is an important upper respiratory tract disease of early childhood and 
the primary reason for young children to visit a physician. The disease has a consider-
able negative impact on the quality of life during childhood and causes much concern to 
parents. OM encompasses a spectrum of conditions, including acute otitis media (AOM) 
and otitis media with effusion (OME), with approximately 80% of children having experi-
enced an episode of AOM by the age of three years. Up to one-third of these children will 
have experienced recurrent infections, with many of these episodes being facilitated by a 
bacterial infection (3,37). In fact, bacteria may be isolated from the middle ear fluid (MEF) 
of approximately 80% of children with AOM, and 30-50% of chronic middle ear effusions 
obtained from children presenting with OME (12). In many countries, OM is a common 
reason to prescribe antibiotics or to undergo surgery for the insertion of ventilation tubes, 
resulting in a significant burden on healthcare systems (21,25,29). This means that the 
direct costs associated with OM are substantial (2), and that the prevention of OM disease 
via alternative methods such as vaccination offer a promising approach to reduce the bur-
den of OM disease and its economic consequences. 
 Traditionally, Streptococcus pneumoniae has been reported to be the predomi-
nant bacterial species cultured in AOM disease, followed by Haemophilus influenzae and 
Moraxella catarrhalis. However, H. influenzae tends to predominate in OME disease, fol-
lowed to a lesser extent by S. pneumoniae and M. catarrhalis (7,9,32). Further, although 
these common OM-related bacterial species may be cultured from the middle ear of chil-
dren during OM episodes, either as single pathogens or as co-cultures (28), research has 
also shown the importance of (frequently culture negative) bacterial biofilm formation in 
the development of middle ear disease (22). Finally, the introduction of a conjugated hep-
tavalent pneumococcal vaccine (PCV7) for use in children in the community has resulted 
in a significant reduction in the overall proportion of S. pneumoniae isolates and vaccine 
serotypes observed in AOM. Indeed, the success of vaccination against S. pneumoniae 
now means that H. influenzae is now becoming the predominant pathogen isolated from 
children suffering from persistent AOM disease (6,10). 
 Children are frequently colonized with bacterial pathogens at an early age and the 
pattern of nasopharyngeal colonization is an important determinant for OM disease (15-
16). Further, research has also indicated that, as well as the presence of particular bacte-
rial species, both the adaptive and innate immune systems, Eustachian-tube dysfunction, 
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viral load, and genetic and environmental factors all may be involved in the pathogenesis 
of OM (19,23,30-31,33,38).
 The recent recognition of M. catarrhalis as an important human pathogen has stimu-
lated active investigation into the molecular mechanisms of its pathogenesis. An essential 
step in colonization and infection is bacterial adherence to the mucosal epithelium of the 
respiratory tract. A growing number of adhesins have been identified in M. catarrhalis and 
most of these proteins are highly conserved, immunogenic and express distinct epitopes 
on the bacterial surface. This means that they may be suitable as potential M. catarrhalis 
vaccine candidates (27). However, relatively little is known regarding the development of 
the natural humoral immune response to these potential vaccine candidates in children. As 
yet, no licensed vaccine has been marketed against M. catarrhalis, and to date, none of 
the putative vaccine candidates so far described in the literature have actually progressed 
to clinical trials.
 On the other hand, vaccination against S. pneumoniae infection is already estab-
lished, for example via the introduction of the PCV7 vaccine. PCV7 was primarily used to 
prevent invasive pneumococcal disease (meningitis and other pneumococcal infections 
such as pneumonia) in children, with the introduction of PCV7 having lead to a notice-
able reduction in the incidence of S. pneumoniae vaccine strains in the etiology of AOM 
(13). However, an increase in the carriage of non-vaccine serotypes has been reported, 
as well as a consequent increase in invasive disease by these non-vaccine serotypes, 
which could reduce, or even negate the benefits initially obtained through vaccination 
with PCV7 (11,26). In fact, S. pneumoniae serotype replacement and subsequent vac-
cine failure in PCV7 vaccinated children has become a serious concern in recent years, 
with most of these problems assigned to the serotype specific nature of the PCV7 vac-
cine. Currently, several pneumococcal surface proteins, either alone or in combinations, 
have been suggested as putative vaccine candidates (1,13,20), and could serve as more 
effective vaccines than those currently available, providing broad coverage against most 
pneumococcal serotypes. However, similar to the situation faced by vaccine candidates 
of M. catarrhalis, relatively little is known about the development of the humoral immune 
response to S. pneumoniae protein-based vaccine candidates in children.
 With this study, we provide insights into the anti-M. catarrhalis and anti-pneumococ-
cal humoral immune response in a cohort comprising Dutch children exhibiting recurrent 
(recurrent acute otitis media, rAOM) and chronic (chronic otitis media with effusion, COME) 
episodes of OM. Currently, there is a common perception that rAOM tends to be caused 
by recurrent episodes of AOM that are associated with bacteria and/or viral infections. 
In contrast, COME is generally considered a sterile inflammation. Studying the immune 
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response and the accompanying pathogens associated with rAOM and COME will allow 
us to better distinguish the types of bacterial and immune factors that are involved in the 
pathogenesis of rAOM and COME, and leading to a better understanding of the pathogen-
esis of these 2 clinical presentations of OM disease.
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Materials & Methods
Study cohort
This study was performed as part of a prospective clinical cohort study set up at Radboud 
University Nijmegen Medical Centre (RUNMC), Nijmegen, The Netherlands, to determine 
the immune response to putative vaccine candidates of M. catarrhalis and S. pneumoniae 
in children suffering OM disease. 
 Patients were enrolled in two hospitals in Nijmegen, The Netherlands, from April 1st 
2008 to July 1st 2009, with ages ranging from birth up to 5 years of age, and all suffering 
from rAOM or COME (for which tympanostomy tube insertion was indicated). Recurrent 
OM was defined as 3 or more episodes of AOM in the last 6 months or 4 episodes in the 
last 12 months. The COME patient population consisted of children who experienced a 
period of persistent OM lasting longer than 3 months. Diagnosis was made by an otolaryn-
gologist based upon signs, symptoms, otoscopy and audiometry including tympanometry. 
Patient characteristics and risk factors were identified using a questionnaire. Permission 
was obtained from the Committee on Research Involving Human Subjects in January 2008 
(CMO 2007/239, international trial register number NCT00847756).
Clinical materials and detection of bacterial pathogens
Middle ear fluid, a nasopharyngeal swab and serum were collected during surgery. Naso-
pharyngeal swabs were cultured according to standard laboratory procedures in order to 
determine the presence of M. catarrhalis and S. pneumoniae. Quantitative real-time PCR 
(Q-PCR) was performed in order to determine the presence of M. catarrhalis and S. pneu-
moniae in MEF.
Moraxella catarrhalis antigens
The previously described M. catarrhalis recombinant proteins used in this study comprised: 
ubiquitous surface proteins A (UspA1557-704 (aa 557–704 of UspA1) and UspA2165-318), two 
fragments of Moraxella immunoglobulin D-binding protein (MID764-913 and MID962-1200), human 
erythrocyte agglutinin (Hag385-863), M. catarrhalis hemagglutinin-like proteins (MhaB and 
MhaC) and M. catarrhalis adherence protein (McaP51-333). Orf238 and orf296 are hypotheti-
cal proteins that share homology with lipoprotein family A proteins and with an M. osloen-
sis disulfide isomerase gene virulence factor, respectively. These 10 recombinant proteins 
(from 8 different OMPs) represented the majority of published M. catarrhalis immunogenic 
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proteins discovered at the time that the study was initiated, and are derived from the ref-
erence M. catarrhalis strains Bc5 (UspA1557-704, UspA2165-318, MID764-913 and MID962-1200) and 
O35E (MhaB, MhaC, McaP51-333 and Hag385-863) (5, 24, 34-35).
Streptococcus pneumoniae antigens
The previously described S. pneumoniae recombinant proteins used in this study com-
prised: choline binding protein A (PspC/CbpA), α-enolase (Eno), hyaluronidase (Hyl), 
immunoglobulin A1 (IgA-1) protease, neuraminidase (NanA), pneumolysin (PLY), a dou-
ble mutant of pneumolysin (PdbD), putative protease maturation protein A (PpmA), pneu-
mococcal surface adhesin A (PsaA), pneumococcal surface protein A (PspA), the pneu-
mococcal histidine triad (Pht) proteins (SP1003 (PhtD) and BVH-3 (PhtE)), streptococcal 
lipoprotein rotamase A (SlrA), S. pneumoniae proteins (SP proteins) SP0189 (hypotheti-
cal protein), SP0376 (response regulator, intracellular location), SP1651 (thiol peroxidase, 
intracellular location), and Pilus A (8, 20).
Multiplex M. catarrhalis and S. pneumoniae antibody assay
Recombinant proteins were coupled to carboxylated SeroMAPTM beads that were devel-
oped for serological application, as detailed by Verkaik et al. (39). Uncoupled beads were 
used as negative control to determine non-specific antibody binding. If non-specific bind-
ing was observed, then the median fluorescence intensity (MFI) values obtained from this 
non-specific binding were subtracted from the antigen-specific results.
 The Luminex multiplex procedure was performed as described previously (39). Brief-
ly, after validation of the assay (achieved by comparison of human pooled serum (HPS) 
MFI values obtained using the multiplex assay with HPS MFI values obtained using the 
singleplex assays), the different antigen-coupled microspheres were mixed to a working 
concentration of 4000 beads per color per well. Serum samples were diluted 1:100 in 
phosphate-buffered saline containing 1% bovine serum albumin (PBS-BN) for measure-
ment of antigen-specific IgG. Fifty microliters per diluted sample were incubated with the 
microspheres in a 96-well filter microtiter plate (Millipore) for 35 min at room temperature 
on a Thermomixer plate shaker (Eppendorf). The plate was washed twice with assay buffer 
(PBS-BN) and aspirated using a vacuum manifold. The microspheres were suspended in 
50 μl of assay buffer, and 50 μl of a 1:200 dilution of R-phycoerythrin (RPE)-conjugated 
AffiniPure goat anti-human IgG (Jackson Immuno Research) was added in separate wells. 
The plate was incubated for 35 min at room temperature and washed. The microspheres 
were suspended in 100 μl of assay buffer. Measurements were performed on the Luminex 
100 instrument (BMD) using Luminex IS software (version 2.2). Tests were performed in 
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duplicate, and the MFI values, reflecting quantitative antibody levels, were averaged. The 
coefficient of variation was calculated for each serum sample and averaged per protein 
and antibody isotype. The procedure for MEF was identical to that outlined above, except 
that IgA and IgM were also measured. Briefly, MEF samples were diluted 1:100 in PBS-BN 
for measurement of antigen-specific IgG and 1:50 for measurement of IgA and IgM. Fifty 
microliters of a 1:100 dilution of RPE-conjugated AffiniPure goat anti-human IgG and IgA 
and 50 μl of a 1:200 dilution of RPE-conjugated donkey anti-human IgM were then added. 
For assay validation, MFI values obtained from pooled MEF (PMEF) using the multiplex 
assay were compared to MFI values obtained from PMEF obtained using the singleplex 
assay.
Statistical analysis
Statistical analyses were performed using SPSS PASW Statistics version 17. Correlations 
between antigen-specific IgG in serum and MEF were assessed using Spearman’s cor-
relation coefficient. The Mann-Whitney U-test was used to compare anti-M. catarrhalis and 
anti-pneumococcal immunoglobulin (Ig) levels between children diagnosed with rAOM and 
COME and to compare differences in Ig levels between colonized and non-colonized chil-
dren. The Bonferroni correction was applied to correct for multiple testing. A P-value of 
≤0.00064 was considered to be statistically significant.
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Results
Correlation between anti-M. catarrhalis and anti-pneumococcal IgG levels in serum 
and MEF
To determine the correlation between the levels of anti-Moraxella and anti-pneumococcal 
IgG in serum compared to MEF, samples from 111 children who donated both blood 
and MEF at tympanostomy surgery were included. The mean IgG levels (reflected by MFI 
values) in these samples were calculated for each protein (figure 1). IgG levels in serum 
showed a strong correlation to IgG levels in MEF for both M. catarrhalis (R2 = 0.97) as well 
as S. pneumoniae (R2 = 0.89).
Dynamics of the anti-M. catarrhalis and anti-pneumococcal antibody response in 
children with recurrent and chronic otitis media disease
A total of 156 children were included in the analysis of the antibody response to M. catarrh-
alis and S. pneumoniae proteins in serum. Forty-two children were diagnosed with rAOM, 
whereas 114 children were diagnosed with COME. No significant difference in anti-M. 
catarrhalis and S. pneumoniae serum MFI values (anti-M. catarrhalis and anti-pneumococ-
cal IgG levels) was observed between the rAOM or COME groups for all antigens tested. 
 A total of 121 children were included in the analysis of the antibody response to M. 
catarrhalis and S. pneumoniae proteins in MEF, with 25 children and 96 children diagnosed 
with rAOM and COME, respectively. No significant difference in anti-M. catarrhalis and anti-
pneumococcal MEF IgG, IgA and IgM levels were found for all proteins tested.
Association between bacterial colonization and infection and anti-M. catarrhalis 
and anti-pneumococcal antibody levels in children with rAOM and COME
A total of 156 children were included in the analysis  of the antibody IgG response to M. 
catarrhalis and S. pneumoniae antigens in serum. Forty-two children were diagnosed with 
rAOM, whereas 114 children were diagnosed with COME. No significant difference was 
observed for the presence of M. catarrhalis and S. pneumoniae and serum IgG levels 
against the Moraxella and pneumococcal antigens.
 A total of 117 children were included in the analysis of the antibody response to M. 
catarrhalis and S. pneumoniae proteins in MEF, including 23 children suffering from rAOM 
and 94 children suffering from COME. Similar to the antibody response in serum, no signif-
icant difference in IgG, IgA and IgM levels in MEF was observed for all M. catarrhalis and 
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S. pneumoniae antigens between OM M. catarrhalis or S. pneumoniae positive and OM M. 
catarrhalis or S. pneumoniae negative children suffering from either rAOM or COME. 
 Figure 2 shows an example of the results obtained; specifically the figure shows a 
comparison of anti-pneumococcal IgA-1 protease IgA levels in COME-positive children in 
the presence and absence of S. pneumoniae in the middle ear. 
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Figure 1. Correlation between IgG 
levels in serum and MEF. Mean IgG 
levels in serum and MEF were used to 
calculate the correlation statistics for 
each respective M. catarrhalis (A) or S. 
pneumoniae (B) protein (Spearman’s 
correlation coefficient, R2 = 0.97 and 
0.89).
Figure 2. Example of the results 
obtained; specifically the figure shows 
a comparison of anti-pneumococcal 
IgA-1 protease IgA levels in COME-
positive children in the presence and 
absence of S. pneumoniae in the mid-
dle ear.
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Discussion
Studies have shown that M. catarrhalis and S. pneumoniae colonize the nasopharynx 
soon after birth and frequent colonization with M. catarrhalis and S. pneumoniae has been 
reported to increase the risk of OM (15). The adaptive immune system and the innate 
immune system are also important factors in the pathogenesis of OM (31). The immune 
response to pathogens develops rapidly during the first few years of life, as children 
become exposed to an increasing number of microbial species and strains. The high inci-
dence and high rate of ‘spontaneous’ recovery from OM suggests that recovery is a natu-
ral phenomenon and part of the gradual maturation of the child’s immune system, though 
a defective or immature antibody response to OM pathogens may explain the increased 
susceptibility of some children to OM (36). 
 Differences in the presence / absence and levels of pathogen-specific IgG and IgM 
at particular body sites may be one of the mechanisms by which OM pathogens are able 
to facilitate the development of OM disease. In this study, no significant difference in anti-
M. catarrhalis and anti-S. pneumoniae serum and MEF IgG levels was observed between 
the rAOM or COME groups for all antigens tested, suggesting that differences in IgG levels 
between body sites does not play a significant role in the development of rAOM or COME 
disease. Interestingly however, a strong correlation was observed between IgG antibody 
levels in serum and IgG antibody levels in MEF, for both M. catarrhalis and pneumococcal 
proteins for the whole study cohort. This is an interesting finding, as it indicates that serum 
antibody levels are predictive of the presence of local (middle ear) IgG antibody (14,17), 
and raises the possibility that the measurement of OM pathogen-specific IgG antibodies 
in the middle ear may be achieved by simply measuring OM pathogen-specific serum 
IgG antibody levels in serum. At this moment in time however, it is not known whether OM 
pathogen-specific IgG is actually produced locally in the middle ear or transudes into the 
middle ear from the general circulation (4,14). From our results, it appears more likely that 
OM pathogen-specific IgG actually transudes into the middle ear rather than being locally 
produced, where it potentially provides some protection against OM disease. No signifi-
cant difference in anti-M. catarrhalis and anti-S. pneumoniae MEF IgM levels was observed 
for either rAOM or COME cohort in this study.
 The local production of secretory antibody is an important immunological defense 
at epithelial surfaces including the surfaces of the upper respiratory tract and middle ear. 
Secretory IgA has been shown to inhibit S. pneumoniae adherence and reduce naso-
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pharyngeal bacterial colonization (18), and it is therefore possible that children with recur-
rent OM might lack OM pathogen-specific secretory IgA. In this study, the MFI levels of 
antigen-specific IgA showed extensive inter-individual variability over time, with IgA levels 
to all M. catarrhalis and S. pneumoniae OMPs being relatively low throughout the study 
period. However, though not significant, S. pneumoniae-negative / COME-positive children 
showed higher MEF IgA levels against the pneumococcal IgA-1 protease protein com-
pared to S. pneumoniae-positive / COME-positive children. In fact, many mucosal patho-
gens, including S. pneumoniae, express an IgA-1 protease that cleaves IgA molecules, 
thereby circumventing the protective effects of IgA production (40). Our results suggest 
that IgA antibody directed against anti-IgA-1 protease may have a restorative effect by 
helping ‘neutralizing’ the effect of secreted anti-IgA-1 protease, thereby facilitating the 
binding of intact IgA to bacterial cells and promoting pathogen recognition and clearance 
by the immune response. However, it should be noted that the possibility exists that the 
differences in antibody levels observed in S. pneumoniae positive and negative COME 
MEFs are simply a product of antibody binding to S. pneumoniae bacterial cells, thereby 
making the antibodies inaccessible to measurement using our Luminex assay. Further 
research will be required in order to determine whether IgA-1 protease antibodies actually 
provide protection in patients suffering from OM disease. 
 Studying the immune response and pathogens associated with rAOM and COME 
disease indicated that COME is not in fact a sterile inflammation as is generally consid-
ered the case. Importantly, investigation into the immune response to potential vaccine 
candidates of M. catarrhalis and S. pneumoniae indicated that there may be a lack of a 
characteristic immune response profiles that will allow clinicians to distinguish between 
rAOM and COME. Our data correlate with the findings of Stol et al., who investigated bac-
terial colonization and infection in the nasopharynx and middle ear of the same prospec-
tive cohort of children and found no clear-cut differences in the microbial flora present in 
middle ear fluids obtained during rAOM and COME disease.
 In summary, the levels of antigen-specific serum IgG and MEF IgG / IgM / IgA 
showed extensive inter-individual variation in our rAOM and COME cohort of children, with 
no significant differences between the 2 groups. Both rAOM and COME children pos-
sessed a range of antibodies (IgG, IgA and IgM) against a variety of novel M. catarrha-
lis and S. pneumoniae recombinant proteins, and there were no distinguishing immune 
response profiles observed between the 2 groups. Factors such as Eustachian-tube dys-
function, viral load, and genetic and environmental factors may play a more important role 
in the pathogenesis of rAOM and COME disease than the humoral immune response to 
OM-associated bacterial pathogens.
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Abstract
Nontypeable Haemophilus influenzae (NTHi) is a Gram-negative, human-restricted patho-
gen. Although this bacterium typically colonizes the nasopharynx in the absence of clinical 
symptoms, it is also one of the major pathogens causing otitis media (OM) in children. 
Complement represents an important aspect of the host defense against NTHi. In gen-
eral, NTHi is efficiently killed by complement-mediated killing; however, various resistance 
mechanisms have also evolved. We measured the complement resistance of NTHi isolates 
isolated from the nasopharynx and the middle ear fluids of OM patients. Furthermore, 
we determined the molecular mechanism of NTHi complement resistance. Complement 
resistance was strongly increased in isolates from the middle ear, which correlated with 
decreased binding of IgM. We identified a crucial role for the R2866_0112 gene in comple-
ment resistance. Deletion of this gene altered the lipooligosaccharide (LOS) composition 
of the bacterium, which increased IgM binding and complement-mediated lysis. In a novel 
mouse model of coinfection with influenza virus, we demonstrate decreased virulence for 
the R2866_0112 deletion mutant. These findings identify a mechanism by which NTHi 
modifies its LOS structure to prevent recognition by IgM and activation of complement. 
Importantly, this mechanism plays a crucial role in the ability of NTHi to cause OM.
Importance
Nontypeable Haemophilus influenzae (NTHi) colonizes the nasopharynx of especially 
young children without any obvious symptoms. However, NTHi is also a major pathogen in 
otitis media (OM), one of the most common childhood infections. Although this pathogen 
is often associated with OM, the mechanism by which this bacterium is able to cause 
OM is largely unknown. Our study addresses a key biological question that is highly rel-
evant for child health: what is the molecular mechanism that enables NTHi to cause OM? 
We show that isolates collected from the middle ear fluid exhibit increased complement 
resistance and that the lipooligosaccharide (LOS) structure determines IgM binding and 
complement activation. Modification of the LOS structure decreased NTHi virulence in a 
novel NTHi-influenza A virus coinfection OM mouse model. Our findings may also have 
important implications for other Gram-negative pathogens harboring LOS, such as Neis-
seria meningitidis, Moraxella catarrhalis, and Bordetella pertussis.
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Introduction
Nontypeable Haemophilus influenzae (NTHi) is a Gram-negative bacterial pathogen that 
colonizes the upper respiratory tract of humans, generally in the absence of clinical symp-
toms. However, NTHi is also able to ascend the Eustachian tube to the middle ear and 
cause inflammation, resulting in otitis media (OM) (1). As such, NTHi accounts for almost 
50% of all bacterial OM infections (2). Although acute OM is typically self-limiting, it can 
also lead to important sequelae such as meningitis and permanent hearing loss (3). 
Despite the fact that OM is one of the most common childhood diseases, the molecular 
processes underlying the migration of NTHi from the nasopharynx to the middle ear are 
poorly understood.
 An important part of the innate immune system intended to clear pathogenic bac-
teria is the complement system. Activation of complement leads to a cascade of protein 
activation and deposition of complement factor C3b on the surface of bacteria, including 
NTHi (4), which may result in direct killing through the formation of the membrane-attack 
complex. NTHi strains are generally considered to be sensitive to complement-mediated 
lysis; however, studies have also shown that NTHi possesses complement resistance 
mechanisms, including variation and modifications in its lipooligosaccharide (LOS) com-
position (4). The LOS structure of NTHi consists of three parts: lipid A, an inner core 
comprised of a single 3-deoxy-d-manno-octulosonic acid (Kdo) linked to three heptoses, 
and an outer core containing a heteropolymer of mainly glucose and galactose moieties. 
Additional modifications have also been reported, including sialic acid, N-acetylgalactosa-
mine, and phosphorylcholine (5,6). Variations in the composition of the LOS structure have 
previously been associated with decreased binding of antibodies and reduced comple-
ment deposition and have been suggested to contribute to the development of disease 
(7-11). Recently an important link between the presence of NTHi-specific IgM antibodies 
and colonization of the host was demonstrated (12). Although IgM binding and comple-
ment resistance were shown to play an important role in the lower respiratory tract during 
exacerbation of chronic obstructive pulmonary disease (COPD) by NTHi (10), it remains 
unclear whether similar immune evasion mechanisms are important during OM.
 In this study, we investigated the contributions of IgM binding and complement-
mediated killing of NTHi during OM. We show that NTHi strains isolated from the middle 
ear of children with OM are more complement resistant than are strains isolated from the 
nasopharynx. This decreased susceptibility correlated with decreased binding of IgM to 
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the bacterium. Expression of the R2866_0112 gene is essential for modifying the LOS 
structure, which prevents binding of IgM and confers bacterial resistance to complement-
mediated killing, similar to our observation in clinical isolates. Finally, using a novel NTHi 
OM mouse model, we show that the R2866_0112 gene plays a crucial role in virulence.
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Materials & Methods
Clinical isolates
Children up to 5 years of age who suffered from recurrent acute OM (rAOM) or chronic 
OM with effusion (COME) were enrolled in a retrospective clinical cohort study, which was 
approved by the Committee on Research Involving Human Subjects of the Radboud Uni-
versity Nijmegen Medical Centre (CMO 2007/239, international trial registration number 
NCT00847756). Legal guardians provided written informed consent. Middle ear fluid was 
collected during surgery using a middle ear fluid aspiration system (Kuijpers Instruments, 
Groesbeek, Netherlands), and nasopharyngeal samples were obtained using a cotton 
wool swab (Copan, Brescia, Italy). Middle ear fluid was mixed with 2 ml saline prior to 
bacterial culture and stored at −80°C. Isolates were serotyped using slide agglutination 
(BD Biosciences). All clinical isolates were minimally passaged in vitro (<4 passages).
Bacterial strains
Strains were grown with shaking at 225 rpm in brain heart infusion (BHI; BD Biosciences) 
supplemented with 10 μg/ml hemin (Sigma) and 2 μg/ml β-NAD (Merck), at 37°C and 5% 
CO2. Live bacterial counts were determined by plating serial dilutions in phosphate-buff-
ered saline (PBS) on BHI plates. For mutant libraries and gene deletion mutants, 150 μg/
ml spectinomycin (Calbiochem) was added.
Generation of H. influenzae R2866 transposon mutant library
Genomic DNA was isolated with Genomic-tip 20/G (Qiagen) as described previously (29). 
The H. influenzae marinerT7 transposon mutant library was generated as described previ-
ously for S. pneumoniae (13) with plasmid pGSF8 as a donor of the marinerT7 transposon 
conferring spectinomycin resistance. Mutagenized genomic DNA was introduced into the 
bacterium with the M-IV transformation method (30).
Identifying genes involved in complement resistance
Genes involved in resistance to complement-mediated killing were identified by GAF 
(13,14). A volume of 0.1 ml (1 × 108 CFU/ml), containing approximately 30,000 unique 
mutants of the R2866 strain, was added to 0.4 ml of 50% normal human serum (NHS; GTI 
Diagnostics) or heat-inactivated (20 min, 56°C) NHS in phosphate-buffered saline (PBS) 
containing 0.1% gelatin (PBSG). Volumes of 100 μl were taken at 0, 30, and 60 min of 
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incubation at 37°C; diluted directly in 5 ml of supplemented BHI (sBHI); and cultured for 
4.5 h. The GAF experiment was performed on two independent days in duplicate.
 GAF readout was performed essentially as described previously, with some minor 
modifications (13). Chromosomal DNA was digested with HpyCH4V (New England Bio-
labs). Two micrograms of Cy3-labeled cDNA was hybridized to custom-made H. influen-
zae R2866 GAF Nimblegen microarrays. Probe signals were normalized using Analysis of 
NimbleGen Arrays Interface Suite (ANAIS) (31). Probes with >2.0-fold probe signal differ-
ences and a Bayesian P value of <0.001 (http://cybert.microarray.ics.uci.edu) were set as 
underrepresented following the challenge.
Generation of NTHi directed gene mutants
Targeted gene deletion mutants of NTHi were generated by allelic exchange of the target 
gene with an antibiotic resistance marker, as described previously for S. pneumoniae (14). 
DNA was introduced into the bacterium with the M-IV transformation method (30). All prim-
ers (Biolegio, Nijmegen, Netherlands) used in this study are listed in Table S1 in the sup-
plemental material.
qRT-PCR
RNA was extracted from mid-log-phase-grown NTHi clinical isolates by using the RNeasy 
minikit (Qiagen) and was DNase treated (Ambion). One microgram of cDNA was synthe-
sized using the SuperScript III reverse transcriptase kit (Invitrogen). Quantitative reverse 
transcription-PCR (qRT-PCR) was performed in a 20-μl reaction mixture with SYBR green 
PCR Master Mix (Applied Biosystems) on a 7500 Fast Real-Time PCR system (Applied 
Biosystems). The gyrA, rpoA, and frdB genes were used as the internal standard genes for 
GeNorm normalization (32).
R2866 expression microarray analysis
RNA was extracted from mid-log-phase-grown NTHi R2866 wild-type or R2866∆0112 
mutant cells by using the RNeasy minikit (Qiagen) and was DNase treated (Ambion). Cy3-
labeled cDNA was obtained according to the Nimblegen array user’s guide (http://www.
nimblegen.com/products/lit/NG_Expression_Guide_v5p1.pdf). Two micrograms of Cy3-
labeled cDNA was hybridized to custom-made H. influenzae R2866 expression Nimblegen 
microarrays. Probe signals were normalized using Analysis of NimbleGen Arrays Interface 
Suite (ANAIS) (31). Genes with a >2.5-fold signal difference and a Bayesian P value of 
<0.001 (http://cybert.microarray.ics.uci.edu) were selected to be significantly regulated.
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Flow cytometric analysis
Hanks’ buffered salt solution (HBSS) without Ca2+/Mg2+, containing 5% (vol/vol) heat-inac-
tivated fetal calf serum, was used for all dilutions and washes. Surface opsonization with 
serum was performed by incubating bacteria in 5% heat-inactivated pooled human serum 
for 1 h at 37°C with 5% CO2. Bacteria were fixed in 2% paraformaldehyde, and surface-
bound IgM or IgG was detected using anti-human IgG- or IgM-fluorescein isothiocyanate 
(FITC)-conjugated antibodies (Sigma) by flow cytometry using a FACSCalibur cytometer 
(BD Biosciences). Data were analyzed using FlowJo version 7.6.3.
Serum IgM depletion
Five milliliters of 20% NHS was incubated with 500 μl of PBS-washed Sepharose beads 
coupled to anti-human IgM antibody (Sigma). After 2 h of incubation on a rotating wheel 
at 4°C, Sepharose beads were removed by centrifugation, and sera were diluted to 10% 
with PBS and immediately stored at −80°C.
Complement resistance assays
All experiments were conducted with the same batch of pooled human serum obtained 
from GTI Diagnostics (catalogue no. PHS-N100). Complement resistance of the NPS and 
MEF isolates was determined with 5% NHS or heat-inactivated NHS as described previ-
ously (10). The complement resistance of NTHi R2866, 3655, 86-028NP, Rd, 1521062, 
∆lgtC mutant, and ∆0112mutant strains was determined as described previously (15). To 
determine the contribution of IgM, complement resistance was determined in 5% IgM-
depleted serum. For competition experiments, wild-type and mutant bacteria were mixed 
in a 1:1 ratio, and serum was added as described above. The competitive index (CI) score 
was calculated by dividing the output ratio of the CFU counts of the mutant to those of the 
wild type by the input ratio of the mutant to the wild-type bacteria.
LOS analysis by Tris-Tricine SDS-PAGE
LOS was prepared by the proteinase K-ethanol precipitation method as described previ-
ously (33). LOS samples were separated on a Tris-Tricine SDS-PAGE gel in a Protean II XI 
cell electrophoresis system (Bio-Rad) and visualized by silver staining (34) or transferred to 
nitrocellulose for Western blotting. Membranes were blocked with 5% bovine serum albu-
min (BSA) in PBS, incubated for 2 h with 2% NHS in PBS, and subsequently incubated 
with goat anti-human IgM coupled to horseradish peroxidase (HRP) in PBS (1:5,000). The 
intensity of IgM binding to LOS bands was calculated using ImageJ software (35).
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Structural characterization of LOS glycoforms by mass spectrometry
LOS was extracted from lyophilized bacteria using phenol-chloroform-light petroleum as 
described previously (36). LOS preparations and LC-ESI-MS experiments were performed 
as described previously (37,38) on a Waters 2690 high-pressure liquid chromatography 
(HPLC) system (Waters, Milford, MA) coupled to a Finnigan LCQ ion trap mass spectrom-
eter (Finnigan-MAT, San Jose, CA). A microbore C18 column [Phenomenex Luna; 5-μm 
C18(2) column; 150 by 0.5 mm; Torrance, CA] was used with an eluent gradient consist-
ing of 0.1 mM sodium acetate and 1% acetic acid in methanol as eluent A and 0.1 mM 
sodium acetate and 1% acetic acid in H2O. Gradient elution was conducted as follows: 
50% A at 0 min, 54% A at 15 min, 100% A at 35 min, 54% A at 55 min, and 50% A at 65 
to 75 min. The flow rate was 0.018 ml/min. Average mass units were used for calculation 
of molecular weight values providing the basis for proposed compositions: hexose (Hex), 
162.14; N-acetyl-hexosamine (HexNAc), 203.19; heptose (Hep), 192.17; reduced anhydro-
Kdo (AnKdo-ol), 222.20; Me, 14.03; Na, 22.99. Relative abundance was estimated from 
the height of the ion peaks relative to the total (expressed as percent).
Influenza virus-NTHi coinfection mouse model
Six- to 8-week-old female, specific-pathogen-free (SPF) BALB/c mice (Harlan, Nether-
lands) were infected intranasally (i.n.) with 104.5 PFU of egg-grown influenza virus strain 
A/Udorn/302/72 in a volume of 10 μl or a similar dilution of naive allantoic fluid (17). 
Three days later, mice were challenged with 5 × 107 CFU in 10 μl PBS of either the 
wild-type 1521062 strain alone or a 1:1 mixture of 1521062 wild-type and mutant strains. 
At 48 and 96 h following challenge with NTHi, mice were euthanized and perfused with 
PBS by intracardiac injection. The entire bulla from each ear was dissected, after which a 
nasopharyngeal lavage was performed. Bullae were immediately homogenized (T10 basic 
Ultra-turrax; IKA), and serial dilutions of bulla homogenates and nasopharyngeal lavages 
were prepared in PBS and cultured on sBHI agar with or without 150 μg/ml of spectino-
mycin (Calbiochem) (39). The CI score was calculated as described above. All animal 
experiments were approved by the Animal Ethics Committee of the Radboud University 
Nijmegen Medical Centre (RU-DEC2-11-246).
Statistical analysis
All statistical analyses were performed in GraphPad Prism version 4.0 for Windows (Graph-
Pad Software, San Diego, CA), where P < 0.05 was considered significant.
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Results 
NTHi isolates from MEF display increased complement resistance
NTHi isolates were obtained from middle ear fluid (MEF) and nasopharyngeal swab (NPS) 
samples collected from children with OM. Isolates collected from MEF (n = 22) were sig-
nificantly more resistant to complement-mediated killing than were isolates collected from 
the nasopharynx (n = 24) (Fig. 1A). To rule out potential attenuation by in vitro culture, 
we passaged complement-resistant isolates for 5 generations in the absence of serum. 
Subsequent analysis of complement resistance showed no significant changes, suggest-
ing that the phenotype of these minimally passaged strains reflects their in vivo phenotype 
(data not shown).
 To investigate the mechanism by which NTHi was killed by serum, we measured 
surface binding of IgM and IgG. We found that serum-sensitive isolates (<10% survival) 
showed increased IgM binding compared to complement-resistant isolates (>10% surviv-
al) (Fig. 1B). This difference was not observed for the binding of IgG (Fig. 1B). The amount 
of IgM binding correlated with the ability of serum to kill the NTHi isolates (Fig. 1C), imply-
ing an important role for IgM in activating the classical complement pathway.
Figure 1. Determination of the complement resistance and IgM binding of clinical NTHi iso-
lates. (A) Survival of MEF (n = 22) and NPS (n = 24) isolates was determined in 5% normal 
human serum and expressed as percent survival compared to that in 5% heat-inactivated 
human serum for 60 min. (B) Serum IgG and IgM binding on 25 serum-sensitive and 21 
complement-resistant NTHi isolates was determined by flow cytometry. Statistical significance 
was determined with an unpaired t test with Welch’s correction. *, P < 0.05; **, P < 0.01. 
(C) Correlation between complement resistance and IgM binding.
A B C
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Table 1. Top list of genes identified in the serum resistance GAF screen at 30 min
Fold 
difference Bayes, P
R2866
gene name R2866 locus tag R2866 annotation
-194.5 <1.00E-16 R2866_0112 Conserved hypothetical protein
-83.2 <1.00E-16 lpsA2 R2866_1629 Lipooligosaccharide glucosyltransferase LpsA
-16.0 <1.00E-16 lic2A R2866_0033 Lipooligosaccharide biosynthesis protein Lic2A
-12.3 <1.00E-16 galE R2866_0222 UDP-glucose 4-epimerase
–10.6 1.11E-16 R2866_0369 Conserved hypothetical protein
-9.6 3.35E-11 bolA R2866_0424 Morphology-related protein BolA
R2866_0425 Lipoprotein, putative
-9.4 <1.00E-16 lgtF R2866_1822 UDP-glucose-lipooligosaccharide beta 1-4 glucosyltransferase
-9.2 <1.00E-16 lgtc R2866_0326 1,4-Alpha-galactosyltransferase (LgtC)
-8.5 2.83E-06 R2866_1530 Hypothetical protein
-6.2 7.52E-07 rfbB R2866_1509 dTDP-glucose 4,6-dehydratase
-4.9 <1.00E-16 galU R2866_1581 Glucose-1-phosphate uridylyltransferase
-4.3 3.14E-09 rfaD R2866_1286 ADP-L-glycero-D-mannoheptose-6-epimerase
-4.0 3.04E-13 tex R2866_0016 Probable transcription accessory protein Tex
-3.9 2.44E-15 lpt6 R2866_0303 PE-tn-6–lipooligosaccharide phosphorylethanolamine transferase
-3.9 5.78E-07 waaQ R2866_0055 ADP-heptose–lipooligosaccharide heptosyltransferase III
-3.9 9.28E-09 hgpB R2866_1813 Hemoglobin and hemoglobin-haptoglobin binding protein B
-3.9 1.60E-07 licA R2866_1070 Phosphorylcholine kinase LicA
-3.8 <1.00E-16 ICE_orf31 R2866_0596 Conserved hypothetical protein p31
-3.6 1.78E-15 R2866_1296 Conserved hypothetical protein
-3.6 1.11E-16 accA R2866_0167 Acetyl coenzyme A carboxylase, subunit alpha
The R2866_0112 gene affects NTHi complement resistance
In order to identify genes affecting IgM binding and complement resistance, the nega-
tive genome-wide screen genomic array footprinting (GAF) was performed (13,14). For 
this screen, the sequenced complement-resistant strain R2866 was used (15). In total, 
57 transposon mutants showed an attenuated phenotype, of which the top 20 most 
attenuated mutants are listed in Table 1. Functional class enrichment analysis showed 
that the majority of the identified genes were involved in LOS biosynthesis (Table 2). The 
R2866_0112 gene, coding for a conserved hypothetical protein, showed the most promi-
nent phenotype, and transcriptional analysis indicated that expression of this gene was 
increased in complement-resistant isolates (Fig. 2A).
 To validate a role for R2866_0112 gene expression in complement resistance, 
we determined survival of the R2866 wild type, the R2866∆0112 mutant, and the 
R2866∆lgtC strain as a control because the lgtC gene has previously been shown to con-
fer complement resistance (8). Furthermore, we included the R2866∆licA mutant because it 
showed a minor phenotype in the GAF screen. The ∆0112 mutant was extremely sensitive 
to complement-mediated killing compared to the wild-type, ∆licA mutant, or ∆lgtC mutant 
strain (Fig. 2B). Heat inactivation of serum abrogated killing of the ∆0112 mutant, which 
showed that the bactericidal activity was dependent on the action of the complement path-
way (Fig. 2B). A polar effect of the R2866_0112 gene deletion was excluded by microarray 
data analysis of the R2866 wild type and the ∆0112 mutant (Table 3). Besides the expres-
sion of R2866_0112 (251-fold decrease), a minor decrease in expression was observed 
for the hemoglobin and hemoglobin-haptoglobin binding protein B gene (hgpB), as was 
an increase in expression of gene locus R2866_1095—R2866_1101. However, the altered 
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expression of hgpB and gene locus R2866_1095—R2866_1101 was not involved in com-
plement resistance because deletion did not alter the complement-sensitive phenotype of 
the ∆0112 mutant (Fig. 2C). To confirm the importance of this gene for complement resist-
ance in other NTHi strains, we also deleted the R2866_0112-homologous gene from NTHi 
Rd, 3655, 86-028NP, and 1521062. All mutant strains showed strongly reduced comple-
ment resistance compared to their respective parental strain, albeit complement resistance 
levels varied extensively (Fig. 2D to G).
R2866_0112 gene expression alters the LOS structure
As our results (Table 2), as well as previous reports, suggested an important role for 
LOS in complement resistance, we determined whether deletion of the R2866_0112 gene 
affected the LOS composition. As a control, the ∆lgtC mutant was included because previ-
ous reports showed an altered LOS structure for this mutant in the R2866 strain (8, 16). 
The ∆0112 mutant showed a different LOS migration pattern than did the R2866 wild type 
and ∆lgtC mutant (Fig. 3A), suggesting that the R2866_0112 gene affects LOS biosynthe-
sis. Deletion of the R2866_0112-homologous gene from NTHi Rd, 3655, 86-028NP, and 
1521062 also altered the LOS migration pattern, which confirms a conserved function for 
this gene.
Table 3. R2866 and R2866∆0112 mutant gene expression array resultsa
R2866 locus tag R2866 annotation
R2866 wild-type 
array signal
R2866∆0112
array signal Bayes, P
Fold difference
R2866_0112 Conserved hypothetical protein 5,345 21 <1.00E-16 -251.3
R2866_1813 Hemoglobin and hemoglobin-haptoglobin binding protein B 5,312 1,249 <1.00E-16 -4.3
R2866_1095 Putative TPRb protein 302 4,685 <1.00E-16 15.3
R2866_1096 Hypothetical protein 302 6,706 <1.00E-16 21.9
R2866_1097 Putative TPR protein 604 10,290 <1.00E-16 16.7
R2866_1098 Hypothetical protein 308 6,610 <1.00E-16 21.3
R2866_1099 Putative TPR protein 200 9,008 <1.00E-16 44.4
R2866_1100 Hypothetical protein 309 6,792 <1.00E-16 21.7
R2866_1101 Putative TPR protein 297 9,918 <1.00E-16 32.7
a   Genes regulated 2.5-fold with P values of <0.001 are included in the table.
b   TPR, tetratricopeptide repeat.
Table 2. Database for annotation, visualization, and integrated d  iscovery (DAVID) analysis
Functional annotation P value Fold enrichment
Lipopolysaccharide biosynthesis 2.40E-05 27.4
Cell outer membrane 7.09E-04 11.9
Glycosyltransferase 1.00E-05 10.1
Signal 9.74E-05 5.9
Cell membrane 1.96E-04 2.8
Membrane 0.001 2.5
Transferase 0.007 2.2
Hexl-Hepl-AnKdo-ol
             HepII
             HepIII
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Figure 3. The R2866_0112 gene deletion mutant expresses an altered LOS structure. (A) 
LOS analysis of R2866, ∆0112 mutant, and ∆lgtC mutant strains by Tris-Tricine SDS-PAGE 
and silver staining. (B and C) Outer membrane stability of R2866 wild type and mutant as 
determined by sensitivity to EDTA (n = 5) (B) or polymyxin B (n = 8) (C). Statistical signifi-
cance was determined with a one-way analysis of variance and the Tukey post hoc test or 
a with a two-way analysis of variance and the Bonferroni post hoc test, respectively. OD620, 
optical density at 620 nm; NS, not significant.
Table 4. Positive-ion ESI-MS data and proposed compositions for glycoforms in dephos-
phorylated and permethylated oligosaccharide derived from NTHi strains R2866 and 
R2866∆0112a
Relative Abundance (%)
[M + Na+] R2866 R2866∆0112 Proposed composition
2,736 Trb Hex7 ⋅ Hep4 ⋅ AnKdo-ol
2,369 9 HexNAc ⋅ Hex4 ⋅ Hep4 ⋅ AnKdo-ol
2,166 8 HexNAc ⋅ Hex3 ⋅ Hep4 ⋅ AnKdo-ol
2,124 19 Hex4 ⋅ Hep4 ⋅ AnKdo-ol
2,080 10 9 Hex5 ⋅ Hep3 ⋅ AnKdo-ol
1,920 13 5 Hex3 ⋅ Hep4 ⋅ AnKdo-ol
1,876 21 7 Hex4 ⋅ Hep3 ⋅ AnKdo-ol
1,716 9 Hex2 ⋅ Hep4 ⋅ AnKdo-ol
1,672 6 6 Hex3 ⋅ Hep3 ⋅ AnKdo-ol
1,521 8 27 Hex1 ⋅ Hep4 ⋅ AnKdo-ol
1,468 5 Hex2 ⋅ Hep3 ⋅ AnKdo-ol
1,265 5 35 Hex1 ⋅ Hep3 ⋅ AnKdo-ol
a The major ions are depicted in bold. All glycoforms contain Hep3 ⋅ AnKdo-ol. Points of elongation appear from HexI 
and/or HepIII in the following structure: 
b Tr, traces.
A B C
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 Although changes in LOS structure may directly affect complement resistance by 
changing membrane stability, this was not the case for the ∆0112 mutant because the 
mutant and wild-type strains showed similar sensitivities to EDTA (Fig. 3B), which inter-
rupts intermolecular associations between LOS phosphate groups (10). Also, sensitivity to 
polymyxin B, which increases membrane permeability, was equal for the R2866 wild-type 
and ∆0112 mutant strains (Fig. 3C). Liquid chromatography-electrospray ionization-mass 
spectrometry (LC-ESI-MS) analysis of the LOS showed that both the R2866 wild-type and 
∆0112 mutant strains contained a conserved inner-core triheptosyl moiety and belong to 
a group of NTHi strains expressing a heptose (HepIV) in the outer core (5). The R2866 
wild-type LOS showed major ions at m/z 2124 and 1876, whereas the spectrum of the 
∆0112 mutant showed smaller major ions at m/z 1521 and 1265 (Table 4). In conclusion, 
the LOS structure of the ∆0112 mutant strain showed various truncations, a finding which 
corresponds to the altered migration pattern (Fig. 3A).
Complement activation is dependent on direct binding of IgM to NTHi LOS
Because our primary observation in clinical isolates showed a correlation between IgM 
binding and complement resistance, we also determined IgG and IgM binding to the R2866 
wild type and the ∆0112 mutant. No significant change in IgG binding was observed. How-
ever, the ∆0112 mutant showed a ~2-fold increase in IgM binding (Fig. 4A). Binding of 
IgM to the bacterial surface was essential for killing the ∆0112 mutant, as depletion of IgM 
from serum completely prevented killing (Fig. 4B). The reduced killing of the ∆0112mutant 
with IgM-depleted serum was not due to decreased bactericidal activity, because an NTHi 
strain dependent on C-reactive protein (CRP)-mediated complement activation was killed 
equally as well with normal serum as with IgM-depleted serum (data not shown). Sera 
with different levels of IgM showed a strong correlation between IgM binding and killing 
of the bacteria, confirming the essentiality of IgM in complement-mediated killing of the 
∆0112 mutant (Fig. 4C).
 To determine whether IgM directly recognizes the LOS of NTHi, Western blot experi-
ments were performed. While IgM predominately binds to the lower band of the wild-type 
LOS, IgM also binds strongly to the truncated LOS band of the ∆0112 mutant (Fig. 4D). The 
∆0112 mutant LOS bound ~2-fold-more IgM than did the R2866 wild-type LOS (Fig. 4E), 
which corresponds to the flow cytometry results (Fig. 4A). Also, the ∆lgtC mutant showed an 
increase in IgM binding, although not significant (Fig. 4E). Furthermore, we determined IgM 
binding to 4 complement-resistant and 4 complement-sensitive isolates. In accordance with 
the data for the complement-sensitive ∆0112 mutant, LOS from complement-sensitive isolates 
bound significantly more IgM than did LOS from complement-resistant isolates (Fig. 4F and G).
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Figure 4. IgM binds R2866∆0112 mutant LOS directly. (A) Serum IgG and IgM binding on 
R2866 and ∆0112 mutant as determined by flow cytometry (n = 9). Statistical significance 
was determined with an unpaired t test with Welch’s correction. (B) Complement resistance 
of R2866 and ∆0112 mutant strains was determined in heat-inactivated NHS (HI-NHS), NHS, 
or IgM-depleted serum (n = 4). Statistical significance was determined with a one-way analy-
sis of variance and the Tukey post hoc test. (C) Correlation between ∆0112 mutant serum 
survival and IgM binding. (D and F) Direct binding of IgM to LOS was analyzed by silver 
staining (loading control) and Western blotting. (E) Relative IgM binding to LOS of R2866, 
∆0112, and ∆lgtC mutant was calculated (n = 3). (G) Signal intensities in arbitrary units (AU) 
of IgM binding to LOS of clinical isolates were calculated (n = 4). Statistical significance 
was determined with a one-way analysis of variance and the Tukey post hoc test or with an 
unpaired t test. *, P < 0.05; **, P < 0.01; NS, not significant.
D
A B C
E
F G
page            102 | IgM binding determines complement resistanceChapter 5
Figure 5. The R2866_0112 gene mutant shows decreased virulence in a murine coinfection 
otitis media model. Mice were inoculated with 104.5 PFU of influenza A virus (IAV) or mock 
treated 3 days before intranasal infection with 5 × 107 CFU of NTHi. (A and B) CFU counts in 
the nose (A) or the middle ears (B) were determined 48 and 96 h postinfection (n = 10). (C, 
D, F, and G) Mice were infected with 104.5 PFU of IAV 3 days before intranasal infection with 
a 1:1 ratio of NTHi 1521062 wild type (WT) and the R2866_0112 mutant (5 × 107 CFU total). 
CFU counts in the nose (C and D) or the middle ears (F and G) were determined 48 and 
96 h postinfection (n = 10). Statistical significance was determined with a Mann-Whitney test. 
(E and H) CI scores were calculated. Statistical significance was determined with a one-way 
analysis of variance and the Tukey post hoc test. **, P < 0.01; ***, P < 0.001.
A B
C D E
F G H
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Deletion of the R2866_0112 gene attenuates colonization and otitis media
Although the ∆0112mutant was significantly less resistant to complement-mediated lysis, 
the consequences with regard to host colonization and/or OM remain uncertain. Because 
NTHi by itself does not infect mice efficiently, we adapted our previously described murine 
model of influenza A virus (IAV)-Streptococcus pneumoniae coinfection (17). In these 
experiments, mice are primed first with influenza virus or mock treated and subsequently 
challenged with NTHi. For these experiments, we used NTHi strain 1521062, which we had 
previously used in animal experiments. Infection of mice with IAV significantly increased 
the number of NTHi bacteria in the nose at both 48 h and 96 h postchallenge (Fig. 5A). 
Importantly, IAV infection also facilitated replication of NTHi in the middle ears (Fig. 5B).
 Similar to R2866, deletion of the R2866_0112 gene from the NTHi 1521062 strain 
(designated the 1521062 mutant) attenuated complement resistance. IAV-NTHi coinfec-
tion experiments with a 1:1 mixture of the wild type and the mutant strain showed that the 
mutant was strongly outcompeted by the wild type. The mutant strain was attenuated in 
the nasopharynx as well as the middle ears, both at 48 h and at 96 h (Fig. 5C to H), sug-
gesting that clearance of the mutant strain already occurs early during infection. Interest-
ingly, although the CFU counts of the wild type in the nose decreased slightly from 48 h to 
96 h, the CFU counts in the middle ears increased, suggesting that there is local bacterial 
replication in the middle ear cavity. In summary, these data demonstrate an important in 
vivo role for the R2866_0112 gene in complement resistance and bacterial pathogenesis.
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Discussion
Although NTHi is generally sensitive to complement-mediated killing, some strains have 
developed immune evasion mechanisms that aid in colonization and disease. Previous 
data from animal models suggest that the complement system comprises an important 
aspect of the host defense against NTHi. For instance, depletion of complement by cobra 
venom resulted in the development of otitis media in chinchillas by “avirulent” NTHi strains 
(18). Recently, it was shown that NTHi isolates from the lower respiratory tract exhibit 
increased complement resistance compared to colonizing strains (10). Here, we provide 
strong evidence that NTHi strains isolated from the middle ears of children suffering from 
otitis media are more resistant to complement-mediated killing than are nasopharyngeal 
isolates.
 The observation that bacterial isolates from the middle ear cavity show increased 
complement resistance may be explained by at least two mechanisms. One explanation is 
that the local inflammatory environment determines the bacterial phenotype of OM strains. 
Evidence to support this mechanism is the observation that serial passage of a serum-
sensitive NTHi strain in the presence of active complement increased its complement 
resistance (10). This is particularly relevant in the context of OM, since large quantities of 
complement factors are present in the middle ears during inflammation of the middle ear 
(19,20). An alternative hypothesis is that only complement-resistant NTHi isolates are able 
to cause OM, which implies the existence of “colonizing” and “otitis media” genotypes. 
Despite a very high level of genetic heterogeneity among NTHi strains, especially for LOS 
synthesis-related genes (5), clinical isolates causing inflammatory diseases, including OM, 
display a distinct genetic profile that confers increased complement resistance (21). Future 
experiments that investigate whether these OM isolates are equally efficient at colonizing 
the mucosal surfaces of the nasopharynx, and whether this changes in the presence of 
inflammation (e.g., due to a viral infection), may shed more light into when and how NTHi 
requires complement resistance. Various modifications in the NTHi LOS structure have 
previously been described to contribute to complement resistance. Modification of LOS 
by the phase-variable LOS synthesis gene lgtC has been shown to delay C4b deposi-
tion on the bacterium, resulting in increased complement resistance (8). Another strategy 
used by NTHi is the incorporation of sialic acid in LOS, which also confers protection 
against complement attack (9) and leads to prolonged survival in the middle ear cavity 
in a chinchilla model (22). In this study, we identified a complement evasion mechanism, 
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which is dependent on the R2866_0112 gene. This gene was also identified in a comple-
ment resistance screen by Nakamura et al. (10), and transposon mutants of Rd showed 
decreased growth or survival in the mouse lungs (23). The R2866_0112 gene is highly 
conserved in all NTHi strains sequenced to date, and deletion of the homologous genes 
from all NTHi strains that we tested resulted in a dramatic decrease in complement resist-
ance. Here, we demonstrate a role for the R2866_0112 gene in LOS structure synthe-
sis. The high number of truncated glycoforms in LOS of mutant strains lacking this gene, 
together with the absence of one dominant LOS glycoform, suggests that the R2866_0112 
gene is not a transferase involved in LOS synthesis directly. Identifying the specific function 
of this gene remains the subject of ongoing investigation.
 Interestingly, the R2866_0112 gene mutant showed an increase in IgM binding, 
which was essential for complement-mediated killing. This was also observed for the clini-
cal isolates, in which IgM binding correlated with complement resistance. Another study 
focusing on COPD also reported decreased binding of IgM to complement-resistant NTHi 
isolates from the lower respiratory tract (10), and recently, Micol et al. showed that patients 
with hyper-IgM syndrome were protected from NTHi colonization but not from other res-
piratory pathogens (12). Our results and these studies both point to an essential function 
for IgM in the recognition of NTHi. Consequently, increasing the level of bactericidal IgM 
antibodies, either by therapeutic administration or by vaccination, may effectively reduce 
NTHi colonization as well as disease. Such a strategy may be highly effective, as an initial 
study using a detoxified NTHi LOS protein conjugate vaccine already showed protection in 
a chinchilla and mouse model of OM (24, 25).
 To assess the importance of the R2866_0112 gene for in vivo virulence, we made 
use of a novel murine IAV-NTHi coinfection model. Here, we show that coinfection of mice 
with IAV and NTHi results in enhanced bacterial colonization and progression to OM, 
similar to S. pneumoniae (17,26,27). A competition experiment between a wild-type strain 
and a mutant strain lacking the R2866_0112 gene resulted in a strong attenuation of the 
mutant in both colonization and survival in the middle ears at 48 h and 96 h. The exact 
mechanism by which mice clear NTHi is currently unclear. Because we used naive mice, 
polyspecific natural IgM antibodies may play an important role in this bactericidal effect. A 
similar effect of natural IgM was observed by Zola et al. (28), who found a role for these 
antibodies in limiting NTHi colonization in mice. Interestingly, in our study, the mutant was 
attenuated not only in the middle ears but also in the nasopharynx, implying similar clear-
ance mechanisms in the middle ears and the nasopharynx. One possibility is that the pri-
mary infection with IAV allows for abundant complement components to be present at the 
mucosal surface of the nasopharynx, thereby providing selective pressure. Although the 
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exact mechanism by which IAV allows NTHi to replicate in either the nasopharynx or the 
middle ear cavity remains currently unclear, these data point to an important in vivo role for 
the R2866_0112 gene in complement resistance and the development of OM.
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Abstract
Otitis Media (OM) is one of the most frequent diseases in childhood, and Streptococcus 
pneumoniae is among the main causative bacterial agents. Since current experimental 
models used to study the bacterial pathogenesis of OM have several limitations, such as 
the invasiveness of the experimental procedures, we developed a non-invasive murine OM 
model.  
 In our model, adapted from previously developed rat OM model, a pressure cabin is 
used in which a 40kPa pressure increase is applied to translocate pneumococci from the 
nasopharyngeal cavity into both mouse middle ears. Wild-type pneumococci were found 
to persist in the middle ear cavity for 144 hours after infection, with a maximum bacterial 
load at 96 hours. Inflammation was confirmed at 96 and 144 hours post infection by IL-1β 
and TNF-α cytokine analysis and histopathology. Subsequently, we investigated the con-
tribution of two surface-associated pneumococcal proteins, the streptococcal lipoprotein 
rotamase A (SlrA) and the putative proteinase maturation protein A (ppmA) to experimental 
OM in our model. Pneumococci lacking the slrA gene, but not those lacking the ppmA 
gene, were significantly reduced in virulence in the OM model. Importantly, pneumococci 
lacking both genes were significantly more attenuated than the ∆slrA single mutant. This 
additive effect suggests that SlrA and PpmA exert complementary functions during experi-
mental OM.
 In conclusion, we have developed a highly reproducible and non-invasive murine 
infection model for pneumococcal OM using a pressure cabin, which is very suitable to 
study pneumococcal pathogenesis and virulence in vivo.
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Introduction
In the first 3 years of life, otitis media (OM) affects 80% of the pediatric population (1). 
Streptococcus pneumoniae, together with non-typeable Haemophilus influenzae and 
Moraxella catarrhalis, is considered to be one of the three major bacterial pathogens 
involved in OM (2-5). OM is the most common reason for children to visit a physician, to 
receive antibiotics or to undergo surgery, which, consequently, results in a high disease 
burden for both children and their parents. Treatment with antibiotics remains controversial 
and is complicated by the rising numbers of isolates resistant to antibiotics (6,7). Despite 
the significant burden of OM on public health, the genetic basis of bacterial OM remains 
largely unclear (8).
 Multiple animal models have been developed to study various aspects of the OM 
disease process, to increase our understanding of OM pathogenesis, and design or 
improve preventive and treatment strategies (9). Different methods are used to provoke 
middle ear inflammation in various animal species: models using mice (3,4,9,10), rats (11-
14), gerbils , guinea pigs, chinchillas (15-17), and monkeys (18) have previously been 
described in literature. Among these, mice are increasingly becoming the model of choice 
in otitis media research. BALB/c mice are considered to be most susceptible to experi-
mental AOM (3,11,19,20). 
 Acute otitis media (AOM) can be evoked by the introduction of live or heat-killed 
bacteria, as well as by inflammatory substances (3,4). In most animal models, AOM is 
induced by direct inoculation of live bacteria into the middle ear cavity, either via a tran-
stympanic or a transbullar route. In the transtympanic model, application of the inoculum 
into the middle ear cavity is achieved by direct injection through  the tympanic membrane. 
The transbullar approach consists of a ventral midline incision in the neck under sedation. 
The bulla is exposed after blunt dissection and the middle ear is infected with a bacterial 
suspension using a thin needle through the bony wall (3,5). Another possibility is intra-
nasal inoculation, where initial bacterial colonization occurs in the nasopharynx, which is 
followed by invasion of the middle ear cavity by the pathogen in about 50% of the cases. 
This model resembles the natural route of infection in humans, and colonization of the 
nasopharynx is highly reproducible. However, development of OM after intranasal chal-
lenge is random and, consequently, reproducibility is low (3,4).
 Reproducible induction of OM that maintains the physiological route of infection has 
been achieved successfully in rats by Tonnaer et al. (14). In their model, rats are inoculated 
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intranasally, after which pneumococci are transferred to the middle ear cavity via the Eus-
tachian tube by an increase of atmospheric pressure. In the current study, we significantly 
adapted this model for mice, allowing us to study pneumococcal OM in reproducible and 
consistent fashion. 
 Furthermore, we explored our model to examine the contribution of two surface-
associated pneumococcal proteins to otitis media: the streptococcal lipoprotein rotamase 
A (SlrA) and the putative proteinase maturation protein A (PpmA). SlrA and PpmA share 
homology with two dinstinct families of peptidyl-prolyl isomerases (PPIases). Both surface-
associated proteins are known to play a key role during pneumococcal infection (21,22). 
Previous research has shown a pivotal role of SlrA in adherence, colonization and immune 
evasion, whereas PpmA is involved in invasive disease and colonization of the naso-
pharyngeal cavity (21-23).
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Materials & Methods
Pneumococcal strains and growth conditions 
The pneumococcal strains used in this study are listed in Table 1, and were kindly provi-
ded by B. Henriques-Normark (24). S. pneumoniae was routinely grown in Todd-Hewitt 
broth supplemented with 0.5% yeast extract or on Columbia blood agar (BA) plates at 
37°C and 5% CO2. Prior to mouse infection experiments, bacteria were passaged in mice 
to maintain virulence as described previously (25). Cultures of mouse-passaged S. pneu-
moniae strains were grown to OD620 of 0.2 (mid-exponential phase) and stored in aliquots 
at -80°C in 15% glycerol. For in vivo challenges, aliquots were spun down and bacteria 
were resuspended in sterile PBS containing 1% methylcellulose, a viscous component, in 
order to minimize leakage of inoculum into the lungs (14). When indicated, antibiotics were 
used at the following concentrations: streptomycin, 100 μg/ml; trimethoprim, 25 μg/ml; and 
erythromycin, 4 μg/ml. 
Construction of pneumococcal mutants
To obtain the streptomycin-resistant SME215::rpsL, the rpsL gene encoding a streptomy-
cin-resistant mutant of the ribosomal protein S12 was amplified from D39::rpsL (21) with 
primer pair HBrpsLF (GTACAGGGACGTGCTGACAA) and HBrpsLR (CCCTTTCCTTAT-
GCTTTTGG). The rpsL-PCR product was introduced into SME215 by CSP-1 induced trans-
Table 1. Pneumococcal strains and mutants used in this study.
Strain    
  
S. pneumoniae
D39   
TIGR4(lux)  
PJ1324(lux)   
SME215(lux)
SME215(lux) strep
SME215(lux) ǻslrA
SME215(lux) ǻppmA
SME215(lux) ǻslrA ǻppmA
 Serotype
2
4
6B
19F
19F
19F
19F
19F
Relevant characteristics
-
Tn4001 luxABCDE operon, Kmr
Tn4001 luxABCDE operon, Kmr
Tn4001 luxABCDE operon, Kmr
SME215(lux) derivative, rpsL; Strr
SME215(lux) derivative, ǻslrA; Eryr
SME215(lux) derivative, ǻppmA; Trimr
SME215(lux) derivative, ǻslrA ǻppmA; Eryr Trimr
Reference
NCTC 7466
(42)
(19)
(19;23)
this study
this study
this study
this study
Kmr : Kanamycin resistance; Strr: Streptomycin resistance; Eryr Erythromycin resistance; Trimr: Trimethoprim 
resistance; slrA: streptococcal lipoprotein rotamase A; ppmA: putatative proteinase maturation protein A.
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formation and selection for streptomycin resistance. To delete the slrA gene from SME215, 
the ∆slrA region was amplified from D39∆slrA (21) with primer pair HBslrAF (GTTCCCAA-
GCGAAATATGGA) and HBslrAR (TACACCAGGGCGCTTTATCT). The ∆slrA-PCR product 
was introduced into SME215 by CSP-1 induced transformation and selection for erythro-
mycin resistance. To obtain the SME215∆ppmA strain, a ∆ppmA-PCR region was ampli-
fied from D39∆ppmA (26) with primer pair HBppmAF1 (CTCTTGATGGCTGAACATGC) and 
HBppmAR1 (GCAGCCTACAGCTAGCTTCC). The ∆ppmA-PCR product was introduced 
into SME215 by CSP-1 induced transformation, and trimethoprim-resistant transformants 
lacking the ppmA gene were selected (21,26). The ∆slrA∆ppmA double mutants were con-
structed by transformation of the ∆ppmA-PCR product (amplified with primer pair HBpp-
mAF1 and HBppmAR1) to each ∆slrA mutant and selecting for trimethoprim and erythro-
mycin resistance. Deletion of slrA and ppmA in resulting transformants was confirmed by 
PCR and sequencing.
Mouse strain and disease monitoring
Experiments were conducted with 7-week old, female, specific pathogen free BALB/c mice 
(Harlan, Horst, the Netherlands) after approval was received from the Dutch animal protec-
tion legislation. 
Pressure cabin
The pressure cabin consists of a perspex tube (l 30cm, Ø 15cm) with a fixed perspex wall. 
The perspex wall contains a manometer, an outlet valve, and a valve connected to a cylin-
der filled with compressed air. The removable front door is sealed with a rubber O-ring. Air 
pressure in the cabin can be increased stepwise (0-100 kPa) and monitored precisely (14). 
Mouse otitis media model; single- and co-infection 
Mice were lightly anesthetized with 2.5% (v/v) isoflurane over oxygen (1.5 liter min-1), and 
subsequently, a 10-μl suspension (containing 5×106 CFU bacteria or PBS/1% methylcel-
lulose as control)  was applied onto both nostrils in alternating fashion (single infection 
and co-infection). Mice were placed in supine position with an initial pressure rise set 
at 10 kPa. When the mice mice regained consciousness and the first swallowing move-
ments occurred, pressure was raised 5 kPa / 15 seconds to 40 kPa in order to transfer 
the inoculum to the middle ear cavity. Thereafter, the pressure was lowered stepwise until 
atmospheric pressure was reached again. Pressure increase was evaluated using otomi-
croscopy and the tympanic membrane was scored for tympanic membrane perforation 
and for increased vascularization or bleeding. 
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 For the single infection with respectively S. pneumoniae D39, TIGR4, SME215 
and PJ1324, groups of 5-9 mice were sacrificed at 96 hours post-inoculation. For the 
single infection with S. pneumoniae SME215, groups of 5 mice were sacrificed at 1.5, 48, 
96, and 144 hours post-inoculation. Blood was collected using orbital puncture. The bulla 
enclosing the right middle ear was dissected from the temporal bone and homogenized in 
the presence of 1 ml sterile PBS, as previously described (14,27). Thereafter bacteria were 
recovered from the nasopharynx by flushing the nose with 1 ml of sterile PBS per naris 
and collection at the controlateral side, a modified method from Wu et al. (28). Both lungs 
were extracted and homogenized in 2 ml sterile PBS. Viable counts were determined by 
serial 10-fold dilutions plated on BA plates. 
 For co-infection, a 10-μl inoculum containing a 1:1 ratio of streptomycin-resistant 
S. pneumoniae SME215 wild-type and either the ∆slrA, ∆ppmA, or ∆slrA∆ppmA mutant 
(5×106 total CFU) was used to infect the mice intranasally as described above. Groups 
of 5 mice were sacrificed at 1.5, 12, 48 and 96 hours post-infection, whereupon samples 
from ear, lungs, nasopharynx, and blood were collected as described above. CFU counts 
were determined by plating serial dilutions of the specimens on BA plates and Columbia 
Agar plates supplemented with 5% (vol/vol) defribrinated sheep blood (Biotrading) contain-
ing the appropriate antibiotics. 
 Co-infection reduces variation between individual mice, inoculation preparation 
and distribution, and sample collection. Competitive index (CI) scores were calculated for 
the co-infection experiments as previously described (29). In short, the competitive index 
for each individual animal was calculated as the output ratio of mutant and wild-type divi-
ded by the input ratio of mutant to wild-type bacteria. For experiments in which no mutant 
bacteria were recovered from a particular mouse, the number 20 (lower limit of detection) 
was used as the numerator. Mice with neither mutant nor wild type bacteria in the middle 
ear were excluded from further analysis. 
Histology
The skulls of all mice including both temporal bones, nose, and maxilla were removed and 
processed for histological analysis. The specimens were formalin fixed in 4% paraformalde-
hyde (Sigma Chemical Co. St. Louis, MO) in 0.1 M phosphate buffer (pH 7.4), decalcified 
using 10% EDTA (Serva, Heidelberg), and embedded in paraffin. Subsequently, all skulls 
were cut into 5 mm thick slices in an oblique direction. After deparaffinization through a 
series of xylene and graded ethanol baths sections were stained with haematoxilin-eosin 
(H&E). Sections were photographed with a microscope (Carl Zeiss Axioskop 2 plus) cou-
pled to a computer (ProgRes Capturepro 2.1) at an original magnification of 25× and 200×.
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IL-1β and TNF-α ELISA
Commercially available kits were used to measure the IL-1β (Becton Dickinson, Breda, 
the Netherlands) and TNF-α (U-cytech, Utrecht, the Netherlands) concentrations in murine 
middle ear homogenate and nasopharyngeal lavage. 
Statistical analysis
All data were analyzed using SPSS 16.0 and GraphPad Prism version 4.0. For single infec-
tion a nonparametric test on log-transformed CFU-counts (mean, p<0.05) was used to 
calculate statistical significance. For co-infection the one sample t-test on log-transformed 
CI-scores (with an arbitrary mean of 0 and p <0.01) and comparative regression coef-
ficients were used to calculate statistical significance. 
 Cytokine levels were calculated according to manufacturer’s instructions. A nonpara-
metric test (mean, standard error of the mean and p<0.05) was performed to calculate 
statistical significance between infected and PBS-infected mice at the corresponding time 
points.
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Results 
Development of a non-invasive murine OM model
The pathogenesis of pneumococcal OM involves bacterial translocation from the nasopha-
rynx to the middle ear cavity through the Eustachian tube. In order to translocate bacteria 
in our model, we used a pressure cabin. First, we identified the appropriate pressure in our 
model with Evans blue dye. Pressure increase of 40kPa was sufficient to transfer Evans 
blue dye from the nasopharynx into the middle ear cavity of BALB/c mice, without causing 
damage to the tympanic membrane: otomicroscopy did not show rupture of the tympanic 
membrane, nor vascular dilatation of blood vessels present at the tympanic membrane 
(data not shown). Subsequently, the pressure cabin was used for bacterial infection with S. 
pneumoniae TIGR4 to test various doses and inoculum volumes. A dose of 5×106 CFU in 
a 10 μl volume resulted in reproducible infection, in line with the mouse colonization model 
used in our laboratory (23,30). To examine strain-specific behavior, mice were infected 
with the pneumococcal strains D39 (serotype 2), TIGR4 (serotype 4), PJ1324 (serotype 
6B) and SME215 (serotype 19F). Ninety-six hours after infection mice were euthanized, 
whereupon ear- and lung-homogenates, nose lavage and blood were cultured. S. pneu-
moniae SME215 and PJ1324 induced a median bacterial load in the middle ear of 1×104 
CFU and 5×102 CFU respectively, at 96 hours post-inoculation (Figure 1). OM induced by 
S. pneumoniae TIGR4 was complicated by pneumonia and sepsis (as confirmed by clini-
cal scores and bacterial culture) and consequently excluded for further analysis. Bacterial 
counts in the middle ear and nasopharynx of S. pneumoniae D39 were significantly lower 
compared to S. pneumoniae SME215 (p-value 0.003) and PJ1324 (p-value 0.039). There-
fore, S. pneumoniae PJ1324 and SME215 were considered most suitable for our model. 
No bacteria or signs of inflammation were detected in middle ears of mice inoculated with 
PBS, indicating that transfer of local nasopharyngeal flora does not occur in our model. 
 Since the bacterial load of S. pneumoniae SME215 in the middle ear was signifi-
cantly higher than S. pneumoniae PJ1324 (p-value 0.015), SME215 was used to examine 
the bacterial kinetics in further detail at 1.5, 48, 96 and 144 hours after infection (Figure 
2). Approximately 1×105 CFU were detected in the middle ear cavity at 1.5 hours post 
inoculation, this number declined 50-fold at 48 h post-inoculation. Wild-type pneumococci 
persisted in the middle ear cavity up to 96 h post infection (median 3×104 CFU). The 
bacterial load in the nasopharynx reached 1×106 CFU up to 96 h post-inoculation and 
4×105 CFU at 144 h. The bacterial load initially detected in the lungs was high, 1×106 
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Figure 1. Bacterial load in the middle ear, nasopharyngeal lavage, lungs and blood 96 h 
after inoculation with S. pneumoniae D39 (serotype 2), TIGR4 (serotype 4), PJ1324 (sero-
type 6B) and SME215 (serotype 19F). Each dot represents a single mouse. Mean values 
are re-presented by horizontal bars. The lower limit of detection, 20 CFU, is indicated by a 
dashed line. (A), Bacterial counts in the middle ear; (B), Bacterial counts in the nasopharyn-
geal lavage; (C), Bacterial counts in lung homogenate; (D), Bacterial counts in blood.
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CFU, but declined rapidly over time with 5×102 CFU at 48 h and 6×101 CFU at 96 h post 
inoculation (Figure 2). No bacteria were recovered from blood (data not shown). Weight 
and temperature of the mice maintained within the normal range and importantly, mice did 
not show any signs of invasive disease; in particular no signs of pneumonia and sepsis 
were observed. 
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Figure 2. Bacterial load in the mid-
dle ear (A), nasopharynx (B) and 
lungs (C), after inoculation with S. 
pneumoniae SME215. Each dot rep-
resents one mouse. Mean values are 
indicated by horizontal bars. The low-
er limit of detection, 20 CFU, is indi-
cated by a dashed line. No bacterial 
counts were detected in blood.
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Immunology and histopathology
Both IL-1β and TNF-α levels in the middle ear were elevated throughout the course of 
infection. Importantly, levels in PBS-inoculated mice which were below the detection limit 
at 1,5, 48, 96 h post inoculation and marginal at 144 h post inoculation (TNF- α: 14,5 pg/
ml; IL-1 β 24,4 pg/ml). The levels of TNF-α and IL-1β in the middle ear at 48 h and 96 
h post-inoculation were significantly different from PBS-inoculated mice collected at the 
corresponding time points (Figure 3A and 3B). The TNF-α cytokine levels detected in the 
nasopharynx were 10-fold lower than the levels in the middle ear, and significantly different 
at 48, 96 and 144 h post inoculation when compared to PBS inoculated mice (Figure 3C). 
There was no significant difference between infected and PBS-infected mice concerning 
the IL-1β levels in the nasopharynx (Figure 3D). 
 Histopathological examination showed an increased inflammation over time (Figure 
4). Neutrophils, lymphocytes and macrophages migrated into the ME cavity at 96 and 
144 h post-inoculation (Figure 4 panel C and panel D). The mucous membrane, which 
is normally lined by a single layer of epithelium, by then is covered with a more irregular 
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Figure 3. IL-1β and TNF-α cytokine levels in the middle ear and nasopharynynx. Each bar 
represents the mean value of 5 mice, error bars indicate the standard error of the means. (A) 
TNF-α in the middle ear; (B) IL-1β in the middle ear; (C) TNF-α in the nasopharyngeal lav-
age; (D) IL-1β in the nasopharyngeal lavage. Statistical significance was calculated between 
infected and mock-infected mice at the corresponding time point of collection. Significance 
with a p<0.05 is depicted with *.
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and multiple layered epithelium (Figure 4 panel C, b + c and panel D, b + c). The loose 
connective tissue has expanded significantly, due to the presence of transient wandering 
immune cells that migrate from local blood vessels to the site of infection (Figure 4 panel 
C, b + c and panel D, b + c). 
                                                        page 123A novel murine infection model for otitis media | Chapter 6
Figure 4. Histopathological changes in the middle ear. Sections were photographed at an 
original magnitude of 25× and 200× respectively. (panel A), Normal, non-infected middle ear; 
(panel B), 48 h after intranasal inoculation with S. pneumoniae SME215; (panel C), 96 h after 
intranasal inoculation with S. pneumoniae SME215; (panel D), 144 h after intranasal inocula-
tion with S. pneumoniae SME215. The mucous membrane, which is normally lined by a single 
layer of epithelium (panel A, b + c), by then is covered with a more irregular and multiple 
layered epithelium (panel C, b + c and panel D, b + c). The loose connective tissue (panel A, 
b + c) has expanded significantly, due to the presence of transient wandering immune cells 
that migrate from local blood vessels to the site of infection (panel C, b + c and panel D, b 
+ c). Abbreviations used in this figure: OE, Outer Ear; TM, tympanic membrane; MEC, middle 
ear cavity; MM, mucous membrane; ET, Eustachian tube.
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Usefulness of the murine otitis media model to study pneumococcal virulence
To assess the role of the pneumococcal proteins SlrA and PpmA in OM, we inactivated 
the slrA and ppmA genes in strain SME215 by insertion deletion mutagenesis, and tested 
the wild-type and ∆slrA, ∆ppmA, or ∆slrA∆ppmA mutants in a co-infection setup. Impor-
tantly, no differences in in vitro growth between the wild-type strains and the mutants were 
detected, indicating that differences in virulence did not originate from altered growth rates.
 In the middle ear, the bacterial load of the ∆slrA mutant was significantly lower rela-
tive to the SME215 parent strain at 48 and 96 hours post-infection (mean CI 0.14 and 
0.07 respectively, a 10-fold reduction) (Figure 5A). A significant difference between the 
wild-type and the ∆ppmA mutant was only found at 1.5 hours after infection, not at later 
time points (mean CI 0.47, a 5-fold reduction) (Figure 5C). Deletion of both slrA and ppmA 
resulted in a significant decrease in middle ear bacterial load compared to wild-type at 
all time points: the CI-score declined from 0.26 at 1.5 h post-inoculation to 0.003 at 96 h 
post-inoculation, representing a 3 to 300-fold reduction over time. In other words, the wild-
type outcompeted the double knock out strain in a progressive and statistically significant 
fashion (Figure 5E). Interestingly, we observed an additive effect upon deletion of both 
genes, as the ∆slrA∆ppmA mutant was significantly more attenuated in OM virulence than 
the ∆slrA or ∆ppmA single mutant (Figures 5A, C and E). 
 Colonization of the nasopharynx was highly reproducible, yielding approximately 
5×105 CFU during all time points. Throughout the course of the experiment, the ∆slrA, 
∆ppmA and ∆slrA∆ppmA mutants were less able to colonize the nasopharynx in compari-
son to the parent strain (Figure 5B, D and F). Deletion of slrA resulted in a significant differ-
ence in colonization of the nasopharynx from wild-type at all time points (mean CI varying 
from 0.06-0.14, a 7 to 17-fold reduction ) (Figure 5B). A significant difference between the 
wild-type and the ∆ppmA-mutant was seen at 12 (mean CI 0.70), 48 (mean CI 0.26) and 
96 (mean CI 0.15) hours post-inoculation (Figure 5D). In line with the ∆slrA∆ppmA mutant 
in the middle ear, outcompetition of the double mutant in the nasopharynx was progressive 
and statistically significant over time (CI 0.10 to 0.01, a 10 to 100-fold reduction) (Figure 
5F). Again, the ∆slrA∆ppmA mutant was significantly more attenuated in virulence than the 
∆slrA or ∆ppmA single mutant (Figures 5B,D and F). 
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Figure 5. Competitive index (CI) in the middle (A,C,E) ear and nasopharynx (B,D,F) after co-
infection, using the murine OM model. Female BALB/C mice were infected intranasally with 
a 1:1 mix of S. pneumoniae SME215 wild-type and S. pneumoniae SME215∆slrA (A, B), S. 
pneumoniae SME215 wild-type and S. pneumoniae SME215∆ppmA (C, D) and S. pneumoni-
ae SME215 wild-type and S. pneumoniae SME215∆slrA∆ppmA (E, F). Each square represents 
one mouse. The CI score of 1 (i.e., no difference between wild-type and mutant) is indicated 
by a dashed line. Statistical significance of p<0.01 is depicted by **.
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Discussion
In the present study we developed a novel non-invasive murine OM model with the use 
of a pressure cabin. The mouse affords many advantages for in vivo research, including 
ease of genetic manipulation, availability of inbred and transgenic strains and an exten-
sively studied immune system. Moreover, experimental reagents for cellular and molecular 
studies are widely available (3,4,9,10). The model, which was adapted from a rat OM 
model described by Tonnaer and co-workers (14), was used to investigate OM caused by 
S. pneumoniae and the contribution of the pneumococcal proteins SlrA and PpmA to the 
pathogenesis of OM. 
 For various reasons, the pressure cabin model is an improvement over the experi-
mental AOM models currently used. First, pressure elevation facilitates the ascending 
infection of pneumococci from the nasopharynx to the middle ear cavity via the Eustachian 
tube, resembling the natural route of infection in humans. In comparison to AOM models 
which rely on spontaneous OM development after nasopharyngeal colonization (4), the 
percentage of successful middle ear infections is 100% in our model. This is of major 
importance for future vaccination and challenge studies, since a 100% successful infec-
tion rate is warranted to monitor the efficiency of a vaccine, i.e. reduction of bacterial load. 
Secondly, dermal pathogens like Staphylococcus epidermidis will not influence experimen-
tal results, whereas with the widely used transtympanic or transbullar approaches, a con-
nection between the middle ear and its surroundings is established. Third, an inflammatory 
response due to local manipulation is avoided. Among others, MacArthur et al. described 
signs of inflammation due to direct instillation of PBS in the middle ear that were equivalent 
to those induced by lower doses of heat killed bacteria. These inflammatory reactions were 
ascribed to the required tympanic membrane incision (10;19). 
 Of the pneumococcal strains tested, BALB/c mice were most susceptible to TIGR4 
(serotype 4), followed by SME215 (serotype 19F), PJ1324 (serotype 6B) and D39 (sero-
type 2). These observations indicate pneumococcal strain-specific behaviour in vivo as 
described previously (31,32). S. pneumoniae SME215 and PJ1324 persisted in the middle 
ear cavity for at least 96 h. These two strains were therefore considered suitable for experi-
mental otitis media studies in vivo, and subsequent experiments were performed using S. 
pneumoniae SME215 only. On the day of inoculation with S. pneumoniae SME215, bacte-
ria were detected in the lungs, but they were cleared rapidly over time. We speculate that 
leakage to the lungs can be partially explained by the use of anesthetics and pressure 
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increase at the time of infection. Importantly, disease scores were low during this study, 
which implies absence of pneumonia or sepsis, and - as a result - moribund state or early 
loss did not occur. This is in contrast to current chinchilla OM models, which often record 
a moribund disease state (31). Since signs and symptoms of human OM mostly show a 
mild course of infection (7), we consider our model to be a clinical representative of OM 
in humans. Moreover infection with heat-inactivated bacteria to avoid systemic complica-
tions, as described in OM mouse models using direct tympanic membrane inoculation, 
was not necessary (19). Polymicrobial interactions between for instance, S. pneumoniae, 
(non-typeable) H. influenzae and M. catarrhalis or combined bacterial and viral infections 
are of interest for future studies (2,7,19,33). 
 The primary cytokines TNF-α and IL-1β were selected to monitor the initiation of the 
acute inflammatory response. TNF-α is produced mainly by macrophages or mast cells and 
is, among others, responsible for neutrophil migration (34). Along with various other func-
tions, IL-1β contributes to permanent pathological changes in the middle ear, mucosal dam-
age, bone erosion, fibrosis, and hearing loss. Higher concentrations of IL-1β were observed 
in purulent, acute, culture-positive effusions  (34-36). Our results indicate a peak TNF-α and 
IL-1β response in the middle ear cavity at 96 h post-inoculation, whereas the maximum 
histopathological changes were shown at 144 h post-inoculation. These data confirm ongo-
ing inflammation after onset of the inflammatory process by the primary cytokines: at 144 
h, levels of both TNF-α and IL-1β were comparable to PBS-treated mice, most likely since 
the number of white blood cells were sufficient to eradicate S. pneumoniae from the middle 
ear cavity. Using a rat OM model Cripps et al. reported a maximum TNF-α level of 1.3×103 
pg/ml at 24 h post infection, while IL-1β was not detectable. They also reported cytokine 
levels in a mouse pneumonia model of pneumococcal infection: a maximum TNF-α level 
around 3.0×102 pg/ml at 8 h post infection and maximum IL-1β level near 6.5×102 pg/ml 
at 24 h post-infection (37). However, as immune responses in in vivo experimental models 
are animal-specific, bacterial-strain specific, and infection-site specific, it is difficult to directly 
compare the results. Unlike the strong inflammation in the middle ear (38), there is a relative 
quiescent host response to colonizing pneumococci in the nasopharynx (8), underscored by 
the marginal levels of IL-1β and TNF-α detected in the nasopharyngeal lavage in our study.
 Bacterial surface-exposed proteins often play an important role in the interaction 
between pathogens and their host. Identification of novel surface-exposed proteins that 
play an important role in virulence can improve our understanding of OM pathogenesis 
and will facilitate new preventive strategies such as vaccine development. Virulence stud-
ies described in literature have shown that most pneumococcal mutants display attenu-
ated phenotypes  in either colonization, pneumonia, or sepsis mouse models, thus indicat-
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ing niche-specific involvement in virulence of the respective genes (6-8,8,21,29,38-41). 
 To our knowledge we report the first OM virulence study performed in mice. Only 
very few studies have investigated the role of virulence factors in OM models (8,36,41). 
Chen et al. very nicely demonstrated the first extensive search of genetic requirement for 
pneumococcal OM by using signature tagged mutagenesis in a chinchilla OM model and 
a murine colonization model (8). Since direct extrapolation from other models is problem-
atic given the animal model specificity (8), we examined the contribution of two factors to 
OM and nasopharyngeal colonization directly. We showed that both single gene deletion 
of slrA and combined deletion of the slrA and ppmA genes significantly reduced the bacte-
rial load during experimental AOM in both the nasopharynx and the middle ear compared 
to the wild-type strain. Pneumococci lacking the slrA gene, but not those lacking the ppmA 
gene were significantly reduced in virulence in the OM model. Interestingly, the virulence of 
the pneumococci lacking both genes was significantly decreased compared to the ∆slrA 
or ∆ppmA single mutant. This observation suggests complementary functions of SlrA and 
PpmA in both experimental OM and nasopharyngeal colonization, resulting in an additive 
decrease in virulence when both genes are absent. Previous studies have shown a role for 
both SlrA and PpmA in the early stage of infection, i.e. colonization (21,23). Our results, 
even in a different mouse background and with a different pneumococcal strain, confirmed 
these findings. SlrA is a functional PPI-ase involved in pneumococcal colonization, most 
likely by modulating the biological function of important virulence proteins, as described by 
Hermans et. al. (21). Although PpmA is a conserved surface protein with potential to elicit 
protective immune responses, the exact role of this protein is still unknown (22). 
 In summary, we developed an OM mouse model in which AOM can be established 
by various pneumococcal strains. This highly reproducible method is non-invasive, and 
infection is established in both ears. Consequently, multiple simultaneous applications are 
feasible, such as bacterial culture and histopathology. The model is highly valuable to 
study OM induced by S. pneumoniae and to study OM-related pneumococcal virulence. 
It is likely to be suitable to investigate the protective capacity of putative vaccine antigens 
against pneumococcal induced OM, since the route of infection does not bypass local 
immunity and the middle ear infection rate is 100%. Whether this model is also appropriate 
for other pathogens like H. influenzae and M. catarrhalis is currently under investigation.
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Abstract 
Streptococcus pneumoniae is an important human bacterial pathogen, causing infections 
such as pneumonia, meningitis, septicemia, and otitis media. Current capsular polysac-
charide-based conjugate vaccines protect against a fraction of the over 90 serotypes 
known, whereas vaccines based on conserved pneumococcal proteins are considered 
promising broad-range alternatives. The pneumococcal genome encodes two conserved 
proteins of an, as yet, unknown function, SP1298 and SP2205, classified as DHH sub-
family 1 proteins. Here, we examined their contribution to pneumococcal pathogenesis 
using single and double knock-out mutants in three different strains: D39, TIGR4, and 
BHN100. Mutants lacking both SP1298 and SP2205 were severely impaired in adherence 
to human epithelial Detroit 562 cells. Importantly, the attenuated phenotypes were restored 
upon genetic complementation of the deleted genes. Single and mixed mouse models 
of colonization, otitis media, pneumonia, and bacteremia showed that bacterial loads in 
nasopharynx, middle ears, lungs, and blood of mice infected with the mutants were signifi-
cantly reduced compared to wild-type-infected mice, with an apparent additive effect upon 
deletion of both genes. Minor strain-specific phenotypes were observed, i.e., deletion of 
SP1298 affected host-cell adherence in BHN100 only, and deletion of SP2205 significantly 
attenuated virulence in lungs and blood in D39 and BHN100, but not TIGR4. Finally, sub-
cutaneous vaccination with a combination of both DHH subfamily 1 proteins conferred 
protection to nasopharynx, lungs, and blood of mice infected with TIGR4. We conclude 
that SP1298 and SP2205 play a significant role at several stages of pneumococcal infec-
tion, and, importantly, these proteins are potential candidates for a multicomponent protein 
vaccine.
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Introduction
Streptococcus pneumoniae is a Gram positive bacterium causing serious invasive dis-
eases such as pneumonia, septicemia, and meningitis. In addition, this human pathogen 
is the causative agent of less serious but highly prevalent mucosal infections such as 
otitis media (OM) and sinusitis. Young children under the age of 2 years, the elderly, and 
immunocompromised individuals account for the majority of pneumococcal morbidity and 
mortality observed worldwide (1). One of the main virulence factors of the pneumococcus 
is its polysaccharide capsule of which over 90 serotypes distinct in biochemical structure 
have been identified to date. The polysaccharide capsule contributes to protection against 
phagocytosis, enabling the pneumococcus to evade the immune system of the host 
(2,3). Current pneumococcal vaccines such as Pneumovax 23® (23-valent; Merck, USA), 
Synflorix™ (10-valent; GlaxoSmithKline, UK) and Prevnar® (7- and 13-valent; Pfizer, USA) 
target this polysaccharide capsule. While these vaccines do provide good immune protec-
tion, it is restricted to the serotypes included in the vaccine. As a result, serotype replace-
ment is already occurring and the need for a serotype-independent vaccine is urgent (4;5).
 A promising alternative vaccine approach explores the use of immunogenic, sur-
face-exposed protective proteins. Pneumococci are estimated to express over 100 sur-
face proteins, of which some are known to have a role in pathogenesis and virulence, 
but mostly their function is unknown (6). Among these surface proteins that are currently 
under investigation as vaccine candidates, are the pneumococcal surface proteins A and 
C (PspA and PspC), and the pneumococcal surface adhesin A (PsaA). The choline-bind-
ing proteins PspA and PspC are key virulence factors due to their ability to interfere with 
complement deposition. PspA is expressed by all pneumococci, is highly immunogenic, 
and is an inhibitor of C3 preventing opsonization and hence phagocytosis (7-9). PspC is 
a paralog of PspA which interacts with the complement-inhibitory factor H (10-12). PsaA 
is a metal-binding lipoprotein with specificity for Mn2+ and Zn2+ (13), both essential ions 
for pneumococcal growth and survival. One of the most well-studied proteins is pneumo-
lysin (Ply). Although Ply is not a surface protein, it is an important virulence factor that is 
produced by all known clinical isolates of S. pneumoniae. Ply is a member of the cho-
lesterol-dependent pore-forming toxin family that can directly damage epithelial surfaces 
and reduce the migration of phagocytic PMNs (14). Vaccination studies using the above-
mentioned proteins have shown that they can protect mice from pneumococcal disease 
(15-23). In addition, these studies have clearly demonstrated that combinations of distinct 
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pneumococcal proteins often enhance protection. Although these results are promising, 
there is still a need for additional protein targets to further improve existing experimental 
protein vaccine formulations.  
 Throughout the last decade, many genomic tools have been developed and used to 
identify potential protein vaccine targets, such as transcriptome analysis (24), differential 
fluorescence induction (25), and signature-tagged mutagenesis (STM) (26-28). We recently 
 III FITOM  II FITOM I FITOM 
SP1298 (16) IIIHRHMKPDPDALGSQVGLKALLEHHF (25) DRAYQGALVIVCDTANTARIDDKRYSQG (0) DFLIKIDHHPNDDVYG
SMU1297 (16) IIIHRHMKPDPDALGSQVGLKEMITSNF (25) DKDYEGALVIVVDTANRPRIDDQRYLNG (0) NFLIKIDHHPDEDHYG
YtqI (14) IILHRHVRPDPDAYGSQCGLTEILRETY (25) NETYEGALVIVCDTANQERIDDQRYPSG (0) AKLMKIDHHPNEDPYG
MgORF1 (18) IVIFHHVRPDGDCLGAQQGLFHLIKANF (27) ESFLKEALAIVVDANYKNRIELRELLDK (3) KAVLRIDHHPNEDDLN
MpORF4 (23) IVIFHHIRPDGDCLGAQHGLARLIQTNF (29) PELMQQALAVIVDANYKERIECRDLLDQ (3) KAVLRIDHHPNEDDLN
SP2205 (339) VFVVGHKNLDMDALGSAVGMQLFASNVI (40) GMVTNRSLLILVDHSKTALTLSKEFYDL (1) TQTIVIDHHRRDQDFP
SMU2140 (339) VFVVGHKNLDMDALGASVGMQAFANNII (38) EQVSDNSLLVMVDHSKLQLTLSRELYNK (1) TEVIVIDHHRRDDDFP
YybT (340) VIIMGHKFPDMDSIGAAIGILKVAQANN (39) EISNDDTLLVIVDTHKPSLVMEERLVNK (1) EHIVVIDHHRRGEEFI
Sp_RecJ (71) ENILVYGDYDADGMTSASIVKESLEQLG (25) IEQEGISLIVTVDNGVAGHEAIALAQSM (1) VDVIVTDHHSMPETLP
Ec_RecJ (81) TRIIVVGDFDADGATSTALSVLAMRSLG (25) AHARGAQLIVTVDNGISSHAGVEHARSL (1) IPVIVTDHHLPGDTLP
  VI FITOM   
SP1298 (15) ITLFAQTTQLALADRDAELLFAGIVGDTGRFLYPSTTARTLRLAAYLREH                    
SMU1297 (15) ITDFALQNQLKLSDQAARLLYAGILGDTGRFLYPATTSKTFIIASELLKY                            
YtqI (18) LYLEGKEHGWKLNTKAAELIYAGIVGDTGRFLFPNTTEKTLKYAGELIQY                            
MgORF1 (16) IVEMATVAKWTIPPVAATLLYIGIYTDSNRFLYSNTSYRTLYLAAILYKA                            
MpORF4 (16) VVDLAVQAKWKLSPPAATALYLGIYTDSNRFLYSNTSWRTLYLGSMLYRA                            
SP2205 (21) LIQFQNSKKNRLSRMQASVLMAGMMLDTKNFTSRVTSRTFDVASYLRTRG                            
SMU2140 (21) LLQFQNGK-YHLNKIQASIVMAGIMLDTKSFSTRVTSRTFDVASYLRTLG                            
YybT (21) LLEYQPKR-LKINMIEATALLAGIIVDTKSFSLRTGSRTFDAASYLRAKG                            
Sp_RecJ (40) AFKLACALLEEVQVELLDLVAIGTIADMVSLTDENRILVQYGLEMLGHTQ                    
Ec_RecJ (25) GWFDERNIAIPNLAELLDLVALGTVADVVPLDANNRILTWQGMSRIRAGK                    
Figure 1. Sequence alignment of DHH motifs from selected bacterial DHH subfamily 1 pro-
teins. The number of amino acids not shown in the alignment are depicted in parenthesis. 
Bold black shading indicates conserved residues, grey shading indicates similarity between 
residues. Dashes indicate gaps created to optimize alignment within motifs. Sequences are 
listed in order of similarity to sequence of SP1298. SP1298, S. pneumoniae TIGR4 SP1298; 
SMU1297, S. mutans AU159 SMU.1297; YtqI, B. subtilis YtqI; MgORF1, M. genitalium MG_190; 
MpORF4, M. pneumoniae MPN140; SP2205, S. pneumoniae TIGR4 SP2205; SMU2140, S. 
mutans AU159 SMU.2140c; YybT, B. subtilis YtqI; Sp_RecJ, S. pneumoniae TIGR4 SP0611 
(RecJ); Ec_RecJ, E. coli RecJ.
 FITOM 1AHHD   
SP1298 (70) LWGIFVEQADGHYRVRLRS-KVHPINEIAKE---------HDGGGHPLASGANSYSL (16)
SMU1297 (70) VWAIFVEQADGHYRVRLRS-KSTVINEVAKR---------HAGGGHPLASGANSYSL (15)
YtqI (70) AWVFFVEEDD-QIRVRFRS-KGPVINGLARK---------YNGGGHPLASGASIYSW (18)
MgORF1 (68) IWLFFIEQANNEIRIDLRS-NGINVRDIAIK---------YGGGGHNNASGAIITNK (17)
MpORF4 (68) IWLFFIEEGKNHYRVEFRS-NGINVREVALK---------YGGGGHIQASGAVLKSK (16)
SP2205 (66) ASFVLAKNTQGFISISARSRSKLNVQRIMEE---------LGGGGHFNLAAAQIKDV (23)
SMU2140 (64) ATFVITRNDERTVCISARSRNKINVQRIMEE---------MGGGGHFNLAACQLKGT (24)
YybT (66) ASFAVARRDEQTVCISARSLGEVNVQIIMEA---------LEGGGHLTNAATQLSGI (23)
Sp_RecJ (115) QTVIVLNIEDGRAKGSARSVEAVDIFEALDPHRDLF----IAFGGHAGAAGMTLEVE (137)
Ec_RecJ (124) PVIAFAPAGDGTLKGSGRSIQGLHMRDALERLDTLYPGMMLKFGGHAMAAGLSLEED (318)
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developed Genomic Array Footprinting (GAF), a mutant library-based negative selection 
screen that uses microarrays to identify conditionally essential genes (29,30). We have 
applied the GAF technology to various in vivo animal models of pneumococcal disease, 
i.e. colonization, bacteremia and meningitis, to identify S. pneumoniae genes essential dur-
ing infection (31-33). Interestingly, two pneumococcal proteins, SP1298 and SP2205, con-
sisting of 311 and 657 amino acids, respectively, were consistently identified in all infection 
models. These two conserved proteins of an, as yet, unknown function are annotated as 
DHH subfamily 1 proteins in the pneumococcal genome. DHH family proteins belong to 
the superfamily of phosphoesterases (PE), and are named after their characteristic amino 
acid signature, Asp-His-His (DHH), found in a conserved N-terminal motif (i.e. motif III) 
(Figure 1). The DHH family can be divided further into two distinct subfamilies which share 
the four conserved N-terminal motifs, but have different C-terminal motifs. Subfamily 1 
proteins are predominantly found in bacteria and archaea, while subfamily 2 proteins are 
also represented in eukaryotes. H-prune, the human homolog of Drosophila prune protein 
is an example of an eukaryotic DHH subfamily 2 protein suggested to be involved in cell 
migration (34). DHH domain proteins have been identified in a variety of prokaryotes, such 
as Bacillus subtilis, Escherichia coli, Helicobacter pylori, Mycoplasma species, and Strepto-
coccus gordonii (35). RecJ of E. coli is one of the most well-known bacterial DHH subfam-
ily 1 proteins possessing exonuclease activity (36,37). Recently, SMU.1297, a DHH-domain 
containing protein, has been described in another streptococcal species, Streptococcus 
mutans (38). Yet, little is known about DHH subfamily 1 proteins of S. pneumoniae. 
 In the current study, we examined the contribution of SP1298 and SP2205 to pneu-
mococcal virulence using single and double knock-out mutants of three different strains 
of S. pneumoniae: D39, TIGR4, and BHN100 (serotypes 2, 4, 19F, respectively). We chose 
to examine the effect of both DHH subfamily 1 proteins in three pneumococcal strains 
as it has been shown that the genetic background can have a major influence on the 
contribution of proteins to virulence (39,40). Using four different murine models of single 
and mixed infections representing major phases of pneumococcal carriage and disease, 
we characterized the role of both DHH subfamily 1 proteins in the pneumococcal patho-
genesis of colonization, otitis media, pneumonia, and bacteremia. We also assessed the 
contribution of both DHH subfamily 1 proteins to pneumococcal adherence in vitro. Finally, 
we provide evidence that vaccination with a combination of recombinant DHH subfamily 
1 proteins can provide substantial protection against TIGR4-induced pneumonia in mice, 
and propose that these proteins should be considered as potential vaccine candidates.
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Materials & Methods
Pneumococcal strains and growth conditions
Pneumococcal strains used in this study are shown in Table 1. S. pneumoniae was routine-
ly grown in Todd-Hewitt broth supplemented with 5 g l-1 yeast extract (THY) or on Columbia 
blood agar (BA) plates (Oxoid) at 37°C and 5% CO2. Prior to mouse infection experiments, 
bacteria were passaged in mice to maintain virulence as described previously (Kerr et al., 
2004). Cultures of mouse-passaged S. pneumoniae strains were grown to an optical den-
sity (OD) at 620 nm (OD620) of 0.2 and aliquots were stored at -80°C in 15% glycerol. Prior 
to infection, defrosted aliquots were centrifuged, and bacteria were resuspended in sterile 
PBS to the desired concentration. When appropriate, antibiotics were used at the following 
concentrations: spectinomycin, 150 μg ml-1, trimethoprim, 25 μg ml-1, and kanamycin, 500 
μg ml-1. The number of CFU per ml in a particular sample was quantified by plating serial 
10-fold dilutions in PBS on BA plates.
Construction of site-directed deletion mutants 
All primers and plasmids used in this study are shown in Table 1. A megaprimer PCR 
method (30) was employed to replace target genes in the genome of the S. pneumoniae 
TIGR4, D39, and BHN100 strains with the spectinomycin resistance cassette amplified 
from plasmid pR412T7 (29). The resulting PCR products were introduced by competence 
stimulating peptide (CSP)-induced transformation into the corresponding strains using 
CSP-1 for D39 and BHN100 and CSP-2 for TIGR4. Transformants were selected on the 
basis of spectinomycin resistance and were checked by PCR for recombination at the 
desired location on the chromosome. In addition, a ∆SP1298∆SP2205 double mutant was 
generated in each of the three pneumococcal strains. To this end, the SP1298 gene was 
inactivated by allelic replacement with a trimethoprim cassette and introduced into the 
respective ∆SP2205 strains (spectinomycin) by transformation. 
Genetic complementation of DHH mutants 
Genetic revertants of the SP1298 and SP2205 BHN100 single mutants were created using 
CEP, a chromosomal expression platform for ectopic, maltose-driven gene expression in S. 
pneumoniae (41). To this end, the genes were amplified with primer pairs HBSP1298atg/
HBSP1298stop and HBSP2205atg/HBSP2205stop, respectively, using BHN100 chro-
mosomal DNA as a template. After digestion by NcoI/BamHI, the SP1298 and SP2205 
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fragments were ligated with NcoI/ BamHI-digested plasmid pCEP. The resulting SP1298 
and SP2205 ligation mixtures were used as donor in transformation of, respectively, 
strains BHN100∆SP1298 and BHN100∆SP2205, followed by selection for kanamycin-
resistant transformants, thus generating the strains BHN100∆SP1298 CEPSP1298 and 
BHN100∆SP2205 CEPSP2205. The complemented mutants were checked by PCR for inte-
gration at the desired location on the chromosome. A control CEPØ strain lacking a gene 
insert was constructed by transforming BHN100 wild-type with HindIII-digested pCEP and 
selecting for kanamycin-resistant transformants. To examine SP1298 and SP2205 gene 
and protein expression levels, bacterial strains were grown to mid-log in THY medium with-
out or with the addition of 0.4% maltose. Aliquots of these cultures were stored at -80°C 
with 15% glycerol for adherence assays.
Real-time PCR 
Total RNA was extracted using the RNeasy Mini kit (Qiagen) after which contaminating 
genomic DNA was removed by treatment with DNase (DNAfree, Ambion). DNA-free total 
RNA (2.5 μg) was reverse transcribed using 300 ng of random hexamers and Superscript III 
reverse transcriptase (Invitrogen). To confirm the absence of genomic DNA, reactions with-
out reverse transcriptase were carried out. Relative amounts of SP1298 and SP2205 tran-
scripts were determined by quantitative real-time-PCR (qRT-PCR) using the SYBR Green 
technology on a 7500 Fast Real-Time PCR System (PE Applied Biosystems) according 
to the manufacturer's instructions. The relative quantification method was used to evalu-
ate the quantitative variation between wild-type and complemented strains for each gene 
examined (42). The gyrA (SP1219) amplicon was used as an internal control for normaliza-
tion of data.
Production of His-tagged SP1298 and SP2205 and generation of polyclonal rabbit 
antisera 
The SP1298 and SP2205 genes of S. pneumoniae TIGR4 were PCR-amplified with oli-
gonucleotide primer pairs LCSP1298AvrH6F/LCSP1298BamR, and LCSP2205AvrH6F/
LCSP2205BamR, respectively. The amplicons were cloned into the pCR2.1 cloning vector 
of the TA cloning kit (Invitrogen) to obtain pLC1a (SP1298) and pLC2 (SP2205). Since 
sequence analysis showed that the AvrII site was not intact for SP1298, we PCR-amplified 
SP1298 from pLC1a using primer pair LCSP1298XbaF/LCSP1298BamR and subcloned 
the amplicon into pCR2.1 to obtain pLC1b. In the next step, the recombinant genes were 
excised with either XbaI/BamHI (SP1298) or AvrII/BamHI (SP2205) digestion and ligated 
to the BamHI/NheI-digested pET11c expression vector to obtain pLC1298 and pLC2205, 
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Strain, plasmid, or primer  Relevant characteristicsa  ecruos/ecnerefeR 
Species and strain 
S. pneumoniae 
)2 epytores( epyt-dliW  93D NCTC 7466
)4 epytores( epyt-dliW  4RGIT (73)
BHN100  Wild-type (serotype 19F) (74)
¨6P1298 Deletion mutant (Spr) This study
¨6P2205 Deletion mutant (Spr) This study
¨6398¨6P2205 Deletion mutant (Spr/Tmr) This study
BHN100¨631298 CEPSP1298 BHN100¨631298 with SP1298 ectopically expressed from CEP (Spr, Kmr) This study
BHN100¨632205 CEPSP2205 BHN100¨632205 with SP2205 ectopically expressed from CEP (Spr, Kmr) This study
BHN100 CEPØ BHN100 wild-type with empty CEP (Kmr) This study
E. coli
DH5D gninolc AND rof niartS (75)
noisserpxe nietorp tnanibmocer rof niartS 12LB Novagen
  sdimsalP
pR412T7 Donor plasmid for Spr cassette (29)
mT rof dimsalp ronoD TOKp r cassette (44)
pCR2.1 Cloning vector (Apr, Kmr) Invitrogen
pET11c Expression vector (Apr) Novagen
)IHmaB( eneg 8921PS gniniatnoc 1.2RCp a1CLp This study
pS ;evitavired 101CSp PECp r, Kmr; carries the S. pneumoniae chromosomal
     expression platform, CEP 
(41)
)IHmaB dna IabX( eneg 8921PS gniniatnoc 1.2RCp b1CLp This study
pLC1298 pET11c containing rHisSP1298 gene This study
)IHmaB dna IIrvA( eneg 5022PS gniniatnoc 1.2RCp 2CLp This study
pLC2205 pET11c containing rHisSP2205 gene This study
Primers Nucleotide sequence (5’ to 3’) Target gene
CJsp1298_L1 CGTAGAAGGTATCTCCTGAG SP1298; Left flank
CJsp1298_L2  CCACTAGTTCTAGAGCGGCGGGTCTGGTTTCATATGACG SP1298; Left flank
CJsp1298_R1 CCTACAGATGAGTCTGGAAC SP1298; Right flank
CJsp1298_R2  GCGTCAATTCGAGGGGTATCTAGCAAGTGGTGCTAATTC SP1298; Right flank
CJsp1298_C GATGTTCCAGCAAGGCTTTC SP1298; control
HBsp1298_L2  GTCCAAGCTCACAAAAATCCGTGGGTCTGGTTTCATATGACG SP1298; Left flank
HBsp1298_R2  CGTCTATGCGCGTCGTAACTAGCAAGTGGTGCTAATTC SP1298; Right flank
CJsp2205_L1 CGCAGAAGATGTATCTCAAG SP2205; Left flank
CJsp2205_L2  CCACTAGTTCTAGAGCGGCGTGGATAAGACTCCAAACGC SP2205; Left flank
CJsp2205_R1 CGAATCGGAGCTTGTACTTG SP2205; Right flank
CJsp2205_R2  GCGTCAATTCGAGGGGTATCGTAACCTTGTCAGAAGCAGG SP2205; Right flank
CJsp2205_C GCTGTCAAACTTTCTTCCGC SP2205; control
PBpR412_L GCCGCTCTAGAACTAGTGG Sp cassette pR412
PBpR412_R GATACCCCTCGAATTGACGC Sp cassette pR412
PBMrTn9 CAATGGTTCAGATACGACGAC Sp cassette; control
HBTmpFw TCGGATTTTTGTGAGCTTGGAC Tm cassette pKOT
HBTmpRv GTTACGACGCGCATAGACG Tm cassette pKOT
HBSP1298atg  GGgTATccATGGAGATTTGCCAACAAATTTTAG SP1298
HBSP1298stop  GTTAAAAAACTTGCTTAAAAACTGATAggATcCTTGCCA SP1298
HBSP2205atg  TTATGGTAccATGGGTGCCAAGAGGTTTTGAATG SP2205
HBSP2205stop  GGAAAAGGAGAAAGAAGAATGAAAGgAtcCTTTcTAG SP2205
b
HBgyrAF AATGAACGGGAACCCTTGGT gyrA, qRT-PCR 
HBgyrAR CCATCCCAACCGCGATAC gyrA, qRT-PCR 
HBSP2205F GGGTCTGCTGCTTCAATCAAG SP2205, qRT-PCR 
HBSP2205R ACACTCCGAATCTTATCTGAAATAGCT SP2205, qRT-PCR 
HBSP1298F GATTACCCTATTTGCCCAAACAA SP1298, qRT-PCR 
HBSP1298R ACAATTCCTGCAAAGAGCAACTC SP1298, qRT-PCR 
LCSP1298AvrH6F CCCTAGGCATCACCATCACCATCACGAGATTTGCCAACAAATTTTAG SP1298, AvrII 
LCSP1298XbaF CCCTAGGCATCACCATCACCATCACGAGATTTGCCAACAAATTTTAG SP1298, XbaI 
LCSP1298BamR CGGATCCTCAGTTTTTAAGCAAGTTTTTTAAC SP1298, BamHI 
LCSP2205AvrH6F CCCTAGGCATCACCATCACCATCACAAGAAACTGAGAGTGCATTATA SP2205, AvrII 
LCSP2205BamR CGGATCCTCATTCTTCTTTCTCCTTTTCC SP2205, BamHI 
a Spr, spectinomycin resistant; Tmr, trimethoprim resistant; Amr, ampicillin resistant; Kmr, kanamycin resistant.
  Underlined sequences are complementary to primers used for amplification of antibiotic resistant cassettes.
  Small letters in the sequence indicate nucleotide changes to introduce convenient restriction sites. The start and  
  stop codons of SP1298 and SP2205 are shown in bold.
b Left flak and right flank indicate positions relative to the target gene; qRT-PCR denotes primers used for real-time   
  PCR; restriction sites introduced for cloning are indicated.
Table 1. Bacterial strains, primers, and plasmids used in this study
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respectively. The nucleotide sequences of the SP1298 and SP2205 genes in pLC1298 and 
pLC2205 were confirmed by sequence analysis.
 For the production of His-tagged SP1298 (rHisSP1298) and His-tagged SP2205 
(rHisSP2205), an overnight culture of E. coli BL21 (pLC1298 or pLC2205) was diluted 
50-fold in pre-warmed (37ºC) 2 × LB supplemented with 0.5% glucose and 100 μg ml-1 
ampicillin. At an OD600 between 0.6 and 0.8, 0.1 mM isopropyl-ß-D-thiogalactopyranoside 
(IPTG) was added to the culture. After 2 h, cells were placed on ice, pelleted by centrifuga-
tion, resuspended in ice-cold lysis buffer consisting of 20 mM sodium phosphate, 0.5 M 
sodium chloride, and 10 mM Imidazole (pH 7.4) to an equivalent of an OD600 of 100 and 
lysed by sonication. For pLC2205, 6 M urea, 1 mM phenylmethylsulfonyl fluoride (PMSF), 
and 0.1% Triton X-100 was added to the lysis buffer. For complete cell lysis of the pLC2205 
culture, 6 M urea, 1 mM PMSF, and 0.1% Triton X-100 was first added to the lysis buffer 
and the suspension was frozen at -20°C. Subsequently, a defrosted cell suspension of 
pLC2205 was sonicated in the presence of 100 mM PMSF, 100 mM benzamidine (BZA), 
and lysozyme (100 mg ml-1). Insoluble debris in both lysates was removed by ultracen-
trifugation (Sorvall WX Ultracentrifuge in a Ti70.1 Beckmann rotor) at 40,000 rpm for 1 h 
at 4°C. The resulting supernatants were loaded onto a 1 ml HiTrap Chelating HP column 
(Amersham Biosciences) preloaded with Ni2+, washed with 10mM Imidazole phosphate 
buffer and eluted with 300 mM Imidazole phosphate buffer, and the fractions containing 
purified rHisSP1298 or rHisSP2205 were combined and dialyzed (Slide-A-Lyzer Dialysis 
Cassette 3500 MWO, 0.5-3 ml capacity; Pierce). Dialysis buffer for rHisSP1298 contained 
10 mM HEPES, while rHisSP2205 was dialyzed against 10 mM HEPES, 6 M urea, and 
0.1% Triton X-100. After dialysis, rHisSP1298 was lyophilized and rHisSP2205 was stored in 
the dialysis buffer; both stored at –20°C until further use. The identities of the purified pro-
teins were confirmed by matrix-assisted laser desorption ionization-time-of-flight analysis, 
and their amounts were determined by the bicinchoninic acid (BCA) assay (Bio-Rad).
 For the generation of anti-SP1298 and anti-SP2205 polyclonal rabbit antibodies, a 
total of 400 μg of each protein was used according to the Speedy program of Eurogentec.
Western blot analysis
Whole-cell bacterial lysates were used in Western blot analysis by separating 2.5 x 107 
CFU/lane on SDS-PAGE gels (12.5%). After electrophoretic transfer onto a nitrocellulose 
membrane, transfer was visualized by staining membranes with Ponceau S (Sigma-
Aldrich). Subsequently, membranes were blocked using PBS with 0.1% Tween 20,  2% 
skim milk powder, and 1% bovine serum albumin (BSA), and incubated with the primary 
antibodies (rabbit polyclonal α-SP1298 or α-SP2205) followed by horseradish peroxidase-
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coupled secondary anti-rabbit antibody. Immunoblots were developed by enhanced chemi-
luminescence (Amersham).
Pneumococcal adherence assay
The human pharyngeal epithelial cell line Detroit 562 (ATCC number CCL-138) was rou-
tinely grown in RPMI 1640 medium without phenol red (Invitrogen, The Netherlands) sup-
plemented with 1 mM sodium pyruvate and 10% (vol/vol) fetal calf serum (FCS). All cells 
were cultured at 37°C in a 5% CO2 environment. For adherence assays, bacteria were 
resuspended in RPMI 1640 medium without phenol red supplemented with 1% FCS. For 
adherence experiments with complemented mutants, maltose was added to the medium 
to a concentration of 0.4%. Adherence of pneumococci to epithelial cells was performed 
as described previously (40,43). Briefly, Detroit 562 cells were seeded into 24-well plates 
and incubated for 48 h. Confluent monolayers were washed twice with 1 ml PBS and 
infected with 1 × 107 CFU ml-1 [multiplicity of infection (MOI) of 10 (bacteria/cells)] and 
pneumococci were allowed to adhere to the cells for 2 h at 37°C in a 5% CO2 environ-
ment. Non-adherent bacteria were removed by 3 washes of 1 ml PBS, after which 200 μl 
of 0.05% trypsin, 1 mM EDTA was added to detach the cells, followed by 800 μl of ice-
cold 0.025% Triton X-100 in PBS to lyse the cells. Samples were plated for CFU count, 
and corrected to account for small differences in the initial inoculum. All experiments were 
performed in triplicate and repeated at least three times. The adherence of the mutants is 
given as the percentage relative to the wild-type. All bacterial strains grew equally well in 
the tissue culture medium.
Mouse studies
Eight-week old female outbred CD-1 mice (Charles River Laboratories, Germany) were 
used for the colonization, pneumonia, and bacteremia models, while the OM experiments 
were performed with 7-week old female inbred specific pathogen free BALB/c mice (Har-
lan, The Netherlands). All mice were housed in filter-top cages and had access to food 
and water ad libitum. Mice were allowed to acclimate for a week prior to each experiment. 
All animal experiments were performed with approval of the Radboud University Nijmegen 
Medical Centre Committee for Animal Ethics.
Pneumonia model
Mice were lightly anesthetized with 2.5% (vol/vol) isoflurane over oxygen, and infected 
intranasally (i.n) by pipetting 50 μl of inoculum (5 × 106 CFU total) onto the nostrils of mice 
while held in an upright position. At predetermined times after infection, groups of mice 
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were sacrificed by injection anesthesia, and blood samples were taken by retro-orbital 
bleeding. Bacteria were recovered from the nasopharynx by flushing each nare with 1 ml 
sterile PBS (nasopharyngeal lavage, NPL) (44). A bronchoalveolar lavage (BAL) was per-
formed by flushing the lungs with 2 ml sterile PBS, after which lungs were removed from 
the body and homogenized in 2 ml sterile PBS using a hand held homogenizer (Polytron 
PT 1200; Kinematica AG). 
Colonization model 
Mice were infected i.n. under anesthesia as mentioned above with a smaller volume of 
inoculum, 10 μl (5 × 106 CFU total). As described previously, nasal instillation of pneumo-
cocci with such a low volume does not cause a lethal infection in mice (40). Mice showed 
no visible signs of disease throughout the course of colonization and had less than 40 
CFU in the lungs at the last time point. At predetermined time points after infection, NPL 
and lungs were collected as described above. 
Otitis media model 
Intranasal infection was performed as described above in the colonization model with the 
following exception: methylcellulose (1%) was added to the inoculum for all OM experi-
ments in order to minimize leakage of inoculum to the lungs (45). Mice were placed in a 
supine position in the pressure cabin after infection as described previously (46). Briefly, 
an initial pressure rise was set at 10 kPa and when the mouse started to regain conscious-
ness and the first swallowing movements occurred, pressure was raised at the rate of 5 
kPa per 15 s until a pressure of 40 kPa was reached, enabling the inoculum to reach the 
middle ear cavity. Then the pressure was lowered gradually until atmospheric pressure was 
reached again. Groups of mice were sacrificed at 24, 48, and 96 h post-infection where 
mice were bled out by retro-orbital puncture, followed by cervical dislocation. The bullas 
enclosing the middle ears (ME) were dissected from the temporal bone and homogenized 
in the presence of 1 ml sterile PBS per ear, as previously described (45,46). Bacteria were 
also recovered from the nasopharynx by performing an NPL using 1 ml of sterile PBS and 
the lungs were extracted and homogenized in 2 ml sterile PBS. 
Bacteremia model 
Mice were infected via the tail vein with a 100 μl inoculum (106-107 CFU total). To confirm 
successful infection, blood was taken from a separate vein immediately after injection (t= 0 
h). Subsequently, blood was recovered via a tail vein puncture from the same mouse at 12 
and 24 h post-infection and by retro-orbital puncture at the last time point, 36 h. 
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Co-infection experiments 
A 1:1 ratio of wild-type and its respective ∆SP1298, ∆SP2205, or ∆SP1298∆SP2205 mutant 
was used to infect the mice as described in the above-mentioned infection models. This 
setup reduces variation between individual mice, inoculation preparation and distribution, 
and sample collection. Viable bacteria were quantified by plating serial dilutions on BA 
plates and BA plates supplemented with either spectinomycin or spectinomycin and tri-
methoprim. Subsequently, competitive index (CI) scores were calculated for each indi-
vidual animal as the output ratio of mutant to wild-type divided by the input ratio of mutant 
to wild-type bacteria. A log CI score <0 indicates that the mutant is outcompeted by the 
wild-type. For samples in which no viable mutant bacteria were recovered, the lower limit 
of detection (20 CFU ml-1) was substituted as the numerator. If in one particular sample 
neither wild-type nor mutant bacteria were detected, the data were excluded from further 
analysis.
Immunizations 
Female CD-1 mice (6 weeks old) were subcutaneously immunized three times at 14-day 
intervals with a total of 50 μg protein in alum adjuvant (aluminum hydroxide gel; Sigma). 
Briefly, mice were either primed singly with rHisSP1298 or rHisSP2205, or with a combina-
tion of the two proteins. The negative control group consisted of mice given a 1:1 ratio 
of alum adjuvant and PBS. One tenth of the human dose of Prevnar® 7 was given to the 
positive control group. Blood samples from all mice were collected via tail vein puncture 
prior to any immunization, at the time of the third boost, and several days before infection. 
Mice were subsequently challenged i.n. with the TIGR4 wild-type strain (1 × 106 CFU total) 
three weeks after the last immunization in our pneumonia model and sampled 48 h post-
infection as described above.
Detection of antigen-specific IgG by ELISA
IgG titers against SP1298 and SP2205 were determined by ELISA analysis. High bind-
ing-capacity microtitre plates (Greiner) were coated with 1 μg μl-1 purified rHisSP1298 or 
rHisSP2205 in 100 μl per well overnight at 4°C. Plates were washed with PBS with 0.05% 
Tween 20 (PBST) and then incubated for 1 h with PBST containing 2% BSA. Three-fold 
serial dilutions of sera were added to the plates and incubated for 1 h at 37°C. After 
washing, the alkaline phosphatase secondary antibody directed to mouse IgG-Fc (Sigma-
Aldrich) was added for 1 h at 37°C using a 1:25,000 dilution. After washing, 100 μl per well 
of p-nitrophenyl phosphate (1 mg ml-1) in substrate buffer (10 mM diethanolamine and 0.5 
mM magnesium chloride, pH 9.5) was added and the absorbance was read at 405 nm.
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Statistical analyses
For adherence assays, comparisons between wild-type and mutant pneumococcal strains 
were performed using Student’s t-test (unpaired). The Mann-Whitney test was used for 
comparison of bacterial load in NPL, ME, BAL, lung homogenate, and blood between the 
wild-type- and their respective DHH mutant-infected mice in all infection models. For the 
co-infection data, a Wilcoxon test on log-transformed CI scores was used to determine 
if the median CI was statistically significantly different from 0 (i.e., no outcompetition). All 
statistical analyses were performed using GraphPad Prism version 4.0. 
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Results
DHH subfamily 1 proteins contribute to pneumococcal adherence in vitro 
To assess the (strain-specific) contribution of the DHH subfamily 1 proteins SP1298 and 
SP2205 to pneumococcal pathogenesis, directed mutants were generated in three strains: 
D39, TIGR4, and BHN100. Western blot analysis of wild-type, ∆SP1298, ∆SP2205, and 
double mutant cell lysates using anti-SP1298 and anti-SP2205 rabbit serum confirmed that 
SP1298 and SP2205 were expressed in all three wild-type strains, but not in their respec-
tive single and double mutants (data not shown). Importantly, no differences in in vitro 
growth between the wild-type strains and the DHH subfamily 1 mutants were detected. 
 Adherence of pneumococci to respiratory epithelial cells is crucial for colonization 
of the nasopharynx. Therefore, we examined adherence of the three wild-type strains and 
their isogenic single and double DHH subfamily 1 mutants to human pharyngeal epithelial 
Detroit 562 cells. Wild-type adherence levels of TIGR4 (~6.5 × 104 adherent CFU) were 
statistically significantly higher than those of the wild types of the D39 or BHN100 strains 
by almost 1 log. Interestingly, no difference in adherence was observed upon deletion of 
the SP1298 gene in TIGR4 and D39, while adherence of BHN100∆SP1298 was reduced 
by ~75%, suggesting that the contribution of SP1298 to adherence is strain-specific (Fig-
ure 2A). In contrast, all three SP2205 mutants showed a significant decrease in adherence 
compared to their wild types, ranging from 60 to 90% (Figure 2A). The ability of the double 
mutants in all three strains to adhere was drastically reduced by >80%, displaying an 
enhanced effect when both genes were deleted (Figure 2A).
 To confirm that the observed phenotypes were indeed due to the deletion of the 
SP1298 and SP2205 genes, we generated genetically complemented mutants by ectopic 
expression of the respective genes from the maltose-inducible CEP site. Given that attenu-
ated adherence of both single mutants was only observed in the BHN100 strain, we chose 
this background for the genetic complementation. As a control, we generated BHN100 
CEPØ, containing the empty chromosomal expression platform. Real-time PCR and West-
ern blot analysis of the genetic revertants showed that SP1298 gene and protein expres-
sion was restored to wild-type levels in normal medium, and was five-fold higher than wild-
type upon addition of maltose (Figure 2B). For SP2205, both gene and protein expression 
was clearly restored in normal medium, but maltose-induction was required to reach wild-
type levels (Figure 2B). Importantly, the ability of the complemented SP1298 mutant to 
adhere to Detroit cells was indistinguishable from wild-type when cells were grown without 
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Figure 2. (A) In vitro adherence of pneumococcal strains to the human pharyngeal epithelial 
cell line Detroit 562. The adherence of the mutants is given as the percentage relative to the 
respective wild-type. (B) Real-time PCR (upper panels) and Western blot analysis (lower pan-
els) of BHN100 complemented for SP1298 (left) or SP2205 (right) mutants. Real-time data are 
expressed as the log2 ratio of expression relative to that for the BHN100 wild-type grown with-
out maltose. Strain names and presence of maltose in growth medium are indicated at the 
bottom. (C) In vitro adherence of BHN100 complemented mutants to Detroit 562 cells, given 
as the percentage relative to that for the BHN100 wild-type grown without maltose. Presence 
of maltose in growth medium is indicated at the bottom. All values are geometric means, and 
error bars represent SEM. *, P<0.0001.
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maltose (Figure 2C), while the maltose-induced overexpression of SP1298 had a slight 
adverse effect on the adherence ability. Moreover, the adherence of the SP2205 mutant 
was also no longer significantly different from wild-type upon complementation, with or 
without maltose-induction. In all cases, BHN100 CEPØ behaved the same as wild-type. 
Thus, the observed attenuated adherence phenotypes of the DHH mutants were not the 
result of an inadvertent mutation in a non-targeted gene. 
DHH subfamily 1 proteins contribute to various stages of pneumococcal patho-
genesis in vivo
(i) Colonization. Since colonization of the nasopharynx is a prerequisite for pneumococ-
cal infection, we first compared all single and double SP1298 and SP2205 mutants to 
their isogenic parental wild types following intranasal infection in our established coloniza-
tion model. All wild-type strains maintained an overall colonization level of approximately 
105 CFU during the course of infection (Figures 3A, C, E). Even though all single and 
double SP1298 and SP2205 mutants were capable of colonizing the murine nasopha-
rynx to varying degrees throughout infection, significant decreases in bacterial load were 
observed compared to their respective wild types over time. Interestingly, SP1298 and 
SP2205 mutants in a BHN100 background maintained a slightly higher level of coloniza-
tion in the nasopharynx in comparison to the SP1298 and SP2205 mutants in the other 
two pneumococcal backgrounds. The most prominent phenotype was observed in the 
TIGR4 genetic background where all single and double SP1298 and SP2205 mutants were 
significantly attenuated at all time points from 24 h post-infection onwards (Figure 3A). The 
double mutants in all three strain backgrounds were significantly impaired in their ability 
to colonize the nasopharynx, but again the most severe attenuation was observed in the 
TIGR4 background with a 2,500-fold decrease compared to the wild-type after just 24 h 
(p<0.005) (Figure 3A). Since both single mutants in TIGR4 only showed a decrease of 
~10-fold, this suggests an additive effect when both genes are absent. Mice infected with 
single and double SP1298 and SP2205 mutants of D39 (Figure 3C) and BHN100 (Figure 
3E) also had lower bacterial loads than their respective wild-type-infected mice, especially 
at the later time-points. 
 To further characterize the potential role of these two DHH subfamily 1 proteins in 
pneumococcal colonization, we examined the phenotype of each mutant when in direct 
competition with its respective wild type, as minor differences between two bacterial 
strains can be unmasked with such a competitive setup. The TIGR4 and BHN100 wild 
types significantly outcompeted their respective single SP1298 and SP2205 mutants 96 h 
post-infection (900-7,000-fold; Figures 3B, F). Interestingly, although outcompetition of the 
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Figure 3. Bacterial load in the nasal lavage fluid of mice intranasally infected with 5 × 106 
CFU of wild-type and/or the respective ∆SP1298, ∆SP2205, or ∆SP1298∆SP2205 mutants. 
Strain data are depicted for TIGR4 (A and B), D39 (C and D), or BHN100 (E and F). Data 
from single-infection experiments are shown in panels A, C, and E; data from coinfection 
experiments are shown in panels B, D, and F. The horizontal line represents lower limit of 
detection, and error bars represent SEM. Each point in panels B, D, and F represents the 
log competitive index score from an individual mouse. Values <0 indicate attenuation of the 
mutant. Horizontal lines represent the mean. *, P<0.05.
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D39 single mutants was significant but much less prominent (<10-fold; Figure 3D) than 
that for the other two strain backgrounds, the double mutants in all strains were outcom-
peted ~500-7,000-fold, suggestive of a strain-specific additive effect (Figures 3B, D, F). 
Especially for the TIGR4 strain, attenuation levels of mutants differed between single- and 
co-infection: both single mutants were outcompeted to the same extent as the double 
mutant in co-infection, whereas a 2-log difference in colonization levels was observed in 
single infection. This is most likely due to the enhanced sensitivity of the competitive setup, 
where both single mutants were already outcompeted to levels below our detection limit 
(20 CFU ml-1). 
 (ii) Otitis media. The pathogenesis of pneumococcal OM involves translocation of 
the bacteria from the nasopharynx to the middle ear cavity through the Eustachian tube, 
accomplished by the use of a pressure cabin in the murine OM model recently described 
(46). We examined the contribution of the DHH subfamily 1 proteins to experimental OM 
using the mutants in TIGR4 and BHN100 since it has been established that these two 
strains produce higher CFU counts in the middle ear in this model than D39 (46). Colo-
nization levels of the middle ear with BHN100 wild-type (>105 CFU ml-1) were higher than 
the TIGR4 wild-type strain (~104 CFU ml-1) throughout the course of OM infection (Figures 
4A, C). 
 Attenuation of the BHN100 double mutant was observed at all time points post-
infection (Figure 4A). Reduced bacterial loads of <103 CFU ml-1 were observed for 
BHN100∆SP1298 throughout OM infection, albeit only statistically significant at the last two 
time points, while BHN100∆SP2205 only appeared to be attenuated at 48 h  (Figure 4A). 
In line with the BHN100 data, the TIGR4 double mutant was incapable of colonizing the 
middle ear at any of the time points (Figure 4C). A consistent reduction in bacterial load 
was observed for TIGR4∆SP1298 and, to a lesser extent, TIGR4∆SP2205 (Figure 4C), but 
this was not statistically significant except for TIGR4∆SP1298 at 96 h due to large spread 
of the wild-type. 
 In the co-infection experiments, both wild types outcompeted their respective single 
and double SP1298 and SP2205 mutants in the middle ear by 20- to 350-fold (Figures 4B, 
D). These observations clearly confirmed the single infection data. Finally, nasopharyngeal 
colonization levels of wild-type and mutants in the OM model were similar to NPL data 
obtained with the colonization model (data not shown).
 (iii) Pneumonia. Pneumococcal pneumonia can occur when bacteria are aspirated 
from the nasopharyngeal niche to the lungs. In the murine pneumonia model, infection 
was monitored at three sites: nasopharynx, lungs, and blood, allowing us to examine 
aspects of both colonization and invasive disease. Nasopharyngeal colonization in the 
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Figure 4. Bacterial load in the middle ear fluid of mice intranasally infected with 1 × 106 CFU 
of the wild-type and/or respective ∆SP1298, ∆SP2205, or ∆SP1298∆SP2205 mutants. Strain 
data are depicted in panels A and B for BHN100 and in C and D for TIGR4. The single infec-
tions shown in panels A and C represent the sum of pneumococci in the left and right middle 
ear fluid. The horizontal line represents lower limit of detection and error bars represent SEM. 
Co-infection data are shown in panels B and D, where each point represents the log competi-
tive index score from one mouse ear. Values <0 indicate attenuation of the mutant. Horizontal 
lines represent the mean. *, P<0.05.
pneumonia model was comparable to the results observed in the colonization and OM 
models (data not shown). Interestingly, similar to our observations in the NPL (Figure 3E), 
the number of BHN100 wild-type in the BAL fluid (~104 CFU) was higher than that of the 
TIGR4 and D39 wild-type strains after 24 h post-infection (Figures 5B, E, H). A very pro-
nounced phenotype was seen with the BHN100 single and double SP1298 and SP2205 
mutants as they were all significantly attenuated ~2 logs in the lungs and BAL 24 and 
48 h post-infection compared to the BHN100 wild-type (Figures 5G-H). In the lung tissue, 
we observed that the D39 double mutant was significantly attenuated at all time points; 
A
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Figure 5. Bacterial load in the lung homogenate and bronchoalveolar lavage fluid of mice 
following intranasal infection with 5 × 106 CFU of the wild-type and/or respective ∆SP1298, 
∆SP2205, or ∆SP1298∆SP2205 mutants. Strain data for TIGR4 (A, B, and C), D39 (D, E, and F), 
or BHN100 (G, H, and I) are shown. Data from single-infection experiments are shown in panels 
A, B, D, E, G, and H, and data from coinfection experiments are shown in panels C, F, and I. The 
horizontal line represents the lower limit of detection, and error bars represent SEM. Each point 
depicted in panels C, F, I indicates the log competitive index score from an individual mouse. 
Values <0 indicate attenuation of the mutant. Horizontal lines represent the mean. *, P<0.05.
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while only D39∆SP1298 was attenuated at 48 h 
(Figure 5D). However, bacterial loads for all D39 
single and double SP1298 and SP2205 mutants 
recovered in BAL at 24 and 48 h were signifi-
cantly lower than wild-type loads (Figure 5E). 
For TIGR4, the single ∆SP1298 and the double 
mutant were also unable to cause infection in the 
lungs and BAL at 24 and 48 h (Figures 5A-B), 
albeit not always statistically significant due to 
a large spread of the wild-type. However, mice 
infected with TIGR4∆SP2205 were capable of 
causing disease at wild-type levels 48 h post-
infection (Figures 5A-B). 
 In the pneumonia coinfections, we 
observed that the TIGR4 and BHN100 wild 
types significantly outcompeted their respective 
SP1298 (20- to 2,200-fold) and SP2205 (70- to 
10,000-fold) mutants at 48 h post-infection in 
the lung and BAL fluid (Figures 5C, I), while the 
D39 wild-type only significantly outcompeted 
the ∆SP2205 (200-fold) and ∆SP1298∆SP2205 
(50,000-fold) mutants only in the lung tissue (Fig-
ure 5F). Moreover, we observed that the TIGR4 
and D39 wild types outcompeted their respective 
double mutants much more than their respective 
single DHH subfamily 1 mutants, displaying an 
enhanced effect when both genes were deleted 
(Figures 5C, F). For example, the TIGR4 dou-
ble mutant was outcompeted by its wild-type 
40,000-fold while the single SP1298 and SP2205 
mutants were outcompeted by only 2,200-fold 
and 10,000-fold, respectively. 
 The TIGR4 and D39 strains and their 
respective mutants were all able to dissemi-
nate from lungs to blood, except for the SP1298 
mutants for which no bacteria were detected at 
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any time-point. Once in the blood, the TIGR4 and D39 wild types and their respective 
∆SP2205 mutants showed growth characteristics similar to those described in the bacte-
remia model below.
 (iv) Bacteremia. Bacteremia is a severe complication which occurs in approximate-
ly 30% of pneumonia cases (47). To assess whether the DHH subfamily 1 proteins are 
required for survival of pneumococci once they have entered the bloodstream, we intrave-
nously infected mice with wild-type and/or mutant pneumococci. Both wild types (TIGR4 
and D39) had higher bacterial counts (7- to 25,000-fold more) in the blood compared 
to their respective SP1298 and SP2205 mutants throughout the course of the infection 
(Figures 6A, C), except for the TIGR4∆SP2205 mutant. The fact that the TIGR4∆SP2205 
mutant behaved as the wild-type in this model is supported by corresponding blood data 
from the pneumonia model. The mice infected with TIGR4∆SP1298 maintained significant-
ly lower levels (~200-fold less) of bacteria after 12 h post-infection. In the case of D39, 
the single ∆SP1298 and double mutants were significantly attenuated at all time points, 
the ∆SP2205 mutant only at 32 h post-infection (Figure 6C). The BHN100 strain was not 
capable of surviving in the blood and was cleared from the bloodstream within 24 h after 
infection (data not shown). Furthermore, we observed that the TIGR4 and D39 wild types 
statistically outcompeted their respective double mutants up to 3 logs more than their 
respective single DHH subfamily 1 mutants, further signifying an additive effect when both 
genes were deleted (Figures 6B, D). Interestingly, the TIGR4∆SP2205 mutant was only 
attenuated in blood in a co-infection setup, suggesting this mutant is only able to effi-
ciently survive during bacteremia when it is not in direct competition with the wild-type.
DHH subfamily 1 proteins confer protection against pneumococcal pneumonia
To evaluate the protection elicited by immunization with recombinant rHisSP1298 and 
rHisSP2205 proteins either singly or in combination, CD-1 mice were immunized with these 
proteins and subsequently challenged with S. pneumoniae TIGR4. The individual IgG titers 
in sera of mice immunized with one or both DHH subfamily 1 proteins or with Prevnar® 
7 were tested three weeks after the final immunization. Analysis showed antigen-specific 
antibody responses that were significantly higher compared to their respective negative 
pool pre-immune serum (data not shown). No difference in IgG titers was seen between 
the single or double vaccinated groups. At 48 h post-infection, protection was evaluated 
by quantifying bacterial load. As expected, mice that received Prevnar® 7 were protected 
(Figure 7), as capsular type 4 is included in this vaccine. While a minor reduction of bac-
teria in the nasopharynx (p<0.013) of rHisSP1298-vaccinated mice was observed (Figure 
7A), mice receiving either rHisSP1298 or rHisSP2205 alone were not protected and suc-
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cumbed to infection just as rapidly as mice receiving adjuvant only. Interestingly, protection 
was only seen with mice who received a combination of both DHH subfamily 1 antigens. 
Bacterial loads in the nasopharynx, blood, and lung of these mice were statistically signifi-
cantly lower (p<0.0001, 0.013, 0.003, respectively) than those of mice receiving adjuvant 
only (Figures 7A, B, D) after subsequent challenge with TIGR4 wild-type. Sixty percent of 
these mice did not develop bacteremia and clinical signs of disease were minimal.
Figure 6. Bacterial load in the blood of mice over time following intravenous infection with 
1 × 106/7 CFU of wild-type and/or respective ∆SP1298, ∆SP2205, or ∆SP1298∆SP2205 
mutants. Strain data for TIGR4 (A and B) or D39 (C and D) are depicted. Data from single-
infection experiments are shown in panels A and C, and data from coinfection experiments 
are shown in B and D. The dotted horizontal line represents the lower limit of detection, and 
error bars represent SEM. Each point depicted in B and D indicates the log competitive index 
score from an individual mouse. Values <0 indicate attenuation of the mutant. Horizontal lines 
represent the mean. *, P<0.05.
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Figure 7. Protection against intranasal challenge with S. pneumoniae TIGR4. Mice subcuta-
neously immunized with alum (open squares), rHisSP1298 (filled triangles), rHisSP2205 (filled 
circles), a combination of rHisSP1298 and rHisSP2205 (filled diamonds), or Prevnar® 7 (filled 
squares) were subsequently challenged with TIGR4 wild type. Pneumococci were recovered 
48 h postinfection from NPL (A), blood (B), BAL fluid (C), or lung homogenate (D). Each dot 
represents one mouse. The dotted horizontal line represents the lower limit of detection. *, 
P<0.05.
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Discussion
Current polysaccharide conjugate vaccines targeting the respiratory tract pathogen S. 
pneumoniae provide excellent protection against invasive disease caused by vaccine 
serotypes, yet remain ineffective against circulating non-vaccine serotypes. Vaccines that 
include conserved (surface) proteins involved in pneumococcal virulence are considered 
promising alternatives. To identify such targets, we previously screened for genes essen-
tial during pneumococcal infection using the GAF technology (29,30,33). These in vivo 
GAF screens have led to the identification of the DHH subfamily 1 proteins SP1298 and 
SP2205. These two proteins have not been identified by previous STM or expression stud-
ies, and have consequently never been considered as virulence factors or vaccine leads 
in S. pneumoniae. This prompted us to examine their role in pneumococcal pathogenesis 
and protection in more detail.
 Our in vitro and in vivo results clearly demonstrate that the two pneumococcal DHH 
subfamily 1 proteins are required for full pneumococcal virulence at several target sites of 
the host, e.g., nasopharynx, middle ear, lungs, and blood. Genetic complementation of 
the SP1298 and SP2205 genes in the BHN100 single mutants resulted in restoration of 
in vitro adherence to wild-type levels, indicating that our observed phenotypes are indeed 
the results of the gene deletions and not an inadvertent mutation in a non-targeted gene. 
Interestingly, an additive effect was observed in vitro and in vivo when both genes were 
deleted. These data suggest that SP1298 and SP2205 may functionally complement each 
other, rendering S. pneumoniae incapable of causing disease when both genes are absent. 
Additive or even synergistic reduction in virulence of pneumococcal mutants lacking mul-
tiple genes of complementary function has been described previously. For example, dur-
ing their investigation of two iron ABC transporter systems, PiuA and PiaA, Brown et al. 
demonstrated that a single deletion of piuA or piaA resulted in only a moderate reduction 
in virulence, whereas a mutant strain lacking both genes displayed severe attenuation in 
both pulmonary and systemic models of infection (48). In another study individual ∆aliA, 
∆aliB, and ∆amiA mutants of the Ami-AliA/AliB oligopeptide permease were only moder-
ately impaired in nasopharyngeal colonization, while the triple knock-out obl mutant was 
severely attenuated (49). 
 Since the pneumococcal genetic background can have a significant impact on the 
contribution of individual genes to virulence, we performed our study using three geneti-
cally distinct strains. Adherence data showed that the ∆SP2205 and double mutants were 
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severely reduced in adherence to Detroit 562 cells in all three genetic backgrounds com-
pared to their respective wild types, whereas the ∆SP1298 mutant showed diminished 
adherence only in a BHN100 background. Conversely, in vivo data of all infection mod-
els demonstrated that the ∆SP1298 and double mutants in all three strain backgrounds 
were significantly attenuated, while the TIGR4∆SP2205 mutant displayed wild-type levels 
of virulence in lungs and blood in single infection. Attenuation of TIGR4∆SP2205 was 
observed only in co-infection experiments, specifically in the pneumonia and bacteremia 
models. These data suggest that not only strain-specific but also host site-specific fea-
tures of strains and their respective mutants can occur. An obvious explanation for strain-
specific phenotypes of mutants is the presence or absence of other virulence genes (in)
directly contributing to observed phenotypes. For instance, the type I pilus that has been 
described to be involved in pneumococcal adherence and colonization (50), is encoded 
by the genomes of the TIGR4 and BHN100 strains but not by that of D39. It does not 
appear to be responsible for the strain-specific adherence observed in our study, though, 
since the D39 and TIGR4 mutants showed similar phenotypes. Strain-specificity has also 
been described for virulence factors present in all strains; for example, the contribution 
of PspC to pneumococcal virulence has been shown to vary between strains, both at 
the level of virulence during pneumonia and bacteremia and at the level of factor H bind-
ing (51,52), and we have demonstrated that the putative proteinase maturation protein A 
(PpmA) contributes to adherence in a strain-specific manner (40). Finally, transcriptional 
response regulators (RR), such as RR04 and RR09, have also been shown to affect both 
virulence and gene expression in a strain-specific manner (39,53,54).
 A reasonable explanation for the observed phenotypes of the DHH subfamily 1 
mutants may be associated with the cellular localization of the DHH subfamily 1 proteins. 
SP2205 is predicted to be surface-exposed by virtue of N-terminal transmembrane heli-
ces, which suggests that its observed contribution to adherence may well be a direct 
effect, since the protein may act as an adhesin. A significant reduction in invasive disease 
was attributed to the deletion of SP1298, which may be the result of an indirect effect, 
since this protein is predicted to be cytoplasmic. SP1298 does not contain known signal 
sequences or typical motifs required for membrane anchoring. However, the presence of 
known export signals is not necessarily a prerequisite for surface exposure, as exemplified 
by two other pneumococcal virulence factors: the plasmin(ogen) binding proteins eno-
lase (Eno) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (55,56). Binding of 
human plasmin(ogen) by pneumococcal Eno and GAPDH enhances bacterial virulence 
by capturing surface-associated proteolytic activity, thus promoting penetration of bacteria 
through reconstituted basement membranes (55,57,58). Even though these proteins are 
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predicted to be cytoplasmic based on their amino acid sequence, immunoelectron micros-
copy and immunoblot analysis have clearly showed that both of these glycolytic enzymes 
are present in the cytoplasm as well as on the bacterial cell surface (55,58). Ply is also a 
signal peptide-lacking protein localized in the cytoplasm that, in addition to formation of 
pores, can activate complement and stimulate host cell apoptosis once released from the 
bacterium (59-61). Interestingly, unlike the SP1298 and SP2205 mutants, a ply-negative 
mutant could be complemented by the presence of the wild-type strain upon co-infection 
(62). This suggests that while Ply acts at distance from the pneumococcus, the DHH sub-
family 1 proteins exert their effects in connection with or very close to the cell. Whether the 
cellular localization of SP1298 and SP2205 is the cell surface, cytoplasm or both, remains 
to be investigated, since preliminary fluorescense-activated cell sorter (FACS) analysis 
using the polyclonal antisera was inconclusive (data not shown).
 Even though the exact function of SP1298 and SP2205 in S. pneumoniae is unknown 
at present, their DHH domain(s) (Figure 1) may shed some light on their putative role 
in pneumococcal pathogenesis. The N-terminal motifs I-IV of DHH family proteins con-
tain the residues required for core catalytic activity, and the C-terminal, subfamily-specific 
motifs contribute to substrate specificity (35). In addition to the N-terminal DHH motifs, 
both SP1298 and SP2205 possess a DHHA1 domain, characteristic of members of the 
DHH subfamily 1. These domains are ~60 residues long and contain a conserved GGG 
motif located near the C-terminus (35). DHH domain proteins are known to function as 
phosphatases or phospho(di)esterases (PDE) capable of hydrolyzing a wide variety of 
substrates from inorganic pyrophosphate to single-stranded DNA (35). A well-studied bac-
terial example is RecJ of E. coli, an exonuclease involved in DNA repair and recombination 
systems (63), of which homologues are found in S. pneumoniae (Figure 1), and in Borde-
tella pertussis, Haemophilus influenzae, and Neisseria meningitidis (35,37). Some less-well 
characterized but interesting examples include two DHH proteins of Mycoplasma geni-
talium and Mycoplasma pneumoniae, located in operons encoding proteins required for 
adherence to the respiratory epithelium (64-66). Furthermore, SMU.1297, a DHH subfamily 
1 protein of S. mutans, was recently found to be involved in superoxide stress tolerance by 
exposing wild-type and SMU.1297 mutant strains to menadione, a quinine compound that 
generates superoxide anions in bacteria (38). Analysis of the SMU.1297 sequence showed 
a high degree of homology to the B. subtilis YtqI protein, which possesses dual activities: 
oligoribonuclease (cleaves small RNAs less than 5-mers) and 3′-phosphoadenosine–5′-
phosphate (pAp) phosphatase in vitro (67). Biochemical analysis of SMU.1297 demon-
strated that it has pAp phosphatase but no oligoribonuclease activity (38). B. subtilis has 
another DHH/DHHA1 domain protein, YybT, which exhibits PDE activity toward cyclic 
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dinucleotides (68). Based on their amino acid sequence, SP1298 is ~68% identical to 
SMU.1297, while SP2205 shares 32% homology with YybT. SMU.1297 and YtqI consist of 
310 and 313 amino acids, respectively, which is comparable to the size of SP1298, while 
the size of YybT (659 amino acids) is comparable to that off SP2205. Given these similari-
ties, it is not unlikely that SP1298 and SP2205 may possess hydrolase and/or nuclease 
activity. Characterization of their biochemical function(s) will be subject of future studies.
 The combination of both DHH subfamily 1 antigens SP1298 and SP2205 provided 
the best protection (60%) against pneumococcal infection, while immunization with the 
individual DHH subfamily 1 antigens did not confer significant protection. For more than 
a decade, the protective potential of various pneumococcal virulence factors, such as Ply, 
PspA, PspC, and PsaA, either as single proteins or in combination, has been examined 
(15,16,20,22,69-72). Two studies performed by Ogunniyi et al. have shown that in general, 
median survival times of mice immunized with different combinations of PspA, PsaA, PdB 
(a genetically detoxified derivative of Ply), and pneumococcal histidine triad (Pht) protein 
PhtB or PhtE were significantly longer upon pneumococcal challenge than survival times 
of mice immunized with single antigens (15,17). Briles et al. have shown that protection 
against pneumonia improved when mice were immunized with the combination of PspA 
and PdB compared to single-protein immunization (20). These studies have convincingly 
demonstrated that a combination protein vaccine improves the level of protection against 
pneumococcal disease in experimental mouse models. Our study also supports the para-
digm that a multicomponent protein vaccine will confer protection against invasive disease 
and perhaps against carriage as well. In our opinion, future experimental protein vaccine 
studies should focus on vaccine formulations that comprise protein antigens sharing com-
plementary functions or even combinations of functional protein families in order to deter-
mine whether the protection will be magnified.
 In conclusion, we have demonstrated that the two conserved pneumococcal DHH 
subfamily 1 proteins, SP1298 and SP2205, play a significant role in four important stages 
of pneumococcal pathogenesis, i.e., colonization, otitis media, pneumonia, and bactere-
mia, and that vaccination with a combination of both proteins is able to confer protection 
against pneumococcal disease. While further research on these two proteins is needed to 
determine their cellular localization during pathogenesis and biochemical function and to 
evaluate the protective potential against other pneumococcal serotypes and genotypes, 
our data suggest that SP1298 and SP2205 are interesting candidates for future protein-
based pneumococcal vaccines. 
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Abstract
The Pneumococcal serine-rich repeat protein (PsrP) is a pathogenicity island encoded 
adhesin that has been positively correlated with the ability of Streptococcus pneumoniae to 
cause invasive disease. Previous studies have shown that PsrP mediates bacterial attach-
ment to Keratin 10 (K10) on the surface of lung cells through amino acids 273–341 located 
in the Basic Region (BR) domain. In this study we determined that the BR domain of PsrP 
also mediates an intra-species interaction that promotes the formation of large bacterial 
aggregates in the nasopharynx and lungs of infected mice as well as in continuous flow-
through models of mature biofilms. Using numerous methods, including complementation 
of mutants with BR domain deficient constructs, fluorescent microscopy with Cy3-labeled 
recombinant (r)BR, Far Western blotting of bacterial lysates, co-immunoprecipitation with 
rBR, and growth of biofilms in the presence of antibodies and competitive peptides, we 
determined that the BR domain, in particular amino acids 122–166 of PsrP, promoted bac-
terial aggregation and that antibodies against the BR domain were neutralizing. Using 
similar methodologies, we also determined that SraP and GspB, the Serine-rich repeat 
proteins (SRRPs) of Staphylococcus aureus and Streptococcus gordonii, respectively, also 
promoted bacterial aggregation and that their Non-repeat domains bound to their respec-
tive SRRPs. This is the first report to show the presence of biofilm-like structures in the 
lungs of animals infected with S. pneumoniae and show that SRRPs have dual roles as 
host and bacterial adhesins. These studies suggest that recombinant Non-repeat domains 
of SRRPs (i.e. BR for S. pneumoniae) may be useful as vaccine antigens to protect against 
Gram-positive bacteria that cause infection.
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Author Summary
Serine-rich repeat proteins (SRRPs) are a family of surface-expressed proteins found in 
numerous Gram-positive pathogens, including Staphylococcus aureus, Streptococcus 
pneumoniae, Group B streptococci, and the oral streptococci that cause infective endo-
carditis. For all of these bacteria, SRRPs have been demonstrated to play pivotal roles 
in adhesion to tissues and the development of invasive disease. It is now known that 
biofilm formation is an important step for bacterial pathogenesis. Bacteria in biofilms have 
been shown to have differences in metabolism, gene expression, and protein produc-
tion that contribute to enhanced surface adhesion and the persistence of an infection. 
Herein we describe a novel role for PsrP, the S. pneumoniae SRRP, as an intra-species 
bacterial adhesin that promotes bacterial aggregation in the lungs of infected mice during 
pneumonia. In vitro we show that the Basic Region domain of PsrP promotes self-inter-
actions that result in denser biofilms, greater biofilm biomass, and altered architectures 
of surface grown cultures; these interactions could be neutralized by antibodies to PsrP 
that are protective against pneumococcal infection. We also demonstrate that the SRRPs 
of S. aureus and Streptococcus gordonii also function as intra-species bacterial adhesins. 
Therefore we conclude that SRRPs have dual roles as host-cell and intra-species bacterial 
adhesins.
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Introduction
Streptococcus pneumoniae is a leading cause of otitis media (OM), community-acquired 
pneumonia, sepsis and meningitis. Primarily a commensal, S. pneumoniae typically col-
onizes the nasopharynx asymptomatically, however in susceptible individuals such as 
infants, the elderly, persons who are immunocompromised, and those with sickle cell ane-
mia, the pneumococcus is often able to cause opportunistic diseases (1-4). Worldwide, S. 
pneumoniae is responsible for up to 14.5 million episodes of invasive pneumococcal dis-
ease (IPD) and 11% of all deaths in children (5,6). In the elderly the mortality-rate associ-
ated with IPD can exceed 20% and for those in nursing homes may be as high as 40% (7). 
Thus, the pneumococcus has been and remains a major cause of morbidity and mortality.
 psrP-secY2A2 is a S. pneumoniae pathogenicity island whose presence has been 
positively correlated with the ability to cause human disease (8). Analyses of the pub-
lished S. pneumoniae genomes has demonstrated that psrP-secY2A2 is present and con-
served in a number of globally distributed invasive clones, in particular those belonging 
to serotypes not covered by the heptavalent conjugate vaccine (9). To date, numerous 
studies have shown that deletion of genes within psrP-secY2A2 attenuated the ability of S. 
pneumoniae to cause disease in mice. psrP-secY2A2 mutants were shown to be unable 
to attach to lung cells, establish lower respiratory tract infection, and were delayed in 
their ability to enter the bloodstream from the lungs. Importantly, the same studies found 
that psrP-secY2A2 did not play an important role during nasopharyngeal colonization or 
during sepsis following intraperitoneal challenge(10-13). Thus psrP-secY2A2 is currently 
understood to be a lung-specific virulence determinant.
 In TIGR4, a virulent serotype 4 laboratory strain, psrP-secY2A2 is 37-kb in length and 
encodes 18 proteins. These include the Pneumococcal serine-rich repeat protein (PsrP), 
which is a lung cell adhesin, 10 putative glycosyltranferases, and 7 proteins homologous 
to components of an accessory Sec translocase (14). To date, the latter 17 genes remain 
uncharacterized; however, based on their homology to genes found within the Serine-rich 
repeat protein (SRRP) locus of Streptococcus gordonii, the encoded proteins are putatively 
responsible for the intracellular glycosylation of PsrP and for its transport to the bacterial 
surface (8,15-18). PsrP in TIGR4 is composed of 4,776 amino acids, has been confirmed 
to be glycosylated, and separates at an apparent molecular mass of 2,300 kDa on an aga-
rose gel (13). It is one of the largest bacterial proteins known. PsrP is organized into mul-
tiple domains including a cleavable N-terminal signal peptide, a small serine-rich repeat 
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region (SRR1), a unique non-repeat region (NR), followed by a second extremely long 
serine-rich region (SRR2), and a C-terminal cell wall anchor domain containing an LPXTG 
motif (Figure 1A). The SRR1 and SRR2 domains of PsrP are composed of 8 and 539 
serine-rich repeats (SRR) of the amino acid sequence SAS[A/E/V]SAS[T/I], respectively, 
and are the domains believed to be glycosylated. The NR domain of PsrP has a predicted 
pI value of 9.9, for this reason it is called the Basic Region (BR) domain.
 S. pneumoniae is surrounded by a polysaccharide capsule that protects the bac-
teria from phagocytosis but also inhibits adhesion to epithelial cells (19). Based on the 
size and domain organization of PsrP we have previously hypothesized that the extremely 
long SRR2 domain serves to extend the BR domain through the capsular polysaccharide 
to mediate lung cell adhesion (Figure 1B) (12,13). Consistent with this model, we have 
previously shown that PsrP is expressed on the bacterial surface, that the BR domain, in 
particular amino acids 273–341, was responsible for PsrP-mediated adhesion to Keratin 10 
(K10) on lung cells, and that complementation of psrP deficient mutants with a truncated 
version of the protein (having only 33 SRRs in its SRR2 domain) restored the ability of 
uncapsulated but not capsulated PsrP mutants to adhere to A549 cells, a human type II 
pneumocyte cell line (13).
 It is now recognized that biofilms play an important role during infectious diseas-
es. Briefly, bacteria in biofilms are more resistant to host-defense mechanisms including 
phagocytosis and serve as a recalcitrant source of bacteria during antimicrobial thera-
py (20,21). For S. pneumoniae, pneumococcal biofilms have been shown to occur in the 
middle ears of children with chronic otitis media and is thought to contribute to its refrac-
tory nature (22). Likewise, biofilms have been detected in the nasopharynx of infected 
chinchillas (23). However, until now biofilm structures have not been described in the lungs 
during pneumococcal pneumonia. This is in contrast to other respiratory tract pathogens, 
such as Pseudomonas aeruginosa and Bordatella pertussis, for which in vivo biofilm pro-
duction is now recognized to be an important pathogenic mechanism (21). Herein, we 
demonstrate for the first time that S. pneumoniae forms biofilm-like aggregates in the 
lungs. We show that this phenomenon is PsrP-dependent and mediated by its BR domain. 
Using recombinant protein and SRRP mutants, we show that the SRRPs of S. gordo-
nii and Staphylococcus aureus, GspB and SraP, respectively, also promote bacterial aggre-
gation, thus describing a previously unrecognized role for members of the SRRP family. 
Collectively, these findings suggest an important dual role for PsrP and other SRRPs dur-
ing infection, host cell and intra-species bacterial adhesion, both of which may be targeted 
for intervention with antibodies against recombinant (r)NR.
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S    SRR1               BR                      SRR2: SAS[A/E/V]SAST X 539
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Figure 1. Hypothetical model of PsrP on the surface of S. pneumoniae.
A) Domain structure of PsrP: N-terminal signal peptide (S); serine-rich repeat motif 1 (SAS[A/
E/V]SAST X 11) (SRR1); basic region (BR); serine-rich repeat motif 2 (SRR2); and the cell wall 
anchoring domain (CW) at the C-terminus. 
B) Illustration of PsrP on the bacterial surface. Based on the structural organization of PsrP and 
studies demonstrating that the BR domain binds to K10 on lung cells [13], we propose that the 
CWAD attaches the protein to the cell wall, while the long glycosylated SRR2 domain serves to 
extend BR through the capsular polysaccharide to mediate interactions.
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Materials & Methods
Bacterial strains and media
Wild type strains used in this study included S. pneumoniae strain TIGR4 and the previous-
ly described clinical isolates IPD-5, TNE-6012, and TBE-6050 (8,12,14). T4R is an unen-
capsulated derivative of TIGR4 (48). S. aureus ISP479C and S. gordonii M99 and their cor-
responding isogenic mutants ISP479C ∆sraP, and M99 ∆gspB have also been previously 
described (17,27). All of the S. pneumoniaemutants used in this study including T4 ∆psrP, 
T4 ΩpsrP-secY2A2, T4 ΩpsrP, and T4R ΩpsrP have been shown not to have polar effects 
on upstream and downstream gene transcription (12,13). S. pneumoniae and S. gordo-
nii were grown in Todd-Hewitt broth (THB) or on blood agar plates at 37°C in 5% CO2. S. 
aureus were grown in Tryptic-Soy Broth (TSB) or on blood agar plates at 37°C. Stocks for 
the PsrP mutants were grown in media supplemented with 1 μg/mL of erythromycin, those 
complemented with the expression vector pNE1 were grown on media supplemented with 
250 μg/mL of spectinomycin. SraP and GspB mutant stocks were grown in media supple-
mented with either 15 μg/mL of erythromycin or 5 μg/mL chloramphenicol respectively. E. 
coli strain DH5α (Invitrogen, Carlsbad CA) expressing recombinant PsrP constructs were 
grown with 50 μg/mL of kanamycin. Recombinant proteins were purified as previously 
described (13,26). To avoid stress effects on the bacteria, no antibiotics were added to the 
media during any of the experiments.
Infection of mice and collection of tissues
Female BALB/cJ mice, 5–6 weeks old, were obtained from The Jackson Laboratory (Bar 
Harbor, ME). Mice were anesthetized with 2.5% vaporized isoflurane prior to challenge. 
Exponential phase cultures of S. pneumoniae were centrifuged, washed, and suspended 
in sterile phosphate buffered saline (PBS). For each experimental cohort at least 6 mice 
were instilled with either 107 cfu of TIGR4 or T4 ∆psrP in 20 μL of PBS into the left nostril. 
After two days mice were sacrificed for tissue collection. For imaging experiments the 
intact lungs were collected and processed as described below. For enumeration of bacte-
rial aggregates, nasal lavage fluid was collected from anesthetized mice by instillation and 
retraction of 20 μl PBS. The same mice were subsequently asphyxiated with compressed 
CO2, and BAL fluid collected by flushing the lungs twice with 0.5 ml of PBS using a sterile 
catheter. All animal experimentation was conducted following the National Institutes for 
Health guidelines for housing and care of laboratory animals. Animal experiments were 
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reviewed and approved by the Institutional Animal Care and Use Committee at The Uni-
versity of Texas Health Science Center at San Antonio.
Scanning electron microscopy (SEM)
Lungs were cut in a sagital orientation, fixed for 2 hours with 2.5% glutaraldehyde in PBS, 
and then rinsed twice for 3 min in 0.1 M phosphate buffer (pH 7.4). Lungs were sub-
merged in 1% osmium diluted in Zetterquist’s Buffer for 30 minutes then washed with the 
same buffer for 2 minutes (49). This was followed by step-wise dehydration with ethanol 
(i.e. 70%, 95%, and 100%); the first two steps for 15 minutes, the last for 30 minutes. Sam-
ples were treated with hexamethyldisilizane for 5 minutes prior to drying in a desiccator 
overnight. The next day samples were sputter coated with gold palladium and viewed with 
a JEOL-6610 scanning electron microscope.
Visualization of bacterial aggregates ex vivo
From each mouse BAL and 1:10 PBS diluted nasopharyngeal lavage elutes were smeared 
onto glass slides, heat fixed, and Gram-stained. Since the nasopharyngeal samples were 
mucoid, dilution of the samples was warranted. Bacteria were visualized using a CKX41 
Olympus microscope at 200× magnification. For each biological sample 100 CFU were 
randomly selected, taking note of the approximate number of diplococci composing each 
CFU, either 1, 2–10, or >10. Images of the bacteria were acquired at 400× magnification 
to better show the multiple bacteria composing the aggregates.
Fluorescent microscopy of tissue sections
Lung tissues were excised and frozen in Tissue Tek O.C.T. solution (Miles Scientific). 5 μm 
thick lung sections were cut at the University of Texas at San Antonio Histopathology Core 
and stored at −80° C. Bacteria in the lung sections were detected by immunofluorescence 
using antibody against the capsular polysaccharide. Sections were thawed, fixed with ice-
cold acetone for 20 minutes, and then rehydrated with 70% ethyl alcohol and then PBS. 
Samples were permeabilized with 0.1% Triton-X-100 for 5 minutes then blocked with 10% 
fetal bovine serum (FBS) in F12 media for 1 hour. Sections were incubated with 1:1,000 
rabbit anti-serotype 4 pneumococcus antiserum (Statens Serum Institut, Denmark) over-
night at 4°C. After washing for three times with 0.5% Tween-PBS, sections were covered 
with FBS-F12 containing goat anti-rabbit FITC conjugated antibody (Invitrogen) at 1:2,000 
and DAPI (5 μg/ml; for DNA) and the sections incubated for 1 hour at room temperature. 
Tissue sections were washed and mounted with FluorSave (Merck Biosciences). Images 
were acquired at 1,000× using a Nikon AX-70 fluorescent Microscope and images pro-
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cessed with SimplePCI software.
Visualization of early and mature biofilms
Early biofilm formation was examined by measuring the ability of cells to adhere and accu-
mulate biomass on the bottom of a 96-well (flat-bottom) polystyrene plates (Costar, Corn-
ing Incorporated, Lowell MA) (24). Microtiter wells with 200 μl THB were inoculated with 
106 CFU of S. pneumoniae taken from cultures at mid-logarithmic phase growth (OD620 =
0.5). Plates were incubated at 37° C in 5% CO2. S. aureus and S. gordonii biofilm formation 
on microtiter plates was done in a similar manner, with the exception that TSB was used 
for S. aureus (50,51). Bacteria were grown for 2, 4, 6, 8, 18, and 24 h, after which the bio-
films were washed gently with PBS and stained with 100 μL of 0.1% CV. Biofilm biomass 
was subsequently quantified by image capture using an inverted microscope at 15× and 
100× magnification and measuring the corresponding optical density (A540) of the super-
natant following washing of the bacteria and solubilization of CV in 200 μL of 95% ethanol.
 Mature S. pneumoniae biofilms were grown under once through conditions in a glass 
slide chamber using a continuous-flow through reactor (25). The flow cell was constructed 
of anodized aluminum containing a chamber (4.0 mm by 1.3 cm by 5.0 cm) having two 
glass surfaces, one being a microscope slide and the other being a glass coverslip serv-
ing as the substratum. S. pneumoniae cells grown to mid-logarithmic phase served as the 
inoculum and were injected into a septum 4 cm upstream from the flow cell. Bacteria were 
allowed to attach to the glass substratum for 2 hours prior to initiating flow. The flow rate 
of the system was adjusted to 0.014 ml/min. Flow through the chamber was laminar, with 
a Reynolds number of <0.5, having a fluid residence time of 180 min. Biofilms were grown 
at 37°C in 5% CO2 for 3 days under once through conditions. Biofilms were then visualized 
by confocal laser microscopy as described below.
 Biofilms were also grown on the interior surface of a 1-meter long, size 16 Masterflex 
silicone tubing (0.89mm Internal Diameter, Cole Parmer Inc.) using once-through continu-
ous flow conditions. The line was inoculated with 5 mL of a mid-logarithmic culture and the 
bacteria were allowed to attach for 2 hours. The flow rate of the system was adjusted to 
0.035 ml/min and bacteria were grown for 3 days at 37°C in 5% CO2. Bacterial cells were 
harvested from the interior surface by pinching the tube along its entire length, resulting 
in removal of the cell material from the lumen of the tubing. Following extraction, exudates 
were gently suspended in 1 ml of PBS and the optical density (OD620) was measured. For 
light microscopy pictures, 50 μl of line exudate in saline was stained by the addition of 50 
μL of 1% CV. A volume of 5 μl of stained line exudates was applied to glass slides, cov-
erslipped, and images taken at 200× magnification using a light microscope. Viable cell 
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counts were determined by plating serial dilutions of exudates following the disruption of 
each sample by vortexing. Biofilm biomass was determined by measuring the total protein 
concentration of the exudates by BCA following the complete lysis of S. pneumoniae with 
saline containing 0.1% deoxycholate and 0.1% sodium-dodecyl sulfate, which activates the 
murein hydrolase autolysin, or use of French press for S. gordonii and S. aureus cultures. 
For studies testing whether antibodies or recombinant protein inhibited bacteria aggrega-
tion media was supplemented with BR antiserum at 1:1,000 or spiked with recombinant 
protein at a final concentration of 1.0 μM.
Confocal scanning laser microscopy and image acquisition
Confocal scanning laser microscopy was performed with an LSM 510 Meta inverted 
microscope (Zeiss, Heidelberg, Germany). Images were obtained with an LD-Apochrome 
40×/0.6 lens and the LSM 510 Meta image acquisition software (Zeiss). To visualize the 
biofilm architecture of 3-day-old biofilms, biofilms were stained using the Live/Dead Bac-
Light stain from Invitrogen (Carlsbad, CA). Quantitative analysis of epifluorescence micro-
scopic images obtained from flow cell-grown biofilms at the 6-day time point was per-
formed with COMSTAT image analysis software (52).
Far Western analysis of BR interactions
Recombinant full-length BR and truncated versions (BR.A, BR.B, BR.C) were expressed 
and purified from E. coli as previously described (13). Glycosylated PsrPSRR2(33)-HIS was 
purified in the same manner from TIGR4, with the exception that cultures were induced 
with 1% fucose and lysed with 1% SDS in PBS. Far Western analysis was carried out 
as described by Takamatsu et al. with minor modifications (53). Nitrocellulose mem-
branes were spotted with either 1 μg of whole cell lysate of S. pneumoniae, S. gordonii, S. 
aureus or E. coli expressing various PsrP constructs or with purified recombinant proteins 
in PBS. Membranes were incubated overnight in PBS with 4% bovine serum albumin and 
0.1% Tween 20 (T-PBS) at room temperature. The next day, membranes were washed with 
T-PBS three times for 5 minutes, and incubated overnight at 4°C on an orbital platform 
rocker with T-PBS containing 1% bovine serum albumin (TB-PBS) with 1 μg/mL of Gst-BR, 
PsrPSRR2(33)-HIS, or the designated NR constructs from S. gordonii and S. aureus. Membranes 
were washed and incubated with monoclonal mouse anti-Gst antibody (1:5,000 dilution) 
(Proto-Tech) overnight at 4°C in TB-PBS. Antibody binding was detected by incubating the 
membranes for 1 h with HRP-conjugated anti-mouse IgG (1:10,000 dilution) (Sigma), fol-
lowed by development with the Super Signal chemiluminescent detection system (Thermo 
Scientific). As a control for inadvertent interactions with the Gst tag, Far Western blots were 
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also performed using an unrelated Gst-tagged Chlamydia trachomatis protein (TC0109). 
No interactions were observed.
Co-immunoprecipitation of Gst-BR with rBR
Co-immunoprecipitation of Gst-BR with the truncated versions of rPsrP was carried out as 
previously described by Shivshankar et al. (13) Protein G Sepharose beads (Amersham) 
were incubated overnight at 4°C with mouse monoclonal penta-His antibody (1:50; Qia-
gen) in 500 ml of F12 media supplemented with 10% fetal bovine serum. Beads were 
incubated with 400 μl of whole bacterial lysates from E. coli expressing penta-His tagged 
recombinant versions of PsrP spiked with 200 μg of recombinant Gst-BR full length and 
incubated overnight at 4°C with gentle agitation. Beads were washed with RIPA buffer, then 
boiled in sample buffer for 10 min (54). Samples were separated on 12% SDS-PAGE gels 
and electrophoretically transferred to nitrocellulose membranes. Membranes were blocked 
with T-PBS containing 4% bovine serum for 30 min at room temperature. Membranes were 
then incubated overnight at 4°C with mouse anti-Gst (1:7500; Proto-tech) in blocking buff-
er. Following incubation, membranes were washed with T-PBS three times for 5 minutes. 
HRP-conjugated goat anti-rabbit Immunoglobulin G (1:10 000; Sigma) was used as the 
secondary antibody, followed by development with the Super Signal chemiluminescent 
detection system (Thermo Scientific).
Visualization of recombinant BR bound to TIGR4
For labeling of bacteria, TIGR4 and T4 ∆psrP were pelleted and suspended in 1 ml of 
carbonate buffer (pH 9.0) containing FITC (1 mg/ml) and incubated in the dark at room 
temperature with constant end-to-end tumbling. FITC-labeled bacteria were washed with 
PBS (pH 7.4) and centrifuged, until the supernatant became clear. rBR fragments were 
labeled using a FluorLink-Ab Cy3 labeling kit (Amersham) using the instructions provided 
by the manufacturer. Labeled bacteria were suspended in serum-free F12 media contain-
ing the labeled constructs for 1 hour and gently mixed. Subsequently, pneumococci were 
washed and suspended in F12 medium. Labeled bacteria and bound recombinant protein 
were visualized using an AX-70 fluorescent microscope and the images were captured 
at 0.1112–0.8886 ms exposure time for Cy2 and Cy3 filters. The magnification used for 
capture of digital images was 1000×. Captured images were processed using Simple PCI 
software.
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Adhesion assays
A549 cells (human alveolar type II pneumocytes; ATCC CRL-185), were grown to 90% 
confluence on 24-well plates (∼106 cells/well). Prior to use, cells were washed with cell 
F12 media to remove serum. For competitive inhibition binding assays, A549 cells were 
incubated with 1μM of either rBR, rBR.C, a synthesized peptide corresponding to AA 122–
167, or BSA for 1 HR. Following incubation, cells were exposed to media that contained 
107 cfu/mL of bacteria and incubated for 1 h at 37°C in 5% CO2. Nonadhering bacteria 
were removed by washing the cells 3 times with T-PBS and the number of adhering bac-
teria was determined by lysis of the monolayer with 0.1% Triton X-100 and plating wells 
per experiment.
Opsonophagocytosis assay
Bacterial cultures were centrifuged and suspended in 0.1M sodium carbonate buffer (pH 
8.0) at an OD620 of 0.2. Care was taken to cause minimal disruption of the biofilm aggre-
gates. The diluted cultures were labeled with fluorescent isothiocyanate (1mg/ml) for 30 
min at room temperature in the dark. Following labeling, cultures were gently washed three 
times with sterile PBS to remove free FITC and suspended in PBS. FITC-labeled bacteria 
were opsonized with 3% control rabbit serum for 30 minutes at 37°C with mild periodical 
tapping. Mouse J774.1, macrophage cultures maintained in 10% FBS containing DMEM 
were used for phagocytosis of the opsonized pneumococci. Macrophages were harvested, 
washed and diluted with opsonophagocytosis buffer (PBS containing 0.2% BSA). FITC-
labeled bacteria in 100 μl were added to 106 macrophage cells in 400 μl and incubated 
for 1 hour at 37°C with periodic shaking. Afterwards, the macrophages were pelleted and 
washed twice in the assay buffer. Cells were suspended in 400μl of 2% paraformaldehyde 
until flow cytometric analysis. A2-Laser BD FACSCaliber Analyzer (Becton Dickinson, NJ; 
Institutional Flow Cytometry Core Facility at the Health Science Center) was employed to 
analyze percent phagocytic uptake of the labeled bacteria by the macrophages. A mini-
mum of 20,000 events were counted for each sample at 480 nm excitation and 530nm 
detection wavelengths. Background fluorescence was nullified by subjecting negative con-
trol macrophages in assay buffer without any fluorescent bacteria to FACS analysis. Data 
were processed using CellQuest software.
Statistical analysis
For pair-wise comparisons of groups statistical analyses were performed using a Stu-
dent’s t-test. For multivariate analyses a 1-Way ANOVA followed by a post-priori test using 
Sigma Stat software was used.
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Results
PsrP promotes pneumococcal aggregation in vivo
To test whether PsrP contributed to biofilm or microcolony formation in vivo mice were 
infected with TIGR4 and its isogenic psrP deficient mutant, T4 ∆psrP, and whole lung sec-
tions were examined using scanning electron microscopy (SEM). As would be expected 
for both wild type and the mutant, the majority of bacteria present were in the form of 
diplococci. However, for TIGR4 we also observed the presence of large bacterial aggre-
gates attached to ciliated bronchial epithelial cells as well as to alveolar epithelial cells 
(Figure 2). For quantitative analysis of this phenomenon, nasal lavage fluid and bronchoal-
veolar lavage (BAL) fluid from mice was collected two days post-challenge. Aliquots from 
each biological sample were heat-fixed to glass slides, Gram-stained, and examined with a 
microscope (Figure 3A). In all, the number of bacterial aggregates composed of 2–9, and 
≥10 diplococci were significantly greater for mice infected with TIGR4 than T4 ∆psrP in 
both the nasopharyngeal and BAL elute fluids (Figure 3B,C). Moreover, the largest aggre-
gates, those composed of >100 bacteria, were observed only in mice infected with TIGR4. 
Fluorescent imaging of bacteria in frozen lung sections confirmed this phenotype; large 
bacterial aggregates were only detected in the lungs of TIGR4 infected mice. Thus we 
determined that PsrP promoted the formation of biofilm-like aggregates in vivo, including in 
the nasopharynx, a site previously shown not to require PsrP for bacterial colonization (12).
PsrP affects intimate bacteria to bacteria interactions
Given the previous results, moreover to develop an in vitro model that was amendable to 
manipulation, the ability of TIGR4 and T4 ∆psrP to form early biofilms was tested using 
microtiter plates (24). As shown in Figure 4A, no differences were observed between wild 
type and the mutant, suggesting that PsrP does not play a role in pneumococcal attach-
ment to polystyrene or the formation of early biofilm structures, in particular the bacteria 
lawn. The role of PsrP was next tested in 3-day old mature biofilms using the once-through 
continuous flow cells as described previously by Allegrucci et al. (25). In this system, a stark 
difference in the architecture of TIGR4 and T4 ∆psrP biofilms was observed (Figure 4B). 
Wild type biofilms displayed a dense cloud-like morphology with extremely large aggre-
gates that covered the glass surface. Closer inspection revealed that these aggregates 
were composed of tightly clustered pneumococci. In contrast, T4 ∆psrP biofilms displayed 
a less intimate phenotype characterized by smaller aggregates, gaps, and the formation 
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Figure 2. PsrP promotes the formation of bacterial aggregates in vivo.
SEM images of bronchial and alveolar epithelial cells following infection with TIGR4 (WT) and 
T4 ∆psrP (∆psrP). White arrows point at attached bacteria. Note the presence of WT bacteria in 
large aggregates of various sizes.
of columns, resulting in an overall patchier phenotype. Quantitative analysis of the biofilm 
structures using COMSTAT software confirmed that TIGR4 biofilms had significantly great-
er total biomass and average thickness than those formed by the T4∆psrP (Figure 4C). No 
differences in either the maximum thickness of the biofilms or the roughness coefficient 
(a measure of biofilm heterogeneity) were observed (Figure 4C; data not shown, respec-
tively), indicating that T4 ∆psrP could still form biofilms, although with distinct architecture. 
Importantly, T4 ΩpsrP-secY2A2, a mutant deficient in the entire psrP-secY2A2 pathogenicity 
island, behaved identically to T4 ∆psrP, forming patchy biofilms with small aggregates and 
less intimate associated bacteria.
 Bacterial biofilms were also grown under once through conditions in silicone tubing. 
After a designated time, the biofilms were extruded from the line and examined for bio-
mass both visually and quantitatively. After 3 days of growth, differences between TIGR4 
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and T4 ∆psrP in opacity of the exudates were visible to the eye (Figure 5A) and could 
be confirmed using a spectrophotometer which showed a >3-fold difference in optical 
density (Figure 5B). Microscopic visualization of the line exudates following crystal violet 
(CV) staining revealed that TIGR4 had formed large aggregates whereas T4∆psrP exu-
dates were composed of small clusters or of individual diplococci (Figure 5C). Increased 
biofilm biomass was supported by measurement of total protein concentrations that 
showed TIGR4 biofilm exudates had 2–3 fold more protein than those corresponding to 
T4 ∆psrP (Figure 5D).
Figure 3. Frequency of bacterial aggregates in the nasopharynx and lungs.
A) Micrographs of TIGR4 (WT) and T4 ∆psrP (∆psrP) Gram-stained bacteria from either 
BAL or nasal lavage (IN) elutes. Images were taken at 400× magnification. Images are not 
representative of the total bacteria population, but instead are shown to demonstrate the typical 
pneumococcal aggregate containing at least 10 or more individual diplococci (10+). 
B) Actual percentages of pneumococcal aggregate based on size in the nasopharynx and  
C) lungs following counting of >100 randomly selected CFUs per biological replicate. Note 
that TIGR4 had significantly greater levels of 2–9 and 10+ aggregates compared to T4 ∆psrP. 
Furthermore, while 10+ aggregates were observed in mice infected with T4 ∆psrP, albeit 
infrequently, the largest of these aggregates were not comparable in size to those formed by 
TIGR4. Statistical analyses were performed using a Student's t-test.
A. B.
C.
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 Of note, during planktonic growth TIGR4, T4 ∆psrP, and T4 ΩpsrP-secy2A2 were 
indistinguishable, growing either as short chains or diplococci with a marked absence of 
aggregates (data not shown). This led us to examine psrP transcription using Real-Time 
PCR and the finding that TIGR4 expressed psrPat levels 47-fold greater during biofilm ver-
sus planktonic culture (P = 0.04 using a Student’s t-test). Thus low expression of psrP may 
be one reason TIGR4 did not form aggregates during liquid culture.
Figure 4. Deletion of psrP alters bacterial interactions in mature biofilms but not during early 
biofilm attachment.
A) Attachment of TIGR4 (WT) and T4 ∆psrP (∆psrP) to the bottom of 96-well polystyrene 
microtiter plate in an early biofilm model. Biofilm biomass was determined using crystal violet 
(CV540) stain as described in the methods. 
B) Micrographs of mature TIGR4 and T4 ∆psrP biofilms grown in a flow cell under once-through 
flow conditions for 3 days. Bacteria were visualized with Live/Dead BacLight stain using an 
inverted confocal laser scanning microscope at 400× magnification. 
C) Quantitative analysis of the biofilms was performed using COMSTAT image analysis software. 
All experiments were performed in triplicate. Statistical analyses were performed using a two-
tailed Student's t-test. For panel C error bars denote standard error.
A. B.
C.
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The BR domain mediates intra-species bacterial interactions
To date a number of groups, including our own, have shown that SRRPs mediate bacte-
rial adhesion to host cells primarily through their NR domain (13,26,27). For this reason 
we sought to test whether the BR domain of PsrP was also involved in biofilm/bacterial 
aggregation. To do this we first utilized a pre-existing collection (described in Figure S3) of 
encapsulated (T4 ΩpsrP) and unencapsulated (T4RΩpsrP) S. pneumoniae mutants defi-
cient in PsrP that either expressed a truncated version of PsrP with 33 SRRs in its SRR2 
domain (PsrPSRR2(33)), a similar truncated version lacking the BR domain (PsrPSRR2(33)-BR), or 
carried the empty expression vector pNE1 (13). These strains were tested for their ability 
to form biofilms in silicone lines under once through conditions.
 Complementation of T4 ΩpsrP with PsrPSRR2(33), but not PsrPSRR2(33)-BR or the empty 
pNE1 vector, partially restored the ability of T4 ΩpsrP to form large aggregates in the lines 
when examined microscopically (Figure 6A). However, measurement of other biofilm mark-
ers such as optical density and total protein concentration showed no differences between 
any of the complemented mutants and the negative controls (Figure 6B–C). Complemen-
tation of T4R ΩpsrP with PsrPSRR2(33), also partially restored the ability of T4R ΩpsrP to 
form aggregates (Figure 6A). In this instance, line exudates from T4R ΩpsrP with PsrP-
SRR2(33) had significant more biofilm biomass than the negative controls (Figure 6B–C). 
Figure 5. PsrP promotes bacterial aggregation in a line biofilm model.
Mid-logarithmic growth phase TIGR4 (WT) and T4 ∆psrP (∆psrP) were used to inoculate 1 
meter of a 0.8 mm diameter silicone-lined plastic tubing. After 3 days, biofilms within the lines 
were extruded.         
A) Representative photograph of the exudate suspension immediately following its collection.  
B) Optical density (OD540) of bacterial exudates.      
C) Microscopic images of CV stained bacteria extracted from the lines. Note the formation of 
aggregates by TIGR4 but not T4 ∆psrP. 
D) Levels of protein in bacteria line exudates as determined by bicinchoninic acid assay (BCA) 
following detergent lysis of the bacteria. Images are representative of at least 3 experiments. 
Statistical analyses were performed using a two-tailed Student's t-test. Error bars denote 
standard error.
A. B. C. D.
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Importantly, the truncated version of PsrP lacking the BR domain failed to restore, even 
partially, T4 ΩpsrP or T4R ΩpsrP suggesting that the BR domain was responsible for the 
intra-species aggregation. This was subsequently confirmed by Far-Western blot analyses 
that showed that Gst-tagged recombinant BR (Gst-BR) bound only to S. pneumoniae cell 
lysates that contained a truncated PsrP with the BR domain (Figure 6D) and a control 
experiment showing that a Gst-tagged Chlamydia trachomatis protein did not interact with 
these lysates.
 To further explore the role of the BR domain in the observed bacteria to bacteria 
interactions, the ability of His-tagged BR constructs (rBR; Figure 7A), purified from Escheri-
chia coli and Cy3 labeled, were tested for their ability to bind to the surface of TIGR4 and 
T4 ∆psrP. Full-length rBR interacted with TIGR4 but not with T4 ∆psrP (Figure 7B), con-
firming not only that PsrP bound to pneumococci, but also suggesting that its ligand was 
another PsrP. Furthermore, only rBR.A retained the ability to attach to PsrP on the pneu-
mococcal surface. This suggested that the binding domain of PsrP was possibly located 
within AA 122–166, the section not shared between rBR.A and rBR.B.
 Hereafter, BR to BR interactions were tested for by Far Western and co-immunopre-
cipitation. Far Western blot experiments using assorted E. coli cell lysates from bacteria 
expressing assorted rBR constructs, confirmed that only lysates containing PsrP constructs 
with AA 122–166 bound successfully to Gst-BR (Figure 7C). This was also observed in co-
immunoprecipitation experiments, whereby Gst-BR was tested for its ability to bind whole 
cell lysates from E. coli expressing versions of PsrP (Figure 7D). Far Western blots using 
purified proteins showed that Gst-BR had affinity to purified rBR, rBR.A, and a synthesized 
peptide corresponding to AA 122–166, but not rBR.B, BR.C, or the control his-tagged 
Streptolysin O (Figure 7E). Hence, using numerous assays it was determined that the BR 
domain, most likely AA 122–166, had self-interacting properties that might be responsible 
for the observed bacterial aggregation.
 Of note, because the BR constructs were purified from E. coli and PsrP is normally 
glycosylated, the above observations may have been an artifact of the unglycosylated 
constructs used. To address this possibility a glycosyated truncated PsrP construct was 
purified from S. pneumoniae (PsrPSRR2(33)-HIS) and tested for its ability to bind S. pneumoni-
ae cell lysates containing either native PsrP or assorted constructs. As shown in Figure 7F, 
it was determined that a glycosylated PsrP probe maintained specificity for the BR domain 
even in the context of glycosylated recipient protein. A finding that supports the notion that 
PsrP to PsrP interactions occur in natural setting when PsrP is always glycosylated.
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The aggregation and K10-binding subdomains of BR are independent
To determine whether the BR aggregation (AA 122–167) and the K10 binding subdomains 
(AA 273–341) of BR had functionally independent roles, competitive inhibition assays were 
performed using rBR constructs. Bacterial adhesion to A549 cells was tested following 
incubation of cells with the AA 122–166 peptide, rBR, and rBR.C (Figure 8A). Pre-treatment 
of A549 cells with AA 122–167 had no impact on adhesion. In contrast and consistent with 
the location of the K10 binding domain within BR.C: 1) TIGR4 adhered significantly less 
Figure 6. The BR domain of PsrP mediates intra-species bacterial interactions.
Encapsulated and unencapsulated mutants of TIGR4, lacking PsrP (T4 ΩpsrP, T4R ΩpsrP, 
respectively), were complemented with plasmids expressing: a truncated version of PsrP having 
only 33 SRR2 repeats (PsrP(33)), the truncated version of PsrP missing the BR domain (PsrP(33)-BR), 
or with the empty expression vector (pNE1). 
A) Microscopic images of CV stained bacteria isolated from the line biofilm model. 
B) Optical density (OD620) of biofilm line exudates. 
C) Biomass of the biofilms as determined by protein levels using the BCA assay. 
D) Far Western analyses of recombinant BR interactions with membrane-bound truncated 
versions of PsrP expressed in S. pneumoniae. 
All images are representative of at least 3 independent experiments. Statistical analyses were 
performed using 1-Way ANOVA analysis. Error bars denote standard error. For panel B and C 
asterisks denote statistical significance versus WT; hash sign denotes statistical significance 
versus the empty vector control.
A.
B. C. D.
page            188 | PsrP mediates biofi lm-like aggregates in the lungsChapter 8
to cells treated with rBR or rBR.C, 2) TIGR4 adhered to BSA treated cells better than T4 
∆psrP. In complementary biofilm experiments the opposite result was observed. Addition 
of 1 μM peptide AA 122–167 to media reduced the aggregation phenotype observed for 
TIGR4 (Figure 8B) and modestly lowered the optical density of the biofilm exudate and 
the total biomass collected from the continuous flow lines versus addition of BR.C (Figure 
8C–D). Thus these findings suggested that the aggregation and K10 subdomains of PsrP 
had distinct roles that did not overlap during host cell adhesion or biofilm formation.
 Finally we sought to determine a biological effect for the aggregation phenotype. 
We observed that after 1 hour, 69±2% of J477 macrophages incubated with planktoni-
cally grown TIGR4 were associated with FITC-labeled bacteria whereas only 51±5% of 
macrophages mixed with biofilm grown TIGR4 were positive (P = 0.024). Macrophages 
exposed to biofilm grown TIGR4 also took up less bacteria than macrophages mixed with 
planktonic (74±1%; P = <0.001) and biofilm (60±1%; P = <0.001) cultures of T4 ∆psrP. 
Interestingly, a 10% reduction in macrophage uptake was observed for the biofilm versus 
planktonic grown T4 ∆psrP cultures (P = 0.077); and no difference was observed between 
macrophage uptake of TIGR4 and T4 ∆psrP when taken from planktonic cultures. These 
findings suggest, that in addition to PsrP, other bacterial factors expressed during growth 
in a biofilm also affect opsonophagoyctosis.
Antibodies to the BR domain, but not to the SASASAST motif, block bacterial 
aggregation
Previously we had shown that antibodies against the SRR1-BR domains of PsrP neutral-
ized the ability of S. pneumoniae to attach to lung cells and that vaccination with rBR 
protected mice against pneumococcal challenge (1213). For this reason we tested the 
ability of polyclonal antiserum against rBR and against a SRR motif peptide to block bac-
terial aggregation in the biofilm line model. Todd Hewitt Broth (THB) supplemented with 
a 1:1000 dilution of antiserum against the BR domain inhibited the formation of bacte-
rial aggregates as observed by microscopic visualization of the biofilm line exudates. In 
contrast, bacteria in media supplemented with antiserum to the SRR motif peptide or that 
from naïve animals, formed aggregates similar to wild type bacteria grown under serum 
free conditions (Figure 9A). Biofilm exudate optical density and protein concentrations sup-
ported these microscopic observations (Figure 9B–C). To determine whether the effect of 
the BR antiserum on biofilm formation was specific for TIGR4, we tested the ability of anti-
bodies to the BR domain to block biofilm formation in unrelated clinical isolates. Antiserum 
against rBR from TIGR4 inhibited biofilm formation in two unrelated clinical isolates that 
carried PsrP. The same sera had no effect on biofilm formation by an invasive serotype 
                                                        page 189PsrP mediates biofi lm-like aggregates in the lungs | Chapter 8
14 isolate that lacked PsrP. Therefore these studies confirmed previous observations that 
increased bacteria aggregation in biofilm models can occur independently of PsrP, but that 
if present, antiserum against BR can block the contribution of PsrP to these processes.
Figure 7. Recombinant BR interacts with pneumococci that carry amino acids 122–166 of PsrP.
A) The designated recombinant PsrP constructs were expressed and purified from E. coli. 
B) Micrographs of FITC-labeled bacteria following their incubation with CY3-labeled rBR or the 
designated truncated versions. Note that only Cy3-labeled rBR and rBR.A bound to TIGR4. 
Moreover, neither bound to T4 ∆psrP. This suggests that recombinant BR binds to PsrP on the 
bacteria surface. 
C) Far Western blot examining the interaction of Gst-BR with cell lysates from E. coli expressing 
assorted rBR constructs spotted on a membrane. 
D) Co-immunoprecipitation of Gst-BR (65 kDa) from spiked E. coli lysates expressing His-
tagged rBR constructs. 
E) Far Western blot examining the interaction of Gst-BR with purified rBR constructs and a 
synthesized peptide corresponding to AA 122–166. 
F) Far Western blot examining the interaction of a glycosylated PsrP construct purified from S. 
pneumoniae, PsrPSRR2(33)-HIS with glycosylated PsrP constructs expressed in TIGR4.
A. B.
C. D. E. F.
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SRRPs mediate intra-species adhesion in pathogenic bacteria
To determine whether other SRRPs also mediated intra-species aggregation we tested the 
effect of gsp Band sraP deletion on S. gordonii and S. aureus biofilm architecture, respec-
tively. Deletion of gspB and sraP negatively impacted biofilm formation in the microtiter 
biofilm model at 24 hours (Figure 10A,B). Growth of wild type and mutant bacteria in the 
line models also demonstrated that both proteins contributed to the formation of large 
aggregates during surface attached growth; although this property was much more dra-
matic for S. gordonii than for S. aureus which did not show a significant difference in the 
optical densities of the exudates (Figure 10C,D). Of note, S. aureus biofilm experiments 
were stopped after 1 day due to bacteria overgrowth and blockage of the lines.
Figure 8. Incubation of bacteria with AA 122–166 impairs bacterial aggregation but not 
adhesion to cells.
A) Adhesion of TIGR4 following pre-incubation of A549 cells with media containing 1.0 μM of the 
designated rBR constructs. All values were normalized against cells incubated with BSA (163±4 
bacteria/106 cells). TIGR4 in media containing 1 μM BR.C or the synthesized peptide 122–126 
was used to inoculate and grow biofilms in the line biofilm model. After 3 days, biofilms within 
the lines were extruded. 
B) Representative photograph of the exudate suspension immediately following its collection 
and staining with CV. Images are representative of at least 3 experiments. 
C) Optical density (OD540) of bacterial exudates. 
D) Levels of protein in bacteria line exudates. Statistical analyses were performed using a 
Student's t-test. Error bars denote standard error.
A.
C.
B.
D.
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 Subsequent Far Western analysis using Gst-BR from S. pneumoniae as well as 
recombinant SRR1-NR from SraP and recombinant NR from GspB showed that these 
proteins have affinity for cell lysates from their parent strain but not for cell lysates from 
isogenic SRRP deficient mutants (Figure 10E). This supports the notion that these pro-
teins might be involved in intra-species aggregation. For PsrP BR fromS. pneumoniae, no 
affinity was observed for cell lysates from either S. gordonii or S. aureus suggesting that 
PsrP does not play a role as an inter-species adhesin (Figure 10E). In contrast, the NR 
constructs from S. aureus and S. gordonii bound to cell lysates from the other bacteria, 
even in the absence of the SRRP (Figure 10E). The discrepancy between PsrP and the 
other SRRPs might be explained by the fact that certain SRRPs have been described to 
have lectin activity (26,27). In contrast PsrP adhesion has been shown to be independent 
of lectin-activity (13).
Figure 9. Antibodies to the BR domain but not the serine-rich motif block intra-species bacterial 
interactions.
THB was supplemented with either a 1:1000 dilution of naïve rabbit serum (control), rabbit 
antiserum from rabbits immunized with a SASASASTSASASAST peptide designed after the SRR 
motif, or rabbit antiserum to recombinant BR. 
A) Micrographs of CV stained bacteria extruded from the biofilm lines.  
B) Optical density of bacterial exudates.
C) Levels of protein in bacterial line exudates as determined by BCA analysis. 
Images are representative of at least 3 independent experiments. Statistical analyses were 
performed using a two-tailed Student's t-test. Number sign denotes statistical significance 
versus whole serum. Asterisks denote statistical significance versus anti-SRR serum. Error bars 
denote standard error.
A. B.
C.
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Figure 10. The SRRPs of S. gordonii and S. aureus promote bacterial aggregation.
Light microscopic images of CV stained 
A) S. gordonii M99 and 
B) S. aureus ISP479C and their respective isogenic SRRP mutants following 24 hours of growth 
in a 96-well polystyrene microtiter plate early biofilm model. B) Average biomass of early biofilms 
as determined by CV540 analyses. Error bars denote standard deviation. 
C) Microscopic images of bacteria extruded from the biofilm lines after 3 days for S. gordonii and 
1 day for S. aureus. 
D) Measurement of optical density of bacterial exudates collected from the biofilm lines. Error 
bars denote standard deviation. 
E) Far-western examining the intra- and inter-species specificity of the NR domains of S. 
pneumoniae, S. gordonii and S. aureus. 
Whole cell lysates from S. gordonii, S. aureus, and their respective isogenic SRRP mutants were 
spotted onto nitrocellulose membranes and probed with these GST-tagged proteins. Images 
are representative of three individual experiments. For panels B) and D) statistical analyses were 
performed using a Student's t-test.
A. B.
C. D.
E.
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Discussion
To date, SRRPs have been described in at least 9 Gram-positive bacteria and have 
been shown to function as adhesins that contribute to virulence. For example, deletion 
of sraP and gspB in S. aureus and S. gordonii, respectively, decreased the ability of these 
bacteria to bind to platelets and form vegetative plaques on heart valves of catheterized 
rats (27,28). Similarly, Srr-1 of Streptococcus agalactiae has been shown to bind human 
Keratin 4, mediate adherence to mucosal epithelial cells, and promote invasion of bacte-
ria through human brain microvasculature endothelial cells (29,30). SRRPs also mediate 
acellular attachment, a role important for colonization of the dental surface by oral strep-
tococci. Froelinger and Fives-Taylor showed that Streptococcus parasanguis containing 
mutations of Fap1 failed to attach to saliva-coated hydroxyapatite (31). Likewise, deletion 
of srpA significantly diminished the ability of Streptococcus cristatus to attach to glass 
slides (32). Thus, while it was well established that SRRPs play an important role in bac-
terial attachment to cells or surfaces, until this report their role as intra-species adhesins 
remained unrecognized.
 A dual role, host and bacterial adhesin for bacterial surface proteins is not unprec-
edented. For example, in Streptococcus pyogenes and S. agalactiae, the pilus proteins 
mediate adhesion to epithelial cells and promote microtiter biofilm formation (33,34). Like-
wise, for Neisseria meningitidis, PilX, also a pilus-associated protein, mediates adhesion 
to epithelial cells and facilitates bacterial aggregation (35). For the pneumococcus, some 
evidence existed that bacterial adhesins may also have dual roles. In 2008, Munoz-Elias et 
al. found that the pneumococcal adhesins Choline binding protein A and the pilus pro-
tein RrgA were both required for robust biofilm formation on microtiter plates and effi-
cient nasopharyngeal colonization (36). However, the attenuated biofilm phenotype was 
observed only with unencapsulated bacteria and encapsulated mutants formed biofilms 
normally. Other pneumococcal proteins shown to affect biofilm formation in vitro include 
Neuraminidase A, which possibly alters the extracellular matrix (37-39), competence pro-
teins, which suggest an altered protein profile (40,41), and capsule synthesis enzymes, 
which were determined to be down regulated in biofilms (36,42,43). Unlike PsrP, which 
would be expected to bridge cells directly, these proteins most likely act indirectly by alter-
ing gene expression, the extracellular milieu, or the surface availability of other adhesins, 
including possibly RrgA and CbpA.
 Our studies determined that the self-aggregating subdomain of PsrP was located in 
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the BR domain and involves amino acids 122–166. Recombinant BR constructs containing 
these amino acids were able to bind S. pneumoniae carrying PsrP, had an affinity for the 
BR domain in other PsrP constructs, and could modestly inhibit biofilm formation when 
added to media. Importantly, adhesion assays using pretreated cells and biofilm assays 
with rBR.C showed that the AA 122–166 was not responsible for adhesion to lung cells 
and that the K10 binding subdomain (AA 273–341) was not involved in bacterial aggrega-
tion. Thus these subdomains appeared to have independent roles during the conditions 
tested. Further studies are warranted to delineate the specific AAs responsible for these 
adhesive properties, also to determine the structure of the BR domain and clarify how 
these subdomains interact with PsrP on other pneumococci and K10 on lung cells.
 GspB and SraP have been previously shown to bind platelets (27,28). While the 
ligand for SraP is unknown, it has been determined that GspB binds to Sialyl T-antigen 
on platelet membrane glycoprotein Ibα (26,27). The observation that the NR domains of 
GspB and SraP bound to cell lysates containing their respective SRRPs but not to their 
mutants and that the mutants had diminished aggregative properties suggests that SRRPs 
in other bacteria might also mediate aggregation in vivo. One could imagine that SraP 
on S. aureus or GspB on S. gordonii mediating attachment to platelets and cells in an 
endocarditic lesion while at the same time mediating adhesion of individual bacteria to 
each other. Similarly, one could envision a microcolony of the pneumococcus in the lungs 
with some bacteria attached to host cells via PsrP/K10 interactions and other bacteria 
attached to these bacteria through PsrP/PsrP interactions. Presumably, this is what was 
observed in the lungs of the infected mice. Interestingly, the finding that GspB and SraP 
NRs bound to cell lysates from other bacteria suggests that these proteins may also medi-
ate inter-species biofilm formation. For S. gordonii, this would be relevant as the dental 
plaque is now recognized to be a multi-species biofilm. Importantly, neutralization of pneu-
mococcal aggregation in biofilms with BR antiserum suggests that SRRPs might have 
utility as vaccine antigens. One caveat is that SRRPs would have to be one-component 
of a multi-valent vaccine because not all strains of S. pneumoniae, S. aureus, or the oral 
streptococci carry these proteins.
 In previous studies we had found that the length of the SRR2 domain was important 
for adhesion to K10 when capsule was present. Consistent with these findings, the inability 
of truncated PsrP to fully complement capsulated mutants supports our hypothetical mod-
el that the SRR2 domain serves to extend the BR domain away from the cell to mediate 
bacterial interactions. This model is also indirectly supported by Munoz-Elias et al., who 
showed that down-regulation of capsule allowed CbpA and RrgA to contribute to biofilm 
production (36). It is also noteworthy to state that Munoz-Elias et al. did not identify PsrP in 
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their screen for biofilm mutants although they used TIGR4 which carries PsrP. This can be 
explained by the fact that we observed no contribution for PsrP in the microtiter plate early 
biofilm model.
 We observed that PsrP-mediated bacterial aggregation occurred in the nasopharynx, 
despite earlier studies demonstrating that K10 was absent from this site and that PsrP 
was not required for nasopharyngeal colonization. Aggregation of S. pneumoniae in the 
nasopharynx may serve as a mechanism to resist opsonophagocytosis as shown herein, 
or we speculate a way to resist desiccation during transmission of infectious particles. The 
observation that aggregates were present at an anatomical site that lacked K10, further 
supports an independent role for these PsrP subdomains. In regards to opsonophagoyc-
tosis, one important consideration is that the pneumococcus most likely has different gene 
expression profiles in vivo as an aggregate attached to a cell versus in vitro as a biofilm 
(44). Thus caution is warranted in applying our vitro observations, such as resistance to 
opsonophagoyctosis or enhanced PsrP expression during biofilm growth, with events that 
occur in vivo.
 Polyclonal antibodies against the BR domain, but not the SRR motif, neutralized the 
ability of TIGR4 and clinical isolates carrying PsrP to form aggregates in the line model. 
These findings were consistent with previous studies showing that antibodies against BR 
also neutralized its ability to mediate adhesion to host cells and protected mice against 
pneumonia (12,13). One possible reason that antibodies against the SRR motif peptide 
failed to have a neutralizing effect is that PsrP is glycosylated and antibodies against the 
peptide failed to recognize the native version of the protein. Alternatively, antibodies to the 
SRR motif may bind away from the BR domain and therefore do not inhibit the ability of 
the BR domain to self-interact. Interestingly, polyclonal antibodies to surface proteins often 
promote aggregation. This did not occur for unknown reasons. Finally, our finding that 
antibodies against rBR neutralized bacterial aggregation in the biofilm line model suggests 
that the same antibodies might also neutralize bacterial aggregation in vivo. This remains 
to be tested, however, the protection that was observed in mice following immunization 
with rBR (13), may have been in part due to inhibition of bacterial aggregation in addition 
to blocking interactions with K10.
 Importantly, because rNR domains produced in E. coli are not glycosylated, yet for 
the tested SRRPs were able to aggregate, immunoprecipitate, and bind to native protein 
in cell lysates, it seems that the BR domain does not require glycosylation to function as 
a self-adhesin. This is supported by the observation that addition of antibodies against 
unglycosylated rBR and that synthetic peptide AA 122–166 both inhibited bacterial aggre-
gation in the biofilm line. In contrast to the latter concept, Wu et al.demonstrated that 
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monoclonal antibodies specific for the glycan motifs of the serine-rich repeat motifs of 
Fap1 were capable of blocking attachment to saliva coated hydroxyapatite by Streptococ-
cus parasanguis (45). Importantly, Fap1 is the most divergent of the SRRPs and has 2 NR 
domains. Fap1 adhesion to saliva coated hydroxyapatite is mediated by glyconjugates on 
the serine-rich repeat domain (46); as evidenced by the fact that inactivation of one of the 
glycosyltranferases known to modify the glycan moieties of Fap1, drastically altered the 
ability of S. parasanguis to form biofilms (45). Thus Fap1 is interesting because it sug-
gests an NR-independent mechanism for SRRP adhesion, which is distinct from those 
discussed for GspB, SraP, or PsrP. Future studies need to further examine the differences 
between these diverse SRRPs and to determine if the two NRs of Fap1 play a role in bac-
terial aggregation. This is especially true given that the NR domain of SraP has a pI of 5.6, 
in contrast to the basic NRs of GspB (9.5 pI) and PsrP (9.9 pI) (47).
 In summary, we have described for the first time the presence of a pneumococcal 
biofilm-like structure in the lungs of infected mice. We have determined that PsrP medi-
ates a more intimate bacterium to bacterium interaction that contributes to the presence of 
large bacteria aggregates in vivo and increased biofilm biomass and aggregates in vitro. 
This property appears to be shared among other SRRPs including those of medically rel-
evant bacteria such as S. aureus and S. gordonii, suggesting that it is a conserved func-
tion for this class of proteins. How these interactions contribute to pathogenesis remains 
to be fully determined, however, studies with other bacteria indicate that biofilms serve to 
inhibit phagocytosis, protect against defensin-mediated killing, and serve as a focal point 
of infection during early stages of disease. Future experiments will be required to deter-
mine the extent to which this may apply for SRRP-mediated aggregates in vivo.
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Summarizing discussion
Acute otitis media (AOM) is one of the most frequent diseases in childhood. In developed 
countries 80% of all children suffer at least from one AOM episode before the age of three 
(1). Although AOM is self-limiting in the majority of the cases, there is a significant group 
of children suffering from recurrent acute otitis media (rAOM) or chronic otitis media with 
effusion (COME), which are both associated with significant morbidity. 
 Optimal treatment for rAOM and COME remains highly controversial. In order to 
understand the underlying mechanisms of OM disease, in particular the microbiology and 
immunology, and to support future treatment and prevention strategies, clinical and experi-
mental studies are warranted. In this thesis a cohort of rAOM and COME patients was 
described, and the microbial profile in the middle ear and nasopharynx was investigated. 
In addition, the association between inflammation and bacterial load in the middle ear 
was demonstrated, as well as the humoral immune response to a selection of Morax-
ella catarrhalis and Streptococcus pneumoniae antigens. We demonstrated an increased 
serum resistance of non-typeable Haemophilus influenzae (NTHi) isolates in middle ear 
fluid. Furthermore, using a novel murine model of AOM infection, several pneumococcal 
proteins were investigated as to their contribution to OM pathogenesis, their protective 
potential against pneumococcal disease and their role in bacterial aggregation and biofilm 
formation.
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Clinical microbiology
Bacteria, viruses and OM
We investigated whether the microbial profiling was useful to differentiate between rAOM 
and COME patients (Chapter 2). Children up to 5 years of age, suffering from rAOM or 
COME and scheduled for tympanostomy tube insertion were enrolled in a retrospective 
study between 2008 and 2009. Our results showed that the same pathogenic bacterial 
species and viruses are implicated in the pathogenesis of both rAOM and COME disease. 
In line with recent studies (2,3) these findings do not support the classical assumption that 
the microbial profile is pathognomic for either r AOM or COME, or that COME is merely a 
consequence of persistent sterile inflammation in the middle ear.
 In children with rAOM and COME, H. influenzae and rhinovirus are the predominant 
pathogens in middle ear and nasopharynx (Chapter 2). Analysis of the middle ear fluid 
using bacterial culture typically revealed the presence of one predominant bacterial spe-
cies per sample, i.e. in 98% of the middle ear fluids one bacterial species was detected. 
With the use of bacterial culture S. pneumoniae, H. influenzae and M. catarrhalis were 
detected in respectively 4%, 20% and 8% of the middle ear fluids. Bacterial PCR is a more 
sensitive method to detect (multiple) bacteria compared to detection by bacterial culture: 
S. pneumoniae, H. influenzae and M. catarrhalis were found in respectively 7%, 34% and 
25% of the middle ear fluids. Co-infections in the middle ear were scarce: 14% of the 
children had multiple bacterial species in the middle ear based on PCR-analysis. In bacte-
rial culture negative specimens S. pneumoniae was detected in 4.1% (NS), H. influenzae 
in 16.5% (P<0.01) and M. catarrhalis in 19% (P<0.01). Thus, in particular detection of M. 
catarrhalis increases with the use of PCR compared to culture. 
 S. pneumoniae, H. influenzae and M. catarrhalis isolates that were detected in the 
middle ear fluids of our cohorts were in the great majority genetically identical (80-100%) 
to those isolates cultured from the nasopharynx, as determined by multi-locus sequence 
typing (4,5) as the genotypes of the bacteria cultured from the middle ear comprised 
a heterogeneous population structure, even though they all originated from a relatively 
restricted geographical region of the Netherlands. Kaur et al. have investigated 165 NTHi 
isolates but were unable to identify predominant MLST-types among strains colonizing 
the nasopharynx versus those causing OM. They suggested that the progression from 
asymptomatic colonization to OM may not be dependent on the strain of NTHi but rather 
on quantitative or qualitative differences in the immune defense of the child. In addition, 
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other factors such as differential expression of specific adhesins might be also involved 
(5). Which bacterial factors contribute to the migration from nasopharynx to middle ear 
remains largely to be investigated. 
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Clinical immunology
Innate immune response and rAOM, COME
To further explore the contribution of bacteria and viruses to OM, we investigated the asso-
ciation of cytokine responses and the presence of bacteria and viruses in the middle ear 
of children with recurrent and chronic OM (Chapter 3). We demonstrated that bacterial 
detection was associated with significantly elevated levels of cytokines compared to MEF 
without bacteria in a bacterial load- and species-dependent manner. Cytokine responses 
for IL-1b, IL-6, IL-8 and IL-10 were significantly higher in MEFs positive for H. influenzae 
compared with MEFs positive for M. catarrhalis. OM caused by M. catarrhalis is gener-
ally believed to be mild in comparison with OM induced by other bacterial pathogens. 
OM caused by M. catarrhalis is characterized by a higher proportion of mixed infections, 
younger age at diagnosis, a lower proportion of spontaneous perforation of the tympanic 
membrane, and no mastoiditis (6). These results are supported by the current data.
 The clinical implications for viruses such as rhinovirus are still of debate. In respec-
tively 19% and 27% of the MEFs collected in our retrospective cohort study, no pathogens 
or only viral pathogens were detected. The presence of virus in MEFs was not associated 
with an increase in cytokine levels compared to MEFs without pathogens. Additionally, 
no significant changes were observed between samples containing only bacteria versus 
MEFs containing both bacteria and viruses, suggesting a more indirect role for viral infec-
tions. 
 Rhinovirus has been shown to play an important role in lower respiratory tract pathol-
ogy, where it can provoke exacerbations of cystic fibrosis, asthma and COPD (7-10). 
Various factors might play a role, such as viruses triggering exacerbations by enhancing 
already existing inflammation in the lower airways. The mechanisms are not fully defined, 
but growing evidence supports the concept that viral modulation of epithelial function may 
initiate the inflammatory response (11). In that case, the role of rhinovirus is different in 
lower respiratory tract pathology compared to upper respiratory tract pathology (Chapter 
3) (12). Another mechanism by which rhinoviruses can induce inflammation in lower res-
piratory tract infections is during co-infection with bacterial pathogens, through the libera-
tion of planktonic bacteria from biofilms (8). Whether rhinovirus is involved in the liberation 
of planktonic bacteria from biofilms in the middle ear remains to be elucidated.
 Importantly, in patients with only viral pathogens detected in their middle fluid and in 
patients without bacterial or viral pathogens in their middle ear fluid, cytokine responses 
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were relatively low and subsequent destructive effects such as sensorineural hearing loss 
and bone erosion as induced by e.g. IL-1β is expected to be limited (13-16). This raises 
the question whether it is valid to discriminate recurrent and chronic OM patients based 
on the detection of pathogens and/or cytokine profile as detected in MEF in order to guide 
treatment rather than based on their clinical presentation. Further research is required to 
optimize diagnostic measurements and treatment in order to accommodate the patients at 
risk for complications.
Humoral immune response and serum resistance 
Chapter 4 describes the humoral immune response in middle ear fluids and serum to 
M. catarrhalis and S. pneumoniae surface antigens in children suffering from rAOM and 
COME, using Luminex xMAP technology. Similar to other studies (17), the levels of anti-
gen-specific IgG, IgA and IgM showed extensive inter-individual variation, and no signifi-
cant differences were found between the rAOM and COME cohort. A strong correlation 
between antigen-specific serum IgG and MEF IgG-levels per child was observed. It is still 
under debate whether antibodies are (in part) produced locally (18,19) or primarily tran-
sude from blood to the middle ear cavity (5,20). Based on the strong correlation between 
antigen-specific serum IgG and MEF IgG, our results support the latter. 
 Consistent with other studies (21,22), we did not find a correlation between the pres-
ence of protein-specific antibodies in serum and protection from nasopharyngeal colo-
nization. Prevaes and colleagues showed that in a cohort of children tested at 12 and 
24 months of age, anti-pneumococcal antibodies increased and the anti-staphylococcal 
antibodies declined, corresponding with the natural dynamics of colonization (22). Results 
from murine models suggest a CD4-Th17 mediated immunity rather than antibody medi-
ated immunity to be the primary mechanism of protection against pneumococcal colo-
nization, although this still needs to be confirmed in humans (23,24). In addition, other 
bacterial and host factors possibly play a more significant role, such as bacterial evasion, 
co-infection of various bacterial species or viral-bacterial co-infection, Eustachian tube 
dysfunction or genetic susceptibility.  
The pathogenesis of many microorganisms relies on their capacity to avoid, resist, or 
neutralize the host defense, including the complement system. Therefore, many pathogens 
have evolved mechanisms to avoid complement-mediated killing (25). Recently, it was 
shown that NTHi isolates from the lower respiratory tract exhibit increased complement 
resistance compared to colonizing strains (26). Similarly, we provide strong evidence that 
NTHi OM isolates displayed increased serum resistance to complement-mediated killing 
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compared to isolates collected from the nasopharynx (Chapter 5). This decreased sus-
ceptibility correlated with decreased binding of IgM to the bacterium, which incited us 
to investigate the mechanisms underlying serum resistance. Deletion of this R2866_0112 
gene decreased complement resistance, which coincided with an increased IgM binding. 
Expression of the R2866_0112 gene was increased in serum resistant NTHi isolates, which 
encoded a novel LOS biosynthesis gene.
 Bacterial evasion of the immune system by NTHi is feasible due to various aspects 
of LOS: (i) LOS is very heterogeneous and contains a number of phase varying epitopes 
(ii) LOS can mimic human blood group antigens, the pk antigen and paragloboside and 
(iii) LOS sialylation in H. influenzae has been shown to affect its ability to evade the lytic 
effects of human serum. Although the LOS structure is very heterogeneous, the existence 
of bactericidal IgM to NTHi-LOS makes it worthwhile to pursue LOS as a vaccine target in 
the prevention of otitis media. Previous studies already suggested to use detoxified LOS 
as a vaccine component to prevent OM caused by NTHi (27-29). A detoxified NTHi LOS 
protein conjugate vaccine showed protection in a chinchilla and mouse model for OM 
(27,29). In these mice, there was an inverse correlation between the IgG/IgM antibody lev-
els in MEF and the NTHi bacterial load in the middle ear (29). Importantly, another study 
performed by Gergova et. al. showed that an IgM monoclonal antibody raised against 
M. catarrhalis LOS cross-reacted with NTHi LOS (30). This suggests that in the develop-
ment of a LOS-based vaccine against M. catarrhalis, immunization could result in immune 
response to epitopes conserved in other important respiratory pathogens, such as NTHi 
(30).
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Microbial pathogenesis
Development of a murine model for OM infection
One of the limitations of the current experimental models used to study the bacterial 
pathogenesis of OM is the invasiveness of the experimental procedures. In most animal 
models, AOM is induced by direct inoculation of live bacteria into the middle ear cavity, 
either via a transtympanic or transbullar route (31,32). In order to investigate pneumococ-
cal AOM pathogenesis in a non-invasive experimental setting, we developed a murine 
model for AOM infection (Chapter 6). With the use of a pressure cabin we were able to 
develop a highly reproducible and non-invasive murine infection method. In our model, 
pressure is applied to translocate pneumococci from the nasopharygeal cavity into both 
mouse middle ears. Wild-type pneumococci were found to persist in the middle ear cavity 
up to six days after infection. Inflammation was confirmed by IL-1β and TNF-α cytokine 
analysis and histopathology. 
 The use of a pressure cabin is an improvement over the experimental AOM models 
currently used for various reasons. First, pressure elevation facilitates the ascending infec-
tion of pneumococci from the nasopharynx to the middle ear cavity and thus resembles 
the natural route of infection in humans. Second, an inflammatory response due to local 
manipulation is avoided (33). Third, the percentage of successful infections is 100%. This 
is of importance, since a 100% successful infection is warranted to monitor the efficiency 
of a vaccine, i.e. the reduction of bacterial load. This is in contrast to intranasal inoculation, 
where bacterial colonization occurs in the nasopharynx, which is followed by ‘spontane-
ous’ invasion of the middle ear cavity by the pathogen in about 50% of the cases (31).
 Recently, Short and colleagues also developed a non-invasive model of S. pneumo-
niae induced OM (34). Infant mice co-infected with S. pneumoniae and influenza A virus 
had a high bacterial load in the middle ear, middle ear inflammation and hearing loss. Due 
to viral-bacterial co-infection OM occurred spontaneously in almost all cases. Since viral 
infections may skew the immune system, both models are of interest to study bacterial 
pathogenesis and the host immune response.
 NTHi is unable to cause AOM in mice, as this bacterial pathogen is cleared rapidly 
from the murine middle ear cavity. In parallel to co-infection of the nasopharynx with S. 
pneumoniae and influenza A virus, we developed an experimental model to investigate 
NTHi induced OM (Chapter 5). Mice were inoculated with influenza A virus or mock treat-
ed three days before intranasal infection with NTHi. Infection with influenza A virus signifi-
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cantly increased the number of NTHi bacteria in the nasopharynx and middle ears, which 
resulted in 100% OM.
Identification of novel pneumococcal virulence factors in AOM
Bacterial surface-exposed proteins often play an important role in the interaction between 
pathogens and their host. Identification of novel surface-exposed proteins that play an 
important role in virulence can improve our understanding of OM pathogenesis and 
will facilitate new preventive strategies such as vaccine development. Virulence studies 
described in literature have shown that most pneumococcal mutants display attenuated 
phenotypes in either colonization, pneumonia, or sepsis mouse models, thus indicating 
niche-specific involvement in virulence of the respective genes (35-42). 
 We explored our AOM pressure cabin model to examine the contribution of two 
surface-associated pneumococcal proteins to otitis media: the streptococcal lipoprotein 
rotamase A (SlrA) and the putative proteinase maturation protein A (PpmA) (Chapter 6). 
Both proteins have the potential to elicit protective immune responses (43,44). Previous 
research has shown a pivotal role of SlrA in adherence, colonization and immune eva-
sion (39). PpmA is a conserved protein involved in invasive disease and colonization of 
the nasopharyngeal cavity. Nevertheless, the exact function of this protein is still unknown 
(44,45). 
 We investigated the contribution of SlrA and PpmA to experimental OM in our model. 
Pneumococci lacking the gene encoding SlrA, but not PpmA, were significantly reduced 
in virulence in the otitis media model. Importantly, pneumococci lacking both genes were 
significantly more attenuated than the ∆slrA single mutant. This additive effect suggests 
that SlrA and PpmA exert complementary functions during experimental OM. As described 
by Audouy et. al., intranasal immunization in mice with SlrA-IgA1p or SlrA-IgA1p-PpmA 
showed significant protection against fatal pneumonia in mice (46). Whether the SlrA pro-
tein has potential as a vaccine candidate directed against OM infection remains to be 
elucidated. We showed that our model is valuable to study OM induced by S. pneumoniae 
and to study OM related virulence.
 The genomic array footprinting (GAF) technology is developed to screen for potential 
vaccine targets (47). GAF is a mutant library-based negative selection screen that uses 
microarrays to identify the virulence essential genes. Using the GAF technology, two pneu-
mococcal proteins SP1298 and 2205, were consistently identified in mouse models of 
nasopharyngeal colonization, bacteremia and meningitis to be crucial for bacterial survival 
in vivo. SP1298 and 2205 are two conserved proteins of unknown function, classified as 
DHH subfamily 1 proteins. We examined the contribution of SP1298 and 2205 to pneu-
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mococcal virulence in nasopharyngeal colonization, OM, pneumonia and bacteremia with 
various pneumococcal strains (Chapter 7). The OM mouse model showed that bacterial 
loads in the middle ears of mice infected with the mutants were reduced compared to 
wild-type-infected mice, with a significant reduction in bacterial load upon deletion of both 
genes at all time-points post infection. In co-infection experiments, both wild-types out-
competed their respective single and double SP1298 and 2205 mutants in the middle ear. 
 Site-specific variances were observed, i.e. the SP2205 mutant was attenuated in the 
nasopharynx and middle ears of mice, in contrast to the lungs and blood of mice, where 
the SP2205 mutant was as virulent as the wild-type. Importantly, in all four models an 
apparent additive effect was shown upon deletion of both genes.
 As OM episodes are usually preceded by nasopharyngeal colonization, DHH pro-
teins have potential as vaccine candidates also directed against OM infection. We showed 
that subcutaneous vaccination with (the recombinant forms of) SP1298 and 2205 con-
ferred protection to pneumococcal disease in mice, including nasopharyngeal coloniza-
tion, pneumonia and bacteremia. Thus, these proteins play a significant role at several 
stages of pneumococcal infection and are potential candidates for a multi-component 
protein vaccine.
 Research is currently ongoing to determine the cellular localization during pathogen-
esis and biochemical function. Western blot analysis and 3D prediction modeling revealed 
that the SP1298 mutant is directly or indirectly involved in oxidative stress tolerance. Based 
on homology with proteins from  other bacteria is 3’(2’)-phosphoadenosine-5’-phosphate 
(pAp) activity a possible explanation for impaired growth of the SP1298 deletion mutant.
OM and biofilm formation
Serine-rich repeat proteins (SRRPs) are a family of surface-expressed proteins found in 
numerous Gram-positive pathogens, including Staphylococcus aureus, S. pneumoniae, 
Group B streptococci and oral streptococci. We described a novel role for the pneumo-
coccal serine-rich repeat protein (PsrP), the SRRP of S. pneumoniae as an intra-bacterial 
adhesin that promotes bacterial aggregation during colonization and pneumonia in mice 
(Chapter 8). In vitro we showed that the basic region domain of PsrP promotes self-inter-
actions that result in denser biofilms, greater biofilm biomass, and altered architectures of 
surface grown cultures; these interactions could be neutralized by antibodies to PsrP that 
are protective against pneumococcal infection. Thus, PsrP has a dual role as host-cell and 
intra-bacterial adhesin. 
 The exact role of PsrP in OM is under current investigation. Animals challenged with 
S. pneumoniae T4∆psrP had a higher bacterial load and elevated levels of IL-1β, IL-6 and 
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TNFα versus TIGR4 infected controls. A similar finding has been described for NTHi luxS 
mutants (48,49). They found that LuxS promotes biofilm maturation and persistence of 
NTHi in vivo. Bacterial counts within middle-ear fluids and the severity of the host inflam-
matory response were increased in luxS mutants as compared with parental strains. 
 Although it is generally considered that over half of all bacterial infections are biofilm 
related (50), studies concerning virulence factors involved in biofilm formation related to 
OM are scarce. Experimental studies primarily use a chinchilla model of infection and 
found an association between biofilm formation and the pneumococcal virulence factors 
PcpA, PspA and PspC, all choline binding proteins (51). Bacterial factors important to NTHi 
biofilms include lipooligosaccharide (LOS), pili and double-stranded DNA (52). For future 
research on virulence factors potentially related to biofilm formation, the rat OM model for 
biofilm formation of Chaney et al. might be of additional value (53). Similar to our mouse 
model, a pressure cabin was used to translocate pneumococci from the nasopharynx to 
the middle ear. Whereas we used an acute OM model with singly infected mice, these 
authors repeatedly inoculated the rats every four to seven days, for up to seven months. 
Animals were sacrificed at various time points to monitor biofilm formation in the middle 
ear (53).
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Concluding remarks
Taken together, the data described in this thesis showed that in children with recurrent or 
chronic OM, non-typeable H. influenzae and rhinovirus are the predominant pathogens in 
the middle ear and nasopharynx. MLST analysis showed that the micro-organisms from 
the nasopharynx and the middle ear per child are mostly genetically identical. Based on 
microbial profiling of the nasopharynx and middle ear fluid, no difference can be made 
between rAOM and COME diagnosis. We demonstrated that the cytokine response in the 
middle ear of these patients was associated with the presence of bacteria, but not viruses. 
In addition, we showed that non-typeable H. influenzae isolates obtained from the mid-
dle ear exhibit increased complement resistance and that the lipooligosaccharide (LOS) 
structure determines IgM binding and complement activation. In experimental studies, we 
provided insight into the role of several pneumococcal virulence factors in the molecular 
pathogenesis of S. pneumoniae induced OM. 
 There are a few limitations of the clinical studies described in this thesis. I will high-
light the most important ones. First, the sample size is relatively small (n=176 patients) 
with patients enrolled in a limited region in the Netherlands. Second, the human immune 
system is a complex system which cannot be simulated in vitro. In order to test viru-
lence factors and vaccine candidates the immune response, animal models, in our case 
mouse models, are an inevitable stepping stone towards understanding and unraveling 
the human immune response. Obviously, mice are not men and results can never fully be 
extrapolated to the human situation. 
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Future perspectives
Vaccine Development
Considerable data indicate that OM can be prevented by immunization (54-56). Vaccines 
effective in preventing acute OM will most likely have a large impact on the entire spec-
trum of middle ear disease, including rAOM and COME, since these entities arise from 
early AOM (57). To vaccinate only those children who already developed recurrent and 
chronic disease is unlikely to be effective, in particular because herd immunity will not be 
established (58,59). 
 There are several requirements for an effective vaccine: it should be save and pro-
tective in the target population, and it should elicit sustained protection, induce neutral-
izing antibodies and trigger protective T-cells. In addition there are practical considerations 
such as low costs, biological stability, ease of administration and limited side effects (60). 
Potential vaccine antigens should be non-toxic, conserved among strains and expressed 
in vivo without cross-reactivity. Furthermore, vaccine antigens should not be homologous 
to human factors. The ideal vaccine to prevent OM would cover the 3 bacterial pathogens: 
S. pneumoniae (59), H. influenzae (57) and M. catarrhalis (61). Vaccines with greater cover-
age based on proteins common to all serotypes, or addition of protein-based vaccines to 
the current PCV will be needed in the future (59).
 In contrast to invasive diseases, such as pneumonia, meningitis and sepsis, otitis 
media typically affects the mucosa. It is therefore important to understand how middle ear 
pathogens stimulate the mucosal immunity in order to develop effective vaccines. There 
are various obstacles to overcome in vaccine development for mucosal diseases, i.e. the 
lack of appropriate correlates of protection for mucosal disease. The use of bactericidal 
assays, opsonophagocytotic killing assays and reduction of bacterial load in experimental 
models are explored, however, thus far a direct correlation between immune response and 
bacterial clearance in the middle ear has not been found. 
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Nederlandse samenvatting 
Acute middenoorontsteking (acute otitis media, AOM) is één van de meest voorkomende 
kinderziekten. In westerse landen heeft 80% van alle kinderen voor het derde levensjaar 
tenminste 1 episode met AOM doorgemaakt (1). Hoewel AOM in het merendeel van de 
gevallen vanzelf geneest, is er een grote groep kinderen waarbij de ontsteking regelmatig 
terugkeert (recidiverende AOM, rAOM) of waarbij gedurende langere tijd vocht in het mid-
denoor aanwezig is (chronische otitis media met effusie, COME). Deze vormen van mid-
denoorontsteking (otitis media, OM) gaan gepaard met een aanzienlijke ziektelast. 
 Middenoorontstekingen komen frequent voor bij kinderen, desalniettemin is het niet 
duidelijk wat de beste behandeling is voor rAOM en COME. Het ontwikkelen van effec-
tieve behandelingen vraagt om een grondige kennis van de microbiologische en immu-
nologische aspecten van OM. Derhalve zijn klinische en experimentele studies nodig om 
deze aspecten van OM te doorgronden. Zo wordt een beter inzicht verworven in de wijze 
waarop OM ontstaat en kunnen op basis daarvan nieuwe therapeutische en preventieve 
strategieën ontwikkeld worden. 
 In dit proefschrift zijn een aantal studies beschreven in een cohort kinderen met 
rAOM of COME. Allereerst is de aanwezigheid onderzocht van bacteriën en virussen in 
het middenoor. Vervolgens is de relatie tussen de mate van ontsteking en de hoeveelheid 
bacteriën in het middenoor bestudeerd, alsook de humorale immuunrespons gericht tegen 
een aantal geselecteerde oppervlakte eiwitten van 2 bacteriën die veel voorkomen bij OM: 
Moraxella catarrhalis en Streptococcus pneumoniae (de pneumokok). Daarnaast is de rol 
van resistentie tegen componenten van het afweersysteem in relatie met de ongekapselde 
Haemophilus influenzae bacterie (NTHi; de derde veel voorkomende bacterie bij OM) 
onderzocht. Middels een experimentele studie, met een door ons ontwikkeld nieuw mui-
zenmodel voor AOM, is de rol bestudeerd van verschillende pneumokokken serotypes 
en specifieke pneumokokkeneiwitten in de pathogenese van OM. Tenslotte hebben we 
gekeken naar de rol van één specifiek pneumokokkeneiwit in bacteriële aggregatie en het 
vormen van biofilms.
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Medische Microbiologie
Bacteriën, virussen en OM
We hebben bestudeerd of er op basis van de aanwezigheid van specifieke bacteriën en 
virussen een (microbiologisch) onderscheid tussen rAOM en COME gemaakt kan worden 
(Hoofdstuk 2). Kinderen in de leeftijd van 0-5 jaar met rAOM of COME die middenoor-
buisjes geplaatst kregen, werden na toestemming van ouders, geïncludeerd in de OMVac-
studie in de periode 2008-2009. De resultaten laten zien dat dezelfde bacteriën en virussen 
betrokken zijn bij de pathogenese van rAOM en COME. Daarnaast vonden wij evenals in 
eerder onderzoek (2,3) dat de veronderstelling dat bepaalde bacteriën en virussen speci-
fiek betrokken zijn bij ofwel rAOM ofwel COME onjuist is, evenals de hypothese dat COME 
een gevolg is van een continue steriele ontsteking van he t middenoor.
  H. influenzae en rhinovirus zijn de voornaamste micro-organismen in het middenoor 
en in de neus-keelholte van kinderen met rAOM en COME (Hoofdstuk 2). Analyse van de 
middenoorvloeistof door middel van bacteriële kweken toonde met name mono-infecties 
aan. In 98% van de kweken werd slechts 1 bacteriële soort in het middenoor gedetec-
teerd. S. pneumoniae, H. influenzae en M. catarrhalis werden gekweekt in respectievelijk 
4%, 20% en 8% van de middenoorvloeistoffen.  
 De polymerase kettingreactie (PCR) is in vergelijking met bacteriële kweek een 
gevoeliger methode om (meerdere) bacteriën aan te tonen. S. pneumoniae, H. influenzae 
en M. catarrhalis werden gedetecteerd in respectievelijk 7%, 34% en 25% van de mid-
denoorvloeistoffen. Menginfecties in het middenoor werden beperkt gevonden: 14% van 
de kinderen hadden op basis van PCR-analyse meerdere micro-organismen in het mid-
denoor. In de kweek negatieve middenoorvloeistoffen werd door middel van PCR S. pneu-
moniae aangetoond in 4.1% (NS), H. influenzae in 16.5% (P<0.01) en M. catarrhalis in 19% 
(P<0.01). Vooral de detectie van M. catarrhalis stijgt dus significant met het gebruik van 
PCR ten opzichte van bacteriële kweek. 
 Met behulp van multilocus sequence typing (MLST) hebben we de genetische variatie 
onderzocht van bacteriën uit het middenoor en de neus-keelholte binnen één patiënt. 
Daarnaast bestudeerden we eveneens de genetische variatie van bacteriën uit het mid-
denoor en de neus-keelholte tussen verschillende patiënten. In dit onderzoek vonden we 
dat S. pneumoniae, H. influenzae en M. catarrhalis isolaten in het middenoor in het merendeel 
van de gevallen (80-100%) genetisch identiek waren aan isolaten die gekweekt werden uit 
de neus-keelholte. Conform andere klinische studies (4,5) tonen we aan dat de bacteriële 
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genotypen bij de verschillende patiënten heterogeen zijn, ook al betreft het een patiënten-
populatie uit een relatief beperkte regio in Nederland. Kaur et al. hebben 165 NTHi isolaten 
bestudeerd, maar zij waren niet in staat om een dominant MLST type te identificeren. Ook 
kon aan de hand van het MLST type geen onderscheid gemaakt worden tussen stammen 
die resulteren in dragerschap in de neus-keelholte, versus stammen die naast drager-
schap in de neus-keelholte tevens OM veroorzaken. De auteurs suggereren dat de pro-
gressie van asymptomatische kolonisatie naar OM niet zozeer afhankelijk is van de NTHi 
stam zelf, maar meer van de kwantitatieve en kwalitatieve verschillen in het afweersysteem 
van het kind. Verder zouden andere factoren zoals de expressie van specifieke adhesines, 
ook een rol kunnen spelen (4). De bijdrage van bacteriële factoren aan de migratie van 
neus-keelholte naar middenoor is een nog braak liggend onderzoeksterrein.
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Immunologie
rAOM, COME en de aangeboren immuunrespons
Om de rol van de aangeboren immuunrespons in de pathogenese van OM te onder-
zoeken hebben we de cytokine respons bestudeerd in relatie tot de aanwezigheid van 
bacteriën en/of virussen in het middenoor van kinderen met rAOM of COME (Hoofdstuk 
3). We tonen in dit proefschrift aan dat de aanwezigheid van bacteriën geassocieerd 
is met significant verhoogde cytokine concentraties in vergelijking met middenoorvloei-
stoffen waarin geen bacteriën aanwezig waren. De hoogte van de cytokine respons was 
gerelateerd aan de aanwezigheid van de hoeveelheid bacteriën in het middenoor. Een 
significante correlatie werd aangetoond tussen de aanwezigheid van H. influenzae en de 
cytokines IL-1β, TNF-α, IL-6 en IL-8. Eenzelfde significante correlatie vonden we tussen 
M. catarrhalis en deze cytokines. Voor S. pneumoniae en de cytokine respons werd een 
gelijke trend gezien. Echter, door het kleine aantal middenoorvloeistoffen waarin S. pneu-
moniae werd gedetecteerd, was dit verschil niet significant. De cytokine responsen voor 
IL-1β, IL-6, IL-8 en IL-10 waren significant hoger in de middenoorvloeistoffen waarin H. 
influenzae aanwezig was, in vergelijking met middenoorvloeistoffen die positief waren voor 
M. catarrhalis. OM veroorzaakt door M. catarrhalis is over het algemeen geassocieerd met 
een hoger percentage menginfecties, een lager percentage van perforatie en het uitblijven 
van mastoïditis, een gevreesde complicatie van OM (6). 
 De klinische implicaties van OM veroorzaakt door virussen, zoals het rhinovirus, zijn 
nog steeds onderwerp van discussie. In respectievelijk 19% en 27% van de middenoor-
vloeistoffen in ons klinische cohort waren geen micro-organismen aantoonbaar of alleen 
virussen aanwezig. De aanwezigheid van virussen in middenoorvloeistof was niet geas-
socieerd met verhoogde cytokine concentraties in vergelijking met middenoorvloeistoffen 
waarin geen micro-organismen aanwezig waren. Ook werden er geen significante verschil-
len in cytokine concentraties gezien tussen middenoorvloeistoffen met alleen bacteriën 
versus middenoorvloeistoffen waarin zowel bacteriën als virussen aanwezig waren. Dit 
suggereert een indirecte rol voor virale infecties in de pathogenese van OM.
 Rhinovirus speelt een belangrijke rol in lagere luchtweginfecties: het kan exacerba-
ties van taaislijmziekte, astma en COPD veroorzaken (7-10). Verschillende factoren spelen 
hierbij een rol, zoals de versterking van een reeds aanwezige ontstekingsreactie hetgeen 
door de aanwezigheid van virussen leidt tot een exacerbatie. Het mechanisme hierachter 
wordt niet volledig begrepen, maar er zijn in toenemende mate aanwijzingen dat modulatie 
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van de functie van het epitheel door virussen een ontstekingsreactie uitlokt (11). In dat 
geval verschilt de rol van rhinovirussen in lagere luchtweginfecties ten opzichte van boven-
ste luchtweginfecties zoals OM (Hoofdstuk 3) (12). Een ander mechanisme waarbij rhi-
novirussen ontsteking kunnen induceren is tijdens co-infectie met bacteriële pathogenen, 
door stimulatie van de loslating van bacteriën uit een biofilm (8). Of rhinovirus betrokken 
is bij het losmaken van  bacteriën uit de biofilm die zich in het middenoor kan vormen, is 
nog onbekend.
 Het is van belang te beseffen dat bij kinderen met alleen virussen en bij patiënten 
zonder bacteriën of virussen in de middenoorvloeistof de cytokine concentraties relatief 
laag zijn en eventuele complicaties zoals gehoorschade of boterosie door IL-1β beperkt 
zijn (13-16). Het is daarom de vraag of rAOM en COME niet beter onderscheiden kun-
nen worden op basis van detectie van micro-organismen en/of het cytokineprofiel in de 
middenoorvloeistof dan op basis van klinische presentatie. Verder onderzoek is nodig om 
vroegdiagnostiek te ontwikkelen om kinderen met OM die een verhoogd risico hebben 
voor het ontwikkelen van complicaties in een vroeg stadium te detecteren.
Humorale immuunrespons en serumresistentie
Hoofdstuk 4 beschrijft, gebruikmakend van de Luminex xMAP technologie, de humo-
rale immuunrespons in middenoorvloeistoffen en serum gericht tegen M. catarrhalis en S. 
pneumoniae oppervlakte antigenen van kinderen met rAOM en COME. In vergelijking met 
andere studies (17) laten de concentraties antigeen-specifiek IgG, IgA en IgM een grote 
inter-individuele variatie zien. Hierbij werden geen significante verschillen aangetoond tus-
sen het rAOM en het COME cohort. Per patiënt werd een sterke correlatie gevonden tus-
sen antigeen-specifiek serum IgG en IgG in de middenoorvloeistof. Het is nog onduidelijk 
of antilichamen (deels) lokaal geproduceerd worden (18,19) of diffunderen vanuit het 
bloed naar het middenoor (4,20). Gezien de sterke correlatie gevonden tussen antigeen-
specifiek serum IgG en IgG in de middenoorvloeistof ondersteunen onze resultaten de 
laatstgenoemde hypothese.
 Evenals in andere studies (21,22) vonden we geen correlatie tussen aanwezigheid 
van eiwit-specifieke antilichamen in serum en het voorkómen van nasofaryngeale bac-
teriële kolonisatie. Prevaes en collega’s toonden aan dat in een cohort kinderen getest 
op de leeftijd van 12 en 24 maanden, antilichamen gericht tegen pneumokokken stegen 
en antilichamen gericht tegen stafylokokken daalden, hetgeen overeenkomt met de natu-
urlijke dynamiek van kolonisatie (22). Studies bij de muis suggereren dat een CD4-Th17 
gemedieerde immuniteit een belangrijker rol speelt dan een antilichaam gemedieerde 
immuniteit als afweermechanisme tegen pneumokokken kolonisatie. Deze bevinding moet 
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echter nog wel bevestigd worden in de mens (23,24). Bovendien zouden andere bacteriële 
en gastheerfactoren een prominentere rol kunnen spelen, zoals bacteriële ontsnappings-
mechanismen, co-infectie van verschillende bacteriële species of co-infectie van virussen 
en bacteriën, dysfunctie van de buis van Eustachius en genetische factoren van het kind.
  
De pathogenese van veel micro-organismen is gebaseerd op het vermogen om verschil-
lende afweermechanismen te vermijden, te weerstaan of te neutraliseren. Veel micro-
organismen hebben mechanismen ontwikkeld om complement-gemedieerde ‘killing’ 
te weerstaan (25). Recent is aangetoond dat NTHi isolaten uit de lage luchtwegen een 
grotere complement resistentie hebben in vergelijking met koloniserende stammen uit de 
neus-keelholte (26). Parallel hieraan hebben wij laten zien dat NTHi isolaten uit het mid-
denoor meer complement resistent zijn dan isolaten uit de neus-keelholte (Hoofdstuk 5). 
Deze afgenomen gevoeligheid correleerde met afgenomen binding van IgM aan de bacte-
rie. Deze bevinding gaf aanleiding om het onderliggende mechanisme van serumresisten-
tie nader te onderzoeken. Hierbij bleek dat het R2866_0112 gen een belangrijke rol speelt. 
Expressie van het R2866_0112 gen was hoger in serum-resistente dan serum-gevoelige 
NTHi isolaten, en deletie van het R2866_0112 gen ging gepaard met een sterkere IgM 
binding. Dit gen codeert voor een nieuw lipooligosaccharide (LOS) biosynthese gen. 
 NTHi is in staat aan het immuunsysteem te ontsnappen door de verschillende karak-
teristieken van het LOS: (i) LOS is heterogeen en bevat een aantal epitopen die in staat 
zijn tot fasevariatie, (ii) LOS kan humane bloedgroep antigenen imiteren en (iii) sialysatie 
van LOS in NTHi beïnvloedt de mogelijkheid om de lytische effecten van humaan serum 
te omzeilen. Ook al is de structuur van LOS heterogeen, de bactericide capaciteit van 
IgM gericht tegen NTHi-LOS maakt het de moeite waard om LOS te onderzoeken als een 
potentieel vaccin kandidaat in het kader van preventie tegen OM. Voorgaande studies 
suggereerden reeds om gedetoxificeerd LOS te gebruiken als een vaccincomponent om 
OM veroorzaakt door NTHi te voorkomen (27-29). Een gedetoxificeerd NTHi LOS eiwit 
conjugaat vaccin is beschermend in een chinchilla model en in een muismodel voor OM 
(29). Nota bene, in een studie uitgevoerd door Gergova en collega’s werd aangetoond 
dat een IgM monoklonaal antilichaam gericht tegen M. catarrhalis-LOS kruis reageerde 
met NTHi-LOS (30). Dit suggereert dat in de ontwikkeling van een LOS gebaseerd vaccin 
tegen M. catarrhalis, immunisatie kan resulteren in een immuunrespons tegen epitopen 
geconserveerd in andere belangrijke luchtweg pathogenen zoals NTHi (30).
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Microbiële pathogenese
Ontwikkeling van een muismodel voor OM
Eén van de beperkingen van de huidige experimentele modellen voor de bestudering van 
de bacteriële pathogenese van AOM is de invasieve benadering van de experimentele 
procedures. In de meeste diermodellen wordt AOM geïnduceerd door directe inoculatie 
van levende bacteriën in de middenoorholte, ofwel via het benige gedeelte van het mid-
denoor, ofwel via het trommelvlies (31,32). Om de pathogenese van AOM te onderzoeken 
op non-invasieve wijze werd door ons een muismodel ontwikkeld voor AOM veroorzaakt 
door S. pneumoniae (Hoofdstuk 6). In het model wordt drukverhoging gebruikt om pneu-
mokokken vanuit de neus-keelholte te verplaatsen naar beide middenoren. Gebruikmak-
end van deze methode waren we in staat om op non-invasieve en reproduceerbare wijze 
AOM te induceren: wild-type pneumokokken bleven tot 6 dagen na infectie aanwezig 
in het middenoor en ontsteking van het middenoor werd aangetoond met IL-1β en IL-6 
cytokine analyse en histopathologie. 
 Het gebruik van een druk cabine is een verbetering op de bestaande experimentele 
AOM modellen om verscheidene redenen: i) drukverhoging faciliteert de verplaatsing van 
pneumokokken vanuit de neus-keelholte naar de middenoorholte en komt dus overeen 
met de route van infectie bij de mens; ii) een ontstekingsreactie door lokale manipulatie 
van het middenoor wordt vermeden (33); iii) de succeskans is 100%. Laatstgenoemde is 
van essentieel belang om het effect van vaccinatie, namelijk reductie in de hoeveelheid 
bacteriën in het middenoor, te kunnen monitoren. Dit is een aanzienlijke verbetering ten 
opzichte van intranasale inoculatie zonder drukverhoging, waarbij na bacteriële kolonisatie 
van de neusholte, spontane invasie van het middenoor plaatsvindt in slechts ongeveer 50% 
van de gevallen (31).
 Onlangs hebben Short en collega’s een andere niet-invasieve AOM infectie methode 
in de muis beschreven (34). Co-infectie van babymuizen met S. pneumoniae en influenza 
A virus na intranasale inoculatie toonde een hoge hoeveelheid bacteriën in het middenoor, 
ontsteking van het middenoor en gehoorverlies. Door co-infectie van bacterie en virus 
ontstond OM spontaan in nagenoeg alle gevallen. Omdat virale infecties de immuunre-
spons kunnen beïnvloeden zijn beide modellen van belang om de bacteriële pathogenese 
en de immuunrespons van de gastheer te onderzoeken.
 NTHi is niet in staat om AOM te induceren in muizen, omdat deze bacterie snel 
geklaard wordt uit het middenoor. Wij hebben analoog aan het intranasale S. pneumo-
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niae – influenza A co-infectiemodel een experimenteel model ontwikkeld om OM geïndu-
ceerd door NTHi te bestuderen (Hoofdstuk 5). Muizen werden geïnoculeerd met influenza 
A virus of placebo 3 dagen voorafgaand aan intranasale infectie met NTHi. Infectie met 
influenza A zorgde voor een significant grotere hoeveelheid NTHi bacteriën in de neus-
keelholte en het middenoor in vergelijking met infectie met NTHi alleen, en resulteerde in 
OM in 100% van de gevallen.
Identificatie van nieuwe pneumokokken virulentiefactoren in AOM
Bacteriële oppervlakte eiwitten spelen een belangrijke rol in de interactie tussen gastheer 
en pathogeen. Identificatie van nieuwe oppervlakte eiwitten die een belangrijke rol spelen 
in virulentie kan het inzicht in OM pathogenese versterken en zo vaccinontwikkeling facilit-
eren. Verschillende virulentie studies hebben laten zien dat de meeste pneumokokkenmu-
tanten een verzwakt fenotype hebben in ofwel kolonisatie, ofwel pneumonie, ofwel sepsis. 
De bijdrage aan virulentie van die verschillende pneumokokkencomponenten is afhankelijk 
van de aard en lokalisatie van de infectie (35-42).
 We hebben het AOM druk cabine model gebruikt om de bijdrage van twee verwante 
oppervlakte eiwitten in OM te onderzoeken: het streptokokken lipoproteïne rotamase A 
(SlrA) en het vermeende proteïnase maturatie proteïne A (PpmA) (Hoofdstuk 6). Beide 
eiwitten hebben de potentie om een afweerreactie op te wekken (43,44). Eerder onder-
zoek toonde een cruciale rol aan voor SlrA in adherentie, kolonisatie en immuun evasie 
(39). PpmA is een geconserveerd oppervlakte eiwit en is betrokken bij kolonisatie van de 
neus-keelholte en bij invasieve ziekte. Desalniettemin is de exacte functie van dit eiwit nog 
steeds onbekend (44,45).
 Wij hebben de bijdrage van SlrA en PpmA aan OM onderzocht in ons muismod-
el. Pneumokokken waarbij het coderende gen voor SlrA (maar niet voor PpmA) ontbrak, 
waren significant minder virulent in het OM model. Let wel: pneumokokken waarin beide 
genen ontbraken waren veel minder virulent dan mutanten die alleen het slrA gen mis-
ten. Dit additieve effect suggereert dat SlrA en PpmA een complementaire functie hebben 
in experimentele OM. Zoals beschreven door Audouy en collega’s liet intranasale immu-
nisatie van muizen met SlrA-IgA1p of SlrA-IgA1p-PpmA significante bescherming tegen 
pneumonie zien (46). Of het SlrA eiwit geschikt is als vaccin kandidaat voor bescherm-
ing tegen OM dient nog verder te worden onderzocht. We hebben aangetoond dat ons 
muismodel geschikt is om OM geïnduceerd door pneumokokken te bestuderen en dat 
met behulp van dit experimentele model ook pneumokokken virulentiestudies uitgevoerd 
kunnen worden.
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De ‘genomic array footprinting’ (GAF) technologie is ontwikkeld in ons laboratorium om 
potentiële virulentiefactoren te identificeren (47). De technologie is gebaseerd op een 
selectieprocedure waarbij micro-arrays gebruikt worden om genen te identificeren die van 
cruciaal belang zijn tijdens verschillende stadia van het infectieproces. Met de GAF tech-
nologie werden twee pneumokokken eiwitten, SP1298 en SP2205, op consistente wijze 
geïdentificeerd in muismodellen voor kolonisatie van de neus-keelholte, bacteriëmie en 
meningitis. SP1298 en SP2205 zijn twee geconserveerde eiwitten met een nog onbekende 
functie, geclassificeerd als DHH subfamilie 1 eiwitten. We onderzochten de bijdrage van 
SP1298 en SP2205 aan kolonisatie van de neus-keelholte, OM, pneumonie en bacte-
riëmie (Hoofdstuk 7). Het aantal bacteriën in het middenoor van muizen geïnfecteerd 
met mutanten die beide genen misten, bleek verminderd ten opzichte van de wild-type 
geïnfecteerde muizen op alle onderzochte tijdspunten na infectie. In OM co-infectie experi-
menten was het wild-type virulenter dan zowel de SP1298 en SP2205 enkel mutanten als 
de dubbelmutant. Ook hier speelde de anatomische locatie van de infectie een rol: de 
SP2205 mutant bleek verzwakt in de neus-keelholte en middenoren van muizen, dit in 
tegenstelling tot de longen en het bloed waar de mutant net zo virulent was als het wild-
type. Deletie van beide genen resulteerde in een verminderde virulentie zich uitend in een 
verminderde kolonisatie van de neus-keelholte en lagere aantallen bacteriën in het mid-
denoor, de long en de bloedbaan. 
 Omdat OM episodes meestal voorafgegaan worden door kolonisatie van de neus-
keelholte, hebben de DHH eiwitten potentie als vaccinkandidaten gericht tegen OM. We 
hebben aangetoond dat subcutane vaccinatie met SP1298 en SP2205 bescherming kan 
bieden tegen pneumokokkenziekte in muizen, inclusief nasofaryngeale kolonisatie, pneu-
monie en bacteriëmie. Deze eiwitten spelen dus een significante rol in verschillende sta-
dia van infectie en zijn potentiële kandidaten voor een multi-component eiwitvaccin. Op 
dit moment onderzoeken wij de cellulaire lokalisatie tijdens pathogenese en proberen we 
de biochemische functie van beide eiwitten te achterhalen. Western blot analyse en 3D 
predictie modellering hebben aangetoond dat SP1298 direct of indirect betrokken is bij 
oxidatieve stresstolerantie. Op basis van homologie met eiwitten uit andere bacteriën zou 
SP1298 3’(2’)-phosphoadenosine-5’-fosfaat (pAp) phospatase activiteit kunnen bevatten, 
waardoor de beperkte groei van de SP1298 deletiemutant mogelijk veroorzaakt wordt door 
ophoping van pAp.
OM en biofilm formatie  
Serine-rijke repeat-eiwitten (SRRPs) behoren tot een familie van oppervlakte-eiwitten die 
worden aangetroffen in tal van gram-positieve bacteriën, inclusief Staphylococcus aureus, 
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S. pneumoniae, groep B streptokokken en orale streptokokken. We hebben een nieuwe 
rol voor het pneumokokken serine-rijke repeat eiwit (PsrP) beschreven, het SRRP van S. 
pneumoniae, als een intra-species bacterieel adhesine dat bacteriële aggregatie tijdens 
kolonisatie en pneumonie in muizen bevordert (Hoofdstuk 8). In vitro hebben we aange-
toond dat de basale regio van PsrP eigen interacties bevordert, zich uitend in een toe-
genomen densiteit van de biofilms, een grotere massa van de biofilm en een veranderde 
architectuur van oppervlakte structuren. Deze interacties konden geneutraliseerd worden 
door antilichamen tegen PsrP. PsrP heeft derhalve een duale rol in zowel de interactie met 
cellen van de gastheer als wel de intra-bacteriële interactie.
 De exacte rol van PsrP in OM wordt momenteel onderzocht. Muizen met S. pneu-
moniae TIGR4∆psrP hebben een groter aantal bacteriën in het middenoor en verhoogde 
spiegels van IL-1β, IL-6 en TNF-α in vergelijking met wild-type TIGR4 geïnfecteerde control-
emuizen. Een dergelijke bevinding is eerder beschreven voor NTHi luxS mutanten (48,49). 
De onderzoekers beschreven dat LuxS biofilm maturatie en persistentie voor NTHi in vivo 
bevordert. Ook hier waren bacteriële tellingen in middenoorvloeistoffen en de hoogte van 
de inflammatoire gastheerrespons toegenomen bij muizen geïnfecteerd met luxS mutanten 
in vergelijking met de wild-type stam. 
 In het algemeen wordt de helft van alle bacteriële infecties als biofilm gerelateerd 
beschouwd (50). Toch zijn studies over de rol van virulentiefactoren bij biofilm vorming 
in kader van OM schaars. Experimentele studies in het chinchilla infectie model voor OM 
laten een associatie zien tussen biofilm vorming en de pneumokokken virulentiefactoren 
PcpA, PspA en PspC, allen choline bindingseiwitten (51). Bacteriële factoren belangrijk 
voor NTHi biofilms zijn onder andere LOS, pili en dubbelstrengs DNA (52). Voor verder 
onderzoek met betrekking tot biofilm vorming is het ratten OM model van Chaney en col-
lega’s wellicht van toegevoegde waarde (53). Zoals ook in ons muismodel, werd een druk 
cabine gebruikt om pneumokokken te verplaatsen van de neus-keelholte naar het midde-
noor. Waar wij gebruik maakten van een AOM model met eenmalig geïnfecteerde muizen, 
inoculeerden deze onderzoekers de ratten elke 4-7 dagen gedurende 6 maanden. De rat-
ten werden op verscheidene tijdspunten geofferd om zo biofilm vorming in het middenoor 
te monitoren.
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Conclusie
In dit proefschrift wordt aangetoond dat H. influenzae en rhinovirus de voornaamste micro-
organismen zijn in het middenoor en in de neus-keelholte van kinderen met rAOM of 
COME. MLST analyse toont aan dat de micro-organismen uit de neus-keelholte en het 
middenoor binnen één patiënt meestal genetisch identiek zijn. Het is in onze studie niet 
mogelijk een onderscheid te maken tussen rAOM en COME op basis van de microbiolo-
gische resultaten. We hebben aangetoond dat cytokine concentraties in het middenoor 
geassocieerd zijn met de aanwezigheid van bacteriën maar niet met die van virussen. 
Daarnaast laten we zien dat ongekapselde H. influenzae isolaten uit het middenoor een 
toegenomen complement resistentie hebben en dat de LOS structuur de mate van IgM 
binding en complementactivatie bepaalt. In experimentele studies hebben we het inzicht 
verdiept in de moleculaire pathogenese van pneumokokken virulentie factoren die een rol 
spelen bij de pathogenese van OM. 
 Er zijn een aantal kanttekeningen te plaatsen bij de studies beschreven in dit proef-
schrift. Allereerst is het klinisch cohort relatief klein (n = 176 patiënten) en heeft deze zich 
beperkt tot kinderen die allen woonachtig waren in één regio van Nederland. Ten tweede 
is het menselijk immuunsysteem een complex systeem, dat niet in vitro in al haar details 
gesimuleerd kan worden. Om virulentie- en vaccinkandidaten te testen zijn diermodellen, 
in onze studies een muizenmodel, onvermijdelijk om de menselijke immuunrespons op 
specifieke bacteriële componenten beter te ontrafelen en begrijpen. Het mag duidelijk zijn 
dat de muis geen mens is, en onze resultaten derhalve niet zondermeer geëxtrapoleerd 
kunnen worden naar de humane situatie.
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Toekomstig onderzoek
Vaccinontwikkeling
Diverse studies laten zien dat vaccinatie OM kan voorkómen (54-56). Vaccinaties gericht 
op het reduceren van AOM zullen waarschijnlijk van invloed zijn op het complete spectrum 
van OM, inclusief rAOM en COME, aangezien deze in het merendeel van de gevallen een 
gevolg zijn van AOM. Echter, immunisatie van alleen kinderen met rAOM of COME lijkt niet 
effectief, met name omdat collectieve immuniteit niet wordt bewerkstelligd (57,58). 
 Er zijn verschillende vereisten voor een effectief vaccin: het moet veilig zijn en 
beschermen in de betreffende doelgroep, de bescherming dient langdurig te zijn en zowel 
antilichamen als beschermende T-cellen te activeren. Daarnaast zijn er ook praktische 
overwegingen zoals lage productiekosten, biologische stabiliteit, een gemakkelijke toe-
dieningsroute en een gering aantal bijwerkingen (59). Potentiële vaccinantigenen mogen 
uiteraard niet toxisch zijn, moeten geconserveerd zijn binnen de bacteriesoort, zonder dat 
er sprake is van kruisreactiviteit met andere, niet-pathogene bacteriesoorten. Daarnaast 
dienen vaccinantigenen niet homoloog te zijn aan humane factoren. Het ideale vaccin 
om bacteriële OM te voorkomen beschermt tegen de 3 voornaamste pathogenen in OM: 
S. pneumoniae, H. influenzae (60) en M. catarrhalis (61). Daarbij zal een vaccin met een 
grotere dekkingsgraad, bijvoorbeeld op basis van eiwitten aanwezig bij alle serotypes, of 
toevoeging van een eiwit-gebaseerd vaccin aan het huidige pneumokokken conjugaatvac-
cin in de toekomst nodig zijn (58).
 In tegenstelling tot invasieve ziekten zoals longontsteking, hersenvliesontsteking en 
sepsis, is OM een aandoening van de slijmvliezen. Om effectieve vaccins te ontwikke-
len is het daarom van belang om te begrijpen hoe middenoor pathogenen interacteren 
met het mucosale immuunsysteem. Er zijn verscheidene obstakels in de ontwikkeling van 
mucosale vaccins die nog overwonnen moeten worden. Zo is er bijvoorbeeld nog geen 
goed correlaat om de mate van bescherming tegen mucosale infectie te meten. Er wordt 
momenteel onderzocht of bactericide testen, opsonofagocytose testen en vermindering 
van bacteriële aantallen in verschillende (dier)modellen een goede maat zijn. Een directe 
correlatie tussen immuunrespons en bacteriële klaring in het middenoor is echter nog niet 
gevonden.  
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Abbreviations
AA   Amino Acid
AOM   Acute Otitis Media
BA   Blood Agar
BAL   Bronchoalveolar Lavage
BCA assay Bicinchonic Acid assay
BR   Basic Region
BSA   Bovine Serum Albumin
CBA   Cytometric Bead Array
CEP   Chromosomal Expression Platform
CFU   Colony Forming Unit
ChoP   Phosphorcholine
CI   Competitive Index
COME  Chronic Otitis Media with Effusion
COPD  Chronic Obstructive Pulmonary Disease
CV   Cristal Violet
DHH   the amino acid combination: asparagine-histidine-histidine
DNA   Deoxyribonucleic acid
Eno   Enolase
ENT   Ear-Nose-Throat
FACS  Fluorescence-Activated Cell Sorter
FCS   Fetal Calf Serum
GAF   Genomic Array Footprinting
GAPDH  Glyceraldehyde-3-phosphatedehydrogenase
gstBR  gst tagged recombinant Basic Region
HI   Heat Inactivated
HPS   Human Pooled Serum
i.n.   intranasally
IAV   Influenza A virus
IPD   Invasive Pneumococcal Disease
K10   Keratin 10
LOS   lipooligosaccharide
LPS   lipopolysaccharide
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ME   Middle Ear
MEF   Middle Ear Fluid
MFI   Mean Fluorescence Intensity
MLST  Multilocus Sequence Typing
MOI   Multiplicity Of Infection
NHS   Normal Human Serum
NPL   Nasopharyngeal Lavage
NPS   Nasopharyngeal Swab
NR   Non-Repeat Region
NTHi   Nontypeable Haemophilus influenzae
OM   Otitis Media
OME   Otitis Media with Effusion
OMP   Outer Membrane Protein
ORL   Otorhinolaryngology
PAF   Platelet Activating Factor
PAMP  Pathogen Associated Molecular Pattern
PBS   Phosphate Buffered Saline
PCR   Polymerase Chain Reaction
PDE   Phosphodiesterase
PMN   Polymorphonuclear
PPI   Peptidyl-Prolyl Isomerases
PpmA  Pneumococcal proteinase maturation protein A
PRR   Pathogen Recognition Receptor
PsrP   Pneumococcal serine-rich repeat Protein
rAOM  recurrent Acute Otitis Media
rBR   recombinant Basic region
RNA   Ribonucleic Acid
RR   Response Regulators
Rt RT-PCR realtime Reverse Transcriptase PCR
rt-PCR  realtime PCR
RT-PCR  Reverse Transcriptase PCR
SEM   Scanning Electron Microscopy
SEM   Standard Error of the Mean
SlrA   Streptococcal lipoprotein rotamase A
SPF   Specific-Pathogen-Free
SRR   Serine-rich Repeat Region
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SRRP  Serine Rich Repeat Protein
STM   Signature Tagged Mutagenesis
TFP   Type IV pili
THY   Todd-Hewitt Yeast extract
TNF   Tumor Necrosis Factor
URI   Upper Respiratory tract Infection
